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Plasminogen activator inhibitor type 2 (PAI-2) is one of the inhibitors of 
the plasminogen activation cascade mediated by urokinase (uPA) which is 
overexpressed on the surface of metastatic cancer cells. The plasminogen 
activation cascade is the generator of plasmin proteolytic activity on the cell 
surface which is required under normal physiological conditions and is largely 
exploited during cancer invasion and metastasis. The overall aim of this thesis 
was mainly to characterise the inhibition of cell-surface uPA by exogenously 
added PAI-2 and the elucidation of the fate of uPA:PAI-2 complexes once formed 
on the cell surface. PAI-2 was directly confirmed as a potent and rapid inhibitor 
of cell-surface uPA and specifically targets this antigen. PAI-2 internalised 
rapidly in a uPA-dependent manner after complex formation with cell-surface 
receptor (uPAR)-bound uPA. Internalised PAI-2 localised in endosomes/ 
lysosomes where it was presumably degraded. While the majority of 
uPAR/uPA:PAI-2 complexes formed on the cell surface were internalised, cell-
surface uPA appeared to be replenished and uPAR was recycled to the cell 
surface. These findings were significant as they provide new information 
regarding cell-surface regulation of the plasminogen activation system as well as 
a biological rationale for the use of PAI-2 as a delivery vehicle of cytotoxins for 
anti-uPA therapeutic strategies. 
To extend the analyses of PAI-2 binding to cells and its subsequent fate, 
breast cancer cells were genetically modified to provide material for this study. 
Modulation of uPA-receptor (uPAR) expression was found to induce changes in 
iv 
components of the plasminogen activation cascade on the cell-surface. 
Upregulation of cell-surface uPAR on non-invasive, low uPAR/uPA-expressing 
T-47D breast cancer cells caused a concomitant increase in cell-surface uPA. 
This caused an increase in PAI-2 binding capacity to cells, thus directly 
confirming uPA-specificity of PAI-2. In addition, uPAR upregulation induced an 
increase in the lysine-dependent binding of plasminogen to the surface of these 
cells. Although cell-surface uPA was not confidently excluded as receptor for 
plasminogen binding on uPAR-modulated cells, the increase in plasminogen 
binding on these cells is ultimately due to increase in cell-surface plasminogen 
receptors. Finally, upregulation of uPAR also affected cell morphology and all 
together the data confirmed that uPAR/uPA-upregulation is associated with 
adoption of a metastatic genotype/phenotype. These results support other 
interests in our laboratory directed towards concluding whether uPA may act as 
a plasminogen receptor via an active-site independent epitope and elucidating 
plasminogen receptors which may be modulated due to modulation of 
uPAR/uPA expression. 
Finally, this thesis aimed at optimising the preparation of PAI-2 as a 
uPA-targeting vehicle for cancer radiotherapy and radioimaging applications. 
PAI-2 was modified by the addition of the metal chelator cDTPA; the product 
was characterised and radiolabelling with a radioisotope suitable for 
radiotherapy was optimised. These results allowed the development of standard 
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Chapter 1: UROKINASE PLASMINOGEN ACTIVATION 
PATHWAY: CLINICAL RELEVANCE AND THERAPEUTIC 






The term “tumour” describes the abnormal uncontrolled proliferation of 
cells leading to a mass of cells that have no physiological function. Despite its 
common use, the term cancer only refers to an advanced stage of tumour 
progression where tumour cells have gained the ability to invade nearby tissues 
or spread throughout the body. This process, called metastasis, occurs when 
cells detach from the original (primary) tumour site and travel through the 
circulatory systems (lymphatic or bloodstream) to other parts of the body, 
causing new secondary tumours called metastatic foci. Cancer claims the lives 
of millions world wide. In Australia, cancer accounted for 30 % of male deaths 
and 25 % of female deaths in year 2000 (Cancer in Australia 2000, 2003) 
whereas it accounted for 24 % of male and 22 % of female deaths in the US in 
year 2001 (Arias et al., 2003). The leading cause of cancer-related mortality, 
even after extensive treatment regimes, is the inability to control the spread of 
malignant tumours (Woodhouse et al., 1997). Ongoing research is required to 
further understand tumour growth, progression and metastasis to allow the 
development of preventative measures and therapies in order to limit the spread 





The plasminogen activation system generates plasmin proteolytic activity 
which is a key player in tumour progression and cancer invasion and 
metastasis. Proteolysis of the circulatory zymogen plasminogen by these specific 
plasminogen activators produces the serine protease plasmin. Plasmin has a 
broad specificity and is capable of degrading fibrin as well as other extracellular 
matrix (ECM) components, in addition to the activation of other proteinases and 
growth factors (for general reviews see Danø et al., 1985; Mignatti and Rifkin, 
1993; Andreasen et al., 1997). There are two types of mammalian plasminogen 
activators: the urokinase-type plasminogen activator (uPA) and the tissue-type 
plasminogen activator (tPA). While tPA has high affinity for binding to fibrin, 
uPA binds to the urokinase-type plasminogen activator receptor (uPAR), a cell 
membrane-anchored protein which focuses plasminogen activation activity at 
the cell surface. The two main inhibitors of these activators are plasminogen 
activator inhibitors type-1 and 2 (PAI-1 and PAI-2), whereas plasmin is inhibited 
by α2-anti-plasmin (α2AP). This chapter reviews the components of the 
plasminogen activation system that leads to proteolysis (Figure 1), their 
interactions with other intracellular/extracellular components and roles in 
cancer metastasis. The main focus of this review is the urokinase plasminogen 
activation pathway of the plasminogen activation system as targeting cell-
surface uPA by its inhibitor PAI-2 holds a potential for development of uPA-






















ECM degradation and 
activation of other 
proteolytic enzyme  
Figure 1: Components of the plasminogen activation system that lead to 
increased proteolysis 
 
1.2. CAUSES OF CANCER 
Multiple factors lead to the transformation of normal cells into tumour 
cells, including inherited predisposing genes and environmental factors such as 
ultraviolet light, ionising radiation and tumour-inducing chemicals (chemical 
carcinogens, e.g. asbestos and talc) (Alberts et al., 2002). Lifestyle and dietary 
habits such as tobacco smoking, consumption of alcohol, obesity, stress and 
infection by certain viruses have also been related to generation of tumour cells 
(Alberts et al., 2002). It is not the place here to review the factors leading to or 
associated with tumour onset. However, it is important to state that despite the 
4 
variety of causes, the generation of tumour cells requires cumulative genetic 
mutations (mutagenesis) to alter the biology of normal cells. Indeed, a 
correlation between tumour-cell generation and mutagenesis is clear for three 
classes of tumour-causing agents; chemical carcinogens, ionising radiation and 
viruses (Alberts et al., 2002). Furthermore, these genetic mutations must be 
passed onto progeny in order to maintain the acquired tumour phenotype. In 
agreement, molecular evidence suggests that tumour cells from one tumour 
type are usually clones descendants from a single abnormal cell (Alberts et al., 
2002). The progeny of the first abnormal tumour cell must undergo further mutations 
to obtain characteristics that are required for tumour progression such as high 
rate of proliferation (Alberts et al., 2002). 
Cell proliferation in general is controlled by mechanisms that determine 
whether the cell passes to another round of cell-division cycle, be directed to 
differentiate and cease proliferation or undergo programmed cell death 
(apoptosis). Thus, two routes are available in order to acquire the uncontrolled 
proliferative characteristic of tumour cells (see review by McCormick, 1999; 
Alberts et al., 2002). The first route is by hyper-activating proliferation 
stimulatory genes (proto-oncogenes) to produce mutant genes (oncogenes) 
(reviewed by Bertram, 2001). The second route involves the inactivation of 
proliferation inhibitory genes (tumour suppressor genes) (reviewed by Bertram, 
2001). 
Oncogenesis (activation of proto-oncogenes or deactivation of tumour 
suppressor genes) is a multistep mutational process where each new mutational 
step leads to a clonal expansion of cells bearing the new mutation. This clonal 
expansion is required in order to develop the cancerous (malignant) phenotype 
of transformed tumour cells (McCormick, 1999). Complications in 
understanding cancer biology arise from the randomness of the genetic 
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mutations induced by the variable factors and the subsequent clonal expansion 
required for the establishment of cancerous cells. Nevertheless, all cancers can 
be expected to involve disruption of the normal restraint on cell proliferation 
and cell death (Alberts et al., 2002). Furthermore, despite the randomness of the 
mutation process and the variability of causes leading to cancer, a relatively 
predictable set of genes may be expected to mutate for the acquisition of the 
malignant phenotype (Evans, 1991; McCormick, 1999; Bertram, 2001). Cancer 
metastasis appears to be accounted for by deregulation of expression of so-
called “metastasis genes” (Weber and Ashkar, 2000) which aid the 
immobilisation of tumour cells from the primary tumour cell mass to invade 
throughout the body. These genes include those that encode proteolysis factors 
(e.g. serine proteases, metallo-proteases and cathepsins), angiogenic factors (e.g. 
vascular endothelial growth factor) and factors related to cell adhesion and 
migration (Mignatti and Rifkin, 1993; Andreasen et al., 1997; Murphy et al., 
2000; Weber and Ashkar, 2000; Chapman and Wei, 2001). 
1.3. GENERAL MECHANISMS OF INVASION 
The general steps for metastasis are similar for cells derived from all solid 
tumours (Woodhouse et al., 1997). This involves the detachment of invasive 
tumour cells from the primary tumour site, invasion through surrounding 
tissue and invasion into blood/lymph vessels (Figure 2). These cells migrate 
through the circulatory system to a distance locus. Adhesion of the migrating 
tumour cells to a tissue is the first step for the establishment of a new tumour 
site where invasion of the new hosting tissue via proteolysis and proliferation is 
induced to form a new tumour cell mass (Andreasen et al., 1997; Woodhouse et 
al., 1997; Wang, 2001). 
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Figure 2: Schematic representation of the general mechanism of tumour-cell 
invasion and metastasis 
Tumour cells proliferate to form the primary tumour mass (A), this may encourage the 
growth of new blood vessels (angiogenesis) that will nourish the tumour (B). Cancerous 
cells may detach from the primary tumour mass and invade through tissue barriers and 
blood/lymph-vessel wall to enter the blood/lymph circulatory systems (C). These 
migrating malignant cells may adhere to capillary walls of blood vessels or lymph nodes 
in a distant tissue (D) then proliferate and invade through the tissue leading to the 
formation of new tumour sites (metastates). 
At the cellular level, tumour cell invasion requires local proteolysis at the 
leading edge of the cells to clear the ECM in front of its path (Figure 3 – A and 
B). For the cell to move into the area of lysis, the leading edge must attach 
(adhere) to the ECM, thus proteolysis at the leading edge is stopped (Figure 3 - 
B and C). Proteolysis then occurs at the rear end to detach the cell (Figure 3 – C 
and D) and forward-movement results as intracellular contractions occur in the 
direction of the leading edge (Figure 3 – D and E) (Woodhouse et al., 1997). 






regulated events of proteolysis/adhesion (detachment/attachment) coupled with 
contractions of the intracellular filaments (cytoskeleton) mimicking 








Figure 3: Tumour cell invasion through the extracellular matrix 
Migrating tumour cells adhere to the ECM of a selected tissue (A) and proteolysis at the 
leading front of the cell breaks the ‘front’ attachments and clears the ECM in front of 
the cell (B). Proteolysis at this side of the cell is stopped and the leading front adheres 
deeply into the cleared ECM (C). Proteolysis at the latter end of the cell breaks the ‘back’ 
attachments (D) and forward (into the ECM) movement occurs as a result of 
intracellular cytoskeletal rearrangements (E). 
Proteolytic processes, coupled with invasion and adhesion, are also 
necessary for normal physiological functions in the body, including normal 
blood vessel maintenance, angiogenesis, clot formation and dissolution, tissue 
growth, tissue remodelling (morphogenesis), embryogenesis and ovulation 
(Woodhouse et al., 1997; Wang, 2001). It is important to note here that there 
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are no qualitative differences between tumour cells and normal cells with 
respect to the basic processes of cell detachment, migration, invasion and the 
formation of colonies at distant sites. However, the moment and the place of the 
expression of these characters by tumour cells are incompatible with normal 
cellular activities (see reviews by Werb et al., 1990; Liotta et al., 1991; van Roy 
and Mareel, 1992; Andreasen et al., 1997). 
Tumour cell invasion into the surrounding ECM is facilitated by a variety 
of cell surface-associated proteolytic enzymes. The ECM degrading proteinases 
can be divided into three major classes: metalloproteinases (MMPs: 
Collagenases, gelatinases and stromelysins), cysteine proteinases (cathepsins B 
and L, and the aspartyl protease cathepsin D) and serine proteinases (reviewed 
by Danø et al., 1985; Liotta et al., 1991; Mignatti and Rifkin, 1993; Andreasen et 
al., 1997; Schmitt et al., 2000; Wang, 2001). New classes of proteinases include 
the transmembrane serine protease matriptase (Wu, 2003) and membrane-type 
metalloproteinases (MT-MMPs) (Zucker et al., 2003). The remainder of this 
thesis focuses on the plasminogen activation system, a cascade of serine 
proteases. This system, which plays an important role under normal 
physiological conditions such as tissue remodelling, ovulation and wound 
healing, has been described as a central pathway exploited by a variety of 
cancer-related processes (Andreasen et al., 1997; Schmitt et al., 2000). 
1.4. PLASMINOGEN ACTIVATION SYSTEM: MAIN COMPONENTS AND 
THEIR INTERACTIONS 
1.4.A. PLASMINOGEN/PLASMIN 
Plasminogen is the single-chain glycoprotein, zymogen form of plasmin 
with an activity that is at least several hundred-fold lower than that of plasmin. 
Plasminogen is produced mainly in the liver and its concentration in the blood 
plasma is approximately 2 µM, but about 40 % of plasminogen is localised 
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extravascularly (see reviews by Collen, 1980; Danø et al., 1985; Saksela and 
Rifkin, 1988; Mignatti and Rifkin, 1993). Plasminogen is 709 amino acids long 
with a molecular weight of 92 kDa (Wiman, 1973, 1977; Sottrup-Jensen et al., 
1978). This zymogen can be observed in several isoforms; the native mature 
circulatory form is called glu-plasminogen for the glutamic acid at the amino 
terminus (Wallèn and Wiman, 1975). This form can be converted to the lys-
plasminogen form by cleavages at Arg67-Met68, Lys76-Lys77 and Lys77-Val78 by 
plasmin (Wallèn and Wiman, 1972; Collen and DeMaeyer, 1975; Lijnen and 
Collen, 1982). The conversion from glu-plasminogen to lys-plasminogen induces 
large conformational changes (Violand et al., 1978) resulting in increased rate of 
conversion from lys-plasminogen to plasmin compared to conversion of glu-
plasminogen to plasmin (Claeys and Vermylen, 1974). 
Plasminogen is cleaved by plasminogen activators at the Arg560–Val561 
bond resulting in plasmin (~ 90 kDa), consisting of A and B chains linked by 
two disulfide bridges (reviews by Andreasen et al., 1997; Ranson and 
Andronicos, 2003). The C-terminal B-chain contains the serine proteinase 
domain responsible for the catalytic activity of the active site which comprises 
the amino acids His602, Asp645 and Ser740 (Sottrup-Jensen et al., 1978). The N-
terminal A-chain contains 5 kringle domains which are triple loop structures 
that can bind to lysine (Sottrup-Jensen et al., 1978) or lysine analogues such as 
ε-amino caproic acid (EACA: Markus et al., 1978) and tranexamic acid (Markus 
et al., 1979). The kringle domains also allow the binding of 
plasminogen/plasmin to lysine residues available on the cell surface or to 
components of the ECM. Candidate plasminogen/plasmin cellular receptors 
include tetranectin, α-enolase, actin and cytokeratin 8 (see reviews by Félez, 1998; 
Ranson and Andronicos, 2003). Binding to receptors significantly enhances the 
rate of plasminogen activation (Andronicos and Ranson, 2001). Plasmin has 
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broad substrate specificity and is able to degrade many ECM proteins, such as 
fibronectin, vitronectin, fibrin and activate zymogen forms of several 
metalloproteinases (reviews by Andreasen et al., 1997; Ranson and Andronicos, 
2003). Plasmin is also responsible for the release of latent growth/angiogenic 
factors from the ECM (Bass and Ellis, 2002; Rakic et al., 2003). 
1.4.B. PLASMINOGEN ACTIVATORS 
1.4.B.1. UROKINASE-TYPE PLASMINOGEN ACTIVATOR 
Urokinase-type plasminogen activator (uPA) is synthesised as a single-
chain, 411-amino acids-long glycoprotein in the proenzyme form (pro-uPA or sc-
uPA), with a molecular weight of ~ 50 kDa (Gunzler et al., 1982a; Gunzler et al., 
1982b). uPA was initially found in human urine, then in human blood, seminal 
fluids as well as many cancer tissues (Danø et al., 1985). The human blood 
plasma concentration of uPA is around 20 pM and mostly complexed with PAI-1 
while the remaining fraction is in the zymogen form (see review by Andreasen et 
al., 1997). uPA is produced by several cell types in vitro including hepatocytes 
(Busso et al., 1994), monocytes, granulocytes and lymphocytes (Carpén et al., 
1986). Pro- or sc-uPA is several hundred-fold less active than uPA (reviews by 
Andreasen et al., 1997; Schmitt et al., 2000). uPA (also called two chain uPA [tc-
uPA] or high molecular weight [HMW] uPA) consists of two polypeptide chains 
which are linked by a disulfide bridge. Conversion of pro-uPA to uPA occurs by 
cleavage of the peptide bond Lys158–Ile159 (reviewed in Andreasen et al., 1997) 
(Figure 4). The conversion of pro-uPA to uPA can be catalysed by plasmin (see 
review by Danø et al., 1985). Other proteinases also have been reported to 
catalyse this activation, at least in vitro (reviews by Andreasen et al., 1997; 
Schmitt et al., 2000): e.g. plasma kallikrein and blood coagulation factor XIIa 
(Ichinose et al., 1986), two trypsin-like proteinases purified from human ovarian 
tumours (Koivunen et al., 1989), T cell–associated serine proteinase (Brunner et 
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al., 1990), cathepsin B (Kobayashi et al., 1991), cathepsin L (Goretzki et al., 
1992), nerve growth factor-γ (Wolf et al., 1993), human mast cell tryptase (Stack 
and Johnson, 1994), prostate-specific antigen (Yoshida et al., 1995) and 
matriptase (Lee et al., 2000). As shown in Figure 4, alternative proteolysis at 
positions preceding the disulfide bridge gives rise to low molecular weight uPA 
(LMW-uPA). Low-molecular weight uPA occurring in urine arises by cleavage 
between Lys135 and Lys136 by unknown proteases and generates a 33 kDa 
molecule that can not bind to its receptor but is still active (Steffens et al., 
1982). The matrix metalloproteinase Pump-1 cleaves the Glu143–Leu144 bond to 























Figure 4: Structure and activation of pro-uPA 
The top panel shows a cartoon representation of pro-uPA as a single-chain polypeptide. 
The domains from the amino-terminus to the carboxyl-terminus include: (i) growth 
factor-like domain (GFD; G for short), (ii) kringle domain (K) and (iii) the serine 
proteinase domain (SPD). The amino-terminal fragment (ATF) in the GFD is 16 amino 
acids long (residues 14 – 30). The bottom panel describes (1) the proteolysis of pro-uPA 
which leads to the formation of two-chain, disulfide-linked, high molecular weight active 
uPA. (2) Proteolysis of pro-uPA at positions NH3-terminal to the disulfide bridge (S-S) 
produces low molecular weight uPA. 
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The two polypeptide chains of active uPA are called the A- and B-chains. 
The N-terminal A-chain is 158 amino acids long (24 kDa) and contains a kringle 
domain (Gunzler et al., 1982b) and a growth factor-like domain (GFD) which is 
homologous to epidermal growth factor (EGF) and transforming growth factor-α 
(TGF-α) (Gunzler et al., 1982b). The A-chain of uPA contains a 16 amino acid 
residues-domain (residues 14 – 30) within the GFD, termed the amino terminal 
fragment (ATF), which is required for binding of uPA to uPAR (Appella and Blasi, 
1987; Appella et al., 1987). The C-terminal B-chain is 253 amino acids long (30 
kDa) and contains the serine proteinase domain (SPD) with the active-site 
catalytic triad composed of His204, Asp255 and Ser356 (Strassburger et al., 1983; 
Verde et al., 1984). 
uPA has a restricted substrate specificity with plasminogen being the 
main substrate (reviews by Danø et al., 1985; Saksela and Rifkin, 1988; 
Mignatti and Rifkin, 1993). However, uPA is also able to catalyse the activation 
of hepatocyte growth factor/scatter factor (HGF/SF) (Naldini et al., 1992; Mars 
et al., 1993) and the latent from of membrane type 1 matrix metalloprotease 
(Kazes et al., 1998), as well as directly cleave uPAR (Høyer-Hansen et al., 1992) 
and fibronectin (Quigley et al., 1987; Gold et al., 1989). 
1.4.B.2. TISSUE-TYPE PLASMINOGEN ACTIVATOR 
Tissue-type plasminogen activator (tPA) is a 70 kDa glycoprotein 
containing 527 amino acids (Rijken, 1995) and, like uPA, is secreted as a single 
chain zymogen (sc-tPA) (Pennica et al., 1983; Fisher et al., 1985). tPA was 
originally identified in tissue extracts and later found in human uterus, plasma 
and conditioned cell culture fluids (Gerard et al., 1986; Lill, 1987). The 
concentration of tPA in human plasma is 5 – 10 ng/ml (van Hinsbergh et al., 
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1991; Lijnen and Collen, 1995; Rijken, 1995). tPA is also synthesised by other 
cell types in vitro such as mast cells (Sillaber et al., 1999). 
Cleavage of the Arg275-Ile276 bond is required for the generation of the 
active two-chain tPA which consists of A- and B-chains held together by a 
disulfide bridge. The N-terminal A-chain contains the active site of tPA 
(Hoylaerts et al., 1982), which also contains a classical serine protease catalytic 
triad (His322, Asp371 and Ser478) (Pennica et al., 1983). The C-terminal B-chain 
contains a fibrin binding domain (also called terminal finger domain, residues 
6-43) (Holvoet et al., 1986), growth factor-like domain (residues 44-91), kringle 2 
between residues 91-173 and kringle 1 between residues 180-261 (Rijken, 
1995). The ability of tPA to bind to fibrin is primarily attributed to the second 
kringle and partly to the finger domain (van Zonneveld et al., 1986b, 1986a; 
Verheijen et al., 1986). Fibrin binding is required for acquiring fully active tPA 
(Hoylaerts et al., 1982) and the A-chain is necessary for this stimulation (Rijken 
and Groeneveld, 1986). 
1.4.B.3. UPA VERSUS TPA 
Although both catalyse the production of plasmin, uPA and tPA are 
independent gene products with distinctive structural and functional properties 
as their protein and complement DNA (cDNA) sequences are quite different 
(Pennica et al., 1983). They only share 40 % homology at the amino acid level 
(Degen et al., 1986). 
In contrast to pro-uPA that has little or no activity, pro-tPA has 
amidolytic activity, binds to fibrin (Higgins and Vehar, 1987), can activate 
plasminogen in the presence of fibrin and is inhibited with plasminogen 
activator inhibitors (Bachmann and Kruithof, 1984; Danø et al., 1985; Hekman 
and Loskutoff, 1987). In vivo, uPA operates as a fibrin-independent, cellular 
receptor-bound activator, whereas tPA functions as a fibrin-dependent 
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circulatory (blood) activation enzyme (review by Chapman, 1997) though it can 
bind to Annexin-II on endothelial cells (Kim and Hajjar, 2002). 
As discussed earlier (Section 1.3), proteolytic activity on the cell-surface 
(pericellular proteolysis) plays a vital role in cancer metastasis. uPA binds to its 
cellular receptor whereas plasma uPA is usually complexed and inhibited by 
PAI-1. Thus, this plasminogen activator primarily functions on the cell surface 
and is a central molecule for the activation of plasmin-dependent pericellular 
proteolysis. The rest of this review addresses the urokinase-type plasminogen 
activation pathway; however, it is appreciated that tPA may have significant 
functions in certain cancer types such as melanoma (Bizik et al., 1996; de Vries 
et al., 1996). 
 
1.4.C. UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR 
Specific and high-affinity binding of uPA was first described and detected 
in human blood monocytes (Vassalli et al., 1985) and the lymphoma cell line 
U937 (Stoppelli et al., 1985). Nielsen et al. (1988) purified and characterised the 
membrane protein responsible for this binding from U937 cells, designated as 
uPAR. The binding of uPA to its cell-surface receptor, in vitro  (Ellis et al., 1991) 
and in vivo (Quax et al., 1991b), significantly increases (at least 20-fold) the rate 
of its catalytic activity towards plasminogen. This indicates that uPAR plays an 
important role in localising uPA activity on the cell surface and is a key player in 
directing uPA-mediated pericellular proteolysis. 
1.4.C.1. GENE STRUCTURE 
uPAR cDNA (1.4 kilo base pairs [kb]) was cloned from the human 
lymphoma cell line U937 (Roldan et al., 1990) and the gene mapped to 
chromosome 19q13.2 (Webb et al., 1994). uPAR cDNA was also cloned from 
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murine (Kristensen et al., 1991) and bovine (Krätzschmar et al., 1993) sources. 
The amino acid sequences from these cDNAs are similar to the sequence of the 
three domains of the human uPAR (see structure in Section 1.4.C.2.). The 
interspecies conservation at the amino acid level of individual repeats in the 
domains is more than 60 % (Ploug and Ellis, 1994). 
1.4.C.2. PROTEIN STRUCTURE 
uPAR is a 55 - 60 kDa cysteine-rich glycoprotein attached to the plasma 
membrane via a covalent linkage of its C-terminus to a glycosyl phosphatidyl 
inositol (GPI) anchor (Nielsen et al., 1988). The GPI anchor is added during 
posttranslational processing involving C-terminal truncation of the primary 
translation product (Ploug et al., 1991a; Ploug et al., 1991b; Møller et al., 1992). 
The nascent uPAR is translated as a 313 amino acid peptide and preceded by a 
21 amino acid signal peptide. The mature uPAR protein is highly glycosylated 
and decreases to 35 kDa upon deglycosylation; consistent with the fact that its 
amino acid sequence contains 3 potential glycosylation sites (Behrendt et al., 
1990; Roldan et al., 1990). 
uPAR consists of three homologous cysteine-rich repeats of about 90 
amino acids each (3 domains, Figure 5). The consensus motif of each domain is 
characterised by a unique pattern of cysteine residues common to other 
proteins of the Ly6 superfamily (Ploug and Ellis, 1994). Stable receptor 
fragments can be produced by limited proteolysis (Behrendt et al., 1991; Ploug 
et al., 1993; Behrendt et al., 1996), which is consistent with the presence of the 
three domains. The disulfide bridge pattern of the N-terminal domain 1 was 
determined and found to be similar to that of α-neurotoxins from snake venoms 
(Ploug et al., 1993; Ohkura et al., 1994). On this basis, Ploug and Ellis (1994) 













Figure 5: The structure of urokinase receptor, uPAR 
The primary sequence of human uPAR polypeptide is shown as encircled amino acids in 
the single letter code and disulphide-bonded cysteine residues are joined by a black bar 
(Ploug and Ellis, 1994). The three domains (D1, D2 and D3) are marked according to 
Ploug and Ellis (1994) and to date the crystal structure of uPAR has not been resolved. 
The uPA-binding residues (7-residue-long Ω loop) are shown; NH2 and COOH represent 
the amino- and carboxyl- termini, respectively. Inset: schematic representation of the 
GPI-anchored uPAR where the GPI anchorage is added during posttranslational 
processing. 
1.4.C.3. UPA/UPAR BINDING 
The binding affinity (dissociation constant, Kd) for the uPA/uPAR 
interaction varies between 0.1 – 1 nM depending on cell type and assay 
conditions (e.g. Nykjær et al., 1994). Pro-uPA and uPA bind to uPAR with similar 
affinity (Cubellis et al., 1986) via their ATF (residues 14 – 30) (Stoppelli et al., 
1985; Appella and Blasi, 1987; Appella et al., 1987). The uPA-binding residues 
of uPAR are located at one side of a 7-residue-long loop (Ω loop, see Figure 5) in 
domain 1 (Behrendt et al., 1991; Ploug et al., 1995; Magdolen et al., 1996). Two 
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sub-regions within domain 1 of uPAR are critical for uPA recognition (Pöllänen, 
1993) and residue 57 in uPAR is specifically involved in binding (Ploug et al., 
1995). The other two domains (2 and 3: residues 88-283) do not have detectable 
uPA binding activity, however inter-domain interactions contribute critically to 
the binding as the affinity of uPA to isolated domain 1 is approximately 1500-
fold lower than that to the intact receptor (Ploug and Ellis, 1994; Behrendt et 
al., 1996). 
Bound uPA can cleave uPAR after Arg83 and Arg89 in the linker region 
between domains 1 and 2 and lead to the release of the uPA binding region 
(Høyer-Hansen et al., 1992; Høyer-Hansen et al., 1997b). GPI-uPAR has a much 
higher susceptibility to uPA-mediated cleavage than soluble forms of uPAR that 
lack the GPI moiety (Høyer-Hansen et al., 2001). Furthermore, uPA-mediated 
cleavage of GPI-uPAR is accelerated on the cell surface and the specific receptor 
binding of active uPA is required for the high-efficiency cleavage (Høyer-Hansen 
et al., 1997b). This form of cleaved uPAR has been identified on several cell lines 
of neoplastic origin (Høyer-Hansen et al., 1992; Solberg et al., 1994; Høyer-
Hansen et al., 1997b; Ragno et al., 1998) and in extracts of experimental 
tumours (Solberg et al., 1994). Since domain 1 of uPAR contains the binding 
site for uPA and, as discussed later (Sections 1.5 and 1.6), intact uPAR is 
required for uPAR/vitronectin-mediated adhesion, the release of domain 1 of 
uPAR by uPA-mediated cleavage is thus likely to affect both pericellular 
proteolysis and adhesion (Wei et al., 1994; Kanse et al., 1996; Høyer-Hansen et 
al., 1997a; Høyer-Hansen et al., 1997b). Høyer-Hansen et al. (1997a) postulated 
that the cleavage and release of domain 1 of uPAR represents an in vivo 
regulatory step. Domain 1-deleted uPAR was detected in vivo in uPA/uPAR-
overexpressing transgenic mice and was related to keratinocyte differentiation 
and lowered pericellular proteolytic activity (Zhou et al., 2000). 
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1.4.C.4. SOLUBLE UPAR 
A soluble form of uPAR (suPAR) has been identified in the plasma of 
healthy individuals (Rønne et al., 1995) and the level of suPAR is elevated in 
patients with some types of cancers (see Section 1.7.). Soluble uPAR (suPAR) 
may be generated by alternative splicing of the uPAR messenger (m)RNA (Pyke et 
al., 1993). suPAR functions as a chemoattractant after cleavage between 
domains 1 and 2 by any of a number of proteinases, including uPA, plasmin or 
chymotrypsin (Resnati et al., 1996). Currently, the role of suPAR in modulating 
cancer progression is thought to ensue by either scavenging uPA or alternatively 
regulating cell signaling (Resnati et al., 1996; Fazioli et al., 1997; Aguirre Ghiso 
et al., 1999b; Degryse et al., 1999; Nguyen et al., 2000; Jo et al., 2003). 
 
 
1.4.D. SERINE PROTEASE INHIBITORS 
In general, proteinase inhibitors represent more than 10 % of total 
protein in human plasma of which the majority regulate serine proteases 
(reviewed by Travis et al., 1990). The serine protease inhibitor (serpin) 
superfamily includes non-inhibitory serpins and inhibitors of various serine 
proteases. They are single chain proteins containing conserved domain 
structure with 80 % of their amino acids organised in secondary elements 
including 7 – 9 α-helices (lettered A - I) and β-sheets A, B and C (see reviews by 
Travis et al., 1990; Gettins et al., 1992; Potempa et al., 1994; Stein and Carrell, 
1995; Whisstock et al., 1998; Silverman et al., 2001). The most important 
feature of inhibitory serpins is the presence of a reactive centre loop (RCL) 
exposed on the surface of the protein which is essential for the inhibitory 
mechanism of these inhibitors. 
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1.4.D.1. INHIBITORY MECHANISM OF SERPINS 
Serpins are mechanism-based enzyme inhibitors (also called suicide 
inhibitors) since they irreversibly inhibit their target proteinase by forming a 
covalent bond with the proteinase. According to Silverman (1996), this class of 
inhibitors is characterised by their ability to bind to the enzyme where the 
enzyme acts on the inhibitor as a substrate. Both the enzyme and the inhibitor 
are then trapped in an inactivated state due to the formation of a covalent bond 
between the inhibitor and the enzyme. Sufficient evidence indicates that the 
mechanism of action of serpins on their target proteinases involves such events 
(see reviews by Travis et al., 1990; Gettins et al., 1992; Potempa et al., 1994; 
Stein and Carrell, 1995; Whisstock et al., 1998; Silverman et al., 2001). The 
events of this mechanism is described below and illustrated in Figures 6 and 7. 
The amino acid sequence of the RCL is the most variable region among 
serpins and minor changes within this loop greatly affects the inhibitor 
specificity (Travis et al., 1990). Serpins have a single reactive site in the RCL 
loop and the amino acids in this region are numbered as …P3-P2-P1-P1`-P2`-P3`-
…-COOH, where the reactive site is the bond between P1 and P1` (review by 
Gettins et al., 1992). This specific bond in the RCL of the serpin (called the 
reactive centre peptide bond, RCPB) provides a pseudo-substrate for the target 
proteinase and, as described next, the enzyme is trapped in an inactive form 
(Andreasen et al., 1997). The serpin initially forms a non-covalent Michaelis-like 
(reversible) complex with the target proteinase by the interaction of the RCL of 
the serpin with the active site of the enzyme (Figure 6 – A and B). The serine 
residue in the active-site of the proteinase attacks the P1-P1` bond (RCPB) of the 
serpin and this bond is cleaved then a covalent linkage is formed between the 
serine residue and the backbone carbonyl of the P1 residue of the serpin. The 
RCL starts to insert into β-sheets A of the serpin and upon complete loop 
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insertion the proteinase/serpin undergo conformational changes, Figure 6 – C, 
where the active site of the enzyme is distorted and the serpin is in high 
conformational-stability state (reviewed by Silverman et al., 2001). The net 
result of the conformational rearrangements is the kinetic trapping of the acyl 
intermediate complex between the serpin and its target (Lawrence et al., 1995; 
Wilczynska et al., 1995). This rearrangement, also called the stressed (S) to 
relaxed (R) transition (Whisstock et al., 1998), is essential for efficient inhibition 
and formation of the stable final complex. The N-terminal portion of the RCL is 
critical for the inhibition mechanism (Chaillan-Huntington et al., 1997) and 
variation in the length of this portion of the RCL markedly reduces the efficiency 
of inhibition and the stability of the final complex (Zhou et al., 2001). 
 





Figure 6: Inhibitory mechanism of serpins and associated conformational changes 
The active serpin (A) in the S state (native) interacts with the active site of the proteinase via the serpin’s RCL (shown in red) to form the initial 
Michaelis-like complex (B). The proteinase cleaves the P1-P1` bond in the RCL of the serpin and a covalent bond is formed between the carbonyl group of 
the P1 residue and the serine residue of the enzyme. This acyl-enzyme intermediate is trapped in a kinetically stable state (R state, C) by conformational 
changes in the serpin structure where the RCL inserts as a β-sheet (shown in red) between the β-sheets A of the serpin (shown in yellow). The 
coordinates of the structures shown are available from Protein Data Bank (PDB: http://www.rcsb.org/pdb) and represent: (A) native α1-antitrypsin 
(α1AT, PDB entry 1QLP), (B) Michaelis-like complex between Serpin 1 and trypsin (PDB entry 1I99) and (C) covalent complex between α1AT and trypsin 




The pathway discussed above describes the complete inhibition of the 
target proteinase and the formation of covalently-bound, sodium dodecyl 
sulphate (SDS)-stable 1:1 stoichiometric serpin:proteinase complex. 
Nevertheless, some evidence suggests that in some cases, due to unusual 
stabilisation of the initial Michaelis-like complex, progression of the reaction is 
blocked and the inhibition of the enzyme by the serpin is reversible (Travis et 
al., 1990; Potempa et al., 1994; Silverman et al., 2001). Furthermore, 
experimental data also show that, in some cases, the serpin acts in a non-
inhibitory pathway, where the active proteinase cleaves the serpin and the 
inactive serpin is released before loop insertion occurs (Silverman et al., 2001). 
This results in release of active proteinase and inactivated serpin where the 
proteinase reacted on the serpin as a substrate. In summary, as shown in 
Figure 7, the current model for serpin mechanism of action describes an initial 
reversible interaction between the serpin (I) and the proteinase (P) to form a 
short-lived Michaelis-like complex (IP). The carbonyl group of P1 residue of the 
serpin is attacked by the active-site serine residue of the protease. The P1-P1` 
bond is cleaved and through a tetrahedral transition state the reaction proceeds 
to produce the acyl-enzyme intermediate complex (IP*). The serpin then 
undergoes the dramatic conformational change and loop insertion to produce 
the stable inhibited serpin/proteinase complex (IPcpx). If loop insertion is not 
rapid enough to compete with de-acylation, then the reaction proceeds to 
produced cleaved inactivated serpin (I*) and active enzyme (E) mimicking the 
normal pathway for the serine protease acting on its substrate. 
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Figure 7: Inhibitory pathway of serpin 
Inhibitory serpins (I) interact with the target proteinase (P) and form the initial 
reversible, short lived Michaelis-like complex (IP). The association/dissociation rates of 
this complex are described by kon and koff, respectively. The acyl-enzyme intermediate 
complex (IP*) is formed at a rate of k2 through a tetrahedral transition state after the 
cleavage of the P1-P1` of the serpin by the active-site serine residue of the proteinase. 
The serpin then undergoes dramatic conformational change and loop insertion to 
produce the stable inhibited serpin/proteinase complex (IPcpx) at a rate of k4. 
Alternatively, the reaction proceeds to produced cleaved inactivated serpin (I*) (i.e. de-
acylation) and active enzyme (E) at a rate of k3 mimicking the normal pathway for the 
serine protease acting on its substrate. The final fate of the acyl-enzyme intermediate 
complex (IP*) depends on whether the rate of loop insertion (k4) can compete with the 
rate of de-acylation (k3). The Figure was modified from Zhou et al. (2001). 
 
 
Loop insertion is not only essential for the inhibitory mechanism of 
serpins, but also plays a role in serpin biology. For example, some serpins may 
adopt an alternative conformation compared to that of the native form (active ‘S’ 
state, Figure 6 - A) where the RCL is inserted into β-sheets A as in the cleaved 
form. This latent form of serpins, Figure 8 – A, is inactive and requires specific 
interaction to produce the active form which can interact with target proteinase 
and produce the cleaved (‘R’ state, Figure 8 – B) (reviewed by Whisstock et al., 
1998; Silverman et al., 2001). Another consequence of serpins’ conformational 
elasticity is the formation of dimers, which are commonly observed under 
certain conditions and explained by loop insertion from one serpin molecule into 




Figure 8: Conformations of serpins 
Serpins adopt three conformational states. The native ‘S’ state where the serpin is active and the RCL is exposed for reaction with target proteinase (see 
Figure 6 – A), (A) the latent conformation where the RCL (shown in red) inserts in the β-sheets A (shown in yellow) and (B) the ‘R’ state where the P1-P1` 
bond is cleaved (by proteinase) and the RCL is inserted into the β-sheets A. The latent conformation resembles the ‘R’ cleaved state; however it can be 
converted to the active native state under certain conditions since bond cleavage has not occurred. The structures were modelled using Swiss-
PdbViewer from the coordinate files of A: latent anti-thrombin III (PDB entry 2ANT) and B: cleaved α1-antitrypsin (PDB entry 7API). 
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The serpin superfamily includes various members from different 
organisms. Only the function and biology of serpins related to the urokinase-
plasminogen activation pathway will be reviewed here. For a list of other serpins 
and their targets see reviews by Potempa et al. (1994), Whisstock et al. (1998) 
and Silverman et al. (2001). PAI-1, PAI-2 and α2AP belong to the serpin 
superfamily and while PAI-1 and PAI-2 target both uPA and tPA, α2AP is the 
primary inhibitor of plasmin. Two other serpins, proteinase nexin-1 (PN-1) and 
protein C inhibitor (PCI), also inhibit uPA and tPA at physiologically relevant 
rates, though they are not specific and react more slowly with these proteinases 
than PAI-1 and PAI-2 (Sprengers and Kluft, 1987; España et al., 1993a; España 
et al., 1993b). The crystal structures of both PAI-1 (Nar et al., 2000) and PAI-2 
(Jankova et al., 2001; Saunders et al., 2001) confirm that these act as classic 
serpins and form SDS-stable 1:1 stoichiometric complexes with the catalytic site 
on their target protease. Since one of the aims of this thesis relates to targeting 
the urokinase-type plasminogen activation pathway as a potential anti-cancer 
strategy, the following sections only address the two main inhibitors of uPA/tPA 
activities, PAI-1 and PAI-2. 
1.4.D.2. PAI-1 
PAI-1 was first described in conditioned media of human endothelial cells 
(Loskutoff and Edgington, 1977) and later detected in a wide variety of cell types 
(see review by Kruithof, 1988). PAI-1 level in plasma is variable but is 
approximately 20 ng/ml (Kruithof et al., 1987). It is a single chain glycoprotein 
with 379 amino acids (~ 52 kDa) and an isoelectric point (pI) of 4.5 – 5.0 
(Erickson et al., 1984; Andreasen et al., 1986a). The active site is located at 
Arg346-Met347 (Andreasen et al., 1986b; Ny et al., 1986; Sanzo et al., 1987) and 
the sequence contains an amino terminal signal peptide (21 – 23 amino acids) 
that is cleaved in the mature protein (Andreasen et al., 1986b; Ginsburg et al., 
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1986; Ny et al., 1986; Pannekoek et al., 1986; Wun and Kretzmer, 1987). PAI-1 
is highly sensitive to oxidation (Baker et al., 1990b), relatively unstable and 
rapidly converts into the latent conformation at 37oC (Levin and Santell, 1987; 
Mimuro et al., 1987; Reilly et al., 1990). This latent form can be re-activated by 
denaturation (Hekman and Loskutoff, 1985) and heat (Katagiri et al., 1988). 
Interaction of active PAI-1 with the matrix protein vitronectin stabilises PAI-1 in 
this active form and reduces the formation of latent PAI-1 (see Section 1.5.A.2. 
for more details). 
PAI-1 efficiently inhibits tPA and uPA (Erickson et al., 1984; Colucci et 
al., 1986) with similar second order rate constants for both targets; 
approximately 2 x 107 M-1s-1 (Declerck et al., 1988; Thorsen et al., 1988). In the 
presence of vitronectin, the second order rate constant of PAI-1 towards uPA is 
lowered to 7.9 x 106 M-1s-1 (Ellis et al., 1990) and by 35 % towards tPA (Declerck 
et al., 1988). PAI-1 is a less efficient inhibitor of pro-tPA (5.5 x 106 M-1s-1) 
compared to tPA (Thorsen et al., 1988) and inhibition of tPA is lowered when tPA 
is bound to fibrin (Kruithof et al., 1984). Similarly, the second order constant 
towards uPA is lowered when uPA is bound to cell-surface uPAR (4.5 x 106 M-1s-) 
(Ellis et al., 1990). 
1.4.D.3. PAI-2 
PAI-2 inhibitory activity was first described in partially purified extracts 
from human placenta (Kawano et al., 1970). Pure PAI-2 was later prepared from 
placenta and human monocyte/macrophage lineages (see reviews by Dear and 
Medcalf, 1995; Kruithof et al., 1995). PAI-2 exists in two forms; a non-
glycosylated form with a molecular weight of 47 kDa and pI of 5.0 (Kruithof et 
al., 1986) and a 60 kDa glycosylated form with pI of 4.4 (Kruithof et al., 1986; 
Genton et al., 1987; Wohlwend et al., 1987b). These two forms also have distinct 
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cellular localisation; the 47 kDa PAI-2 being intracellular and the 60 kDa PAI-2 
being secreted (Genton et al., 1987; Wohlwend et al., 1987a, 1987b). 
PAI-2 is an efficient inhibitor of uPA (second order rate constant of 106  
M-1s-1) and tPA (2 x 105 M-1s-1) (Kruithof et al., 1986; Thorsen et al., 1988; Mikus 
et al., 1993). The second order rate constant for PAI-2 inhibition of pro-tPA is 
much lower than that of tPA (103 M-1s-1) (Åstedt et al., 1985; Kruithof et al., 
1986) and fibrin bound tPA appears to be protected from inhibition by PAI-2 
(Leung et al., 1987). As in the case of PAI-1, the second order rate constant for 
the inhibition of cell-surface uPAR-bound uPA by PAI-2 is lower than that of 
soluble uPA (Ellis et al., 1990). All together, PAI-2 may be accepted to function 
primarily as an inhibitor of uPA and only has a minor role in controlling tPA-
mediated fibrinolysis. This serpin would preferentially target the urokinase 
plasminogen activation pathway on the cell surface, thus an expanded review of 
the structure/function of PAI-2 is described below. 
1.4.D.3.I. PAI-2 GENE STRUCTURE AND EXPRESSION 
PAI-2 gene is 16.5 kb long and consists of 8 exons and 7 introns located 
on chromosome 18q21-23 (Webb et al., 1987; Webb et al., 1994). Three other 
ov-serpins (see Section 1.4.D.3.II.); squamous cell carcinoma antigen (SCCA-1 
and SCCA-2) genes and the maspin gene, are located 300 kb centromeric from 
the PAI-2 gene (Schneider et al., 1995). In addition, the bcl-2 proto-oncogene, 
regulator of apoptosis (Vaux et al., 1994), lays 600 kb centromeric to the PAI-2 
gene suggesting a role for PAI-2 in apoptosis (Silverman et al., 1991; Schneider 
et al., 1995). 
PAI-2, in both forms, is 415 amino acids long encoded by a single mRNA 
of approximately 2.0 kb length (see reviews by Dear and Medcalf, 1995; Kruithof 
et al., 1995). The transcription initiation site for PAI-2 gene resides between 22 
to 25 base pairs (bp) downstream of a consensuses TATAAAA sequence 
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(Kruithof and Cousin, 1988; Ye et al., 1989; Samia et al., 1990) and the 
promoter region contains two alu repeat sequences, 1390 - 1100 and 870 - 580 
(Kruithof and Cousin, 1988). Two closely spaced activator protein (AP)-1 like 
elements (at -116 to -97) and a cyclic adenosine monophosphate (cAMP) 
response element (CRE)-like element (-189 to -182) in the PAI-2 promoter are 
essential for basal gene transcription and for phorbol ester-mediated induction 
of PAI-2 expression (Cousin et al., 1991). Retinoic acid receptor/glucocorticoid 
element (at -1659 to -1620) mediates the retinoic acid response of the PAI-2 
gene (Schuster et al., 1994). The region around -1150, homologous to dioxin 
response element, may mediate the response of PAI-2 gene to the toxin dioxin 
(Sutter et al., 1991). The sequences at -3.4 and at -4.1 kb in PAI-2 promoter 
bind a protein with a similar size to that of an interferon-gamma activated DNA 
binding element (Antalis et al., 1993). As suggested by the structure and 
characteristics of the promoter of PAI-2, various agents affect the expression of 
PAI-2 gene. These agents are summarised in Figure 9. For more details refer to 
reviews by Bachmann (1995), Dear and Medcalf (1995) and Kruithof et al. 
(1995). 
1.4.D.3.II. PAI-2 BIOCHEMISTRY 
The polypeptide chain of PAI-2 has three potential N-glycosylation sites 
(Asn75, Asn115 and Asn339), which all appear occupied in the glycosylated form of 
PAI-2 (Ye et al., 1988), and the reactive centre (P1-P1`) maps to Arg380-Thr381 
bond (Kiso et al., 1988). There are two common variants of PAI-2 which differ at 
three amino acid positions; Asn120, Asn404 and Ser413 for Type A compared to 
Asp120, Lys404 and Cys413 for Type B (Ye et al., 1987; Ye et al., 1989). The extra 
cysteine in Type B PAI-2 may mediate dimerisation (Mikus et al., 1993) and the 
formation of disulfide bridges with other proteins as that described with 

























Figure 9: Regulation of PAI-2 gene expression 
Agents that affect PAI-2 gene expression are classified in the groups shown in balloons. 
Shaded balloons indicate suppressors of PAI-2 gene expression while the remaining 
(clear) are activators of PAI-2 gene expression (modified from Dear and Medcalf, 1995). 
These agents have been shown experimentally to modulate PAI-2 expression in several 
different cell lines. Abbreviations: EGF: epidermal growth factor, M-CSF: macrophage 
colony stimulating factor, GM-CSF: granulocyte-macrophage colony stimulating factor, 
TNF: tumour necrosis factor, IL-1 and IL-2: interleukin-1 and -2. 
PAI-2 does not have a cleavable signal peptide (Ye et al., 1988; von Heijne 
et al., 1991) as the case in ovalbumin (a non-inhibitory serpin). In fact, evidence 
suggests that PAI-2 belongs to a subfamily of serpins called ov-serpins, which 
includes ovalbumin, chicken gene Y and other serpins (reviewed by Bachmann, 
1995; Silverman et al., 2001). Members of this subfamily show additional amino 
acid sequence homology compared to other serpins, lack N-terminal and C-
terminal extensions, often contain a non-conserved loop between their C and D 
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helices (C-D interhelical region) and lack a cleavable signal peptide (Bachmann, 
1995). As many other ov-serpins, PAI-2 is mainly found intracellularly in almost 
all cell types studied (Genton et al., 1987; Wohlwend et al., 1987b; Medcalf et 
al., 1988a; Medcalf et al., 1988b; Belin et al., 1989). However, extracellular 
traces of PAI-2 under normal conditions were reported and under certain 
conditions secreted PAI-2 may represent a significant part of total PAI-2, 
indicating that cellular targeting of synthesised PAI-2 may be modulated (Ye et 
al., 1988; Quax et al., 1990). The differential translocation of the two forms of 
PAI-2, which are encoded by a single mRNA species, may be explained by the 
presence of two internal hydrophobic signal regions. Increasing the 
hydrophobicity of these regions, which are homologous to an internal 
hydrophobic signal region in ovalbumin, enhances the extracellular 
translocation of PAI-2 (von Heijne et al., 1991; Belin, 1993). These regions may 
explain the secretion of PAI-2 to the endoplasmic reticulum (ER)-Golgi 
apparatus pathway, however other evidence suggests that secretion of PAI-2 by 
monocytes occurs via ER-Golgi-independent and vesicle-independent pathway 
(Ritchie and Booth, 1998). To date, the exact mechanism of PAI-2 secretion is 
unknown. 
1.4.D.3.III. FUNCTIONS OF PAI-2 
The principal known target proteinases of PAI-2 are uPA and tPA. This is 
intriguing considering that PAI-2 is mainly localised intracellularly and its 
secretory pathway is poorly understood. Thus, the physiological role of PAI-2 
has been a subject for research. PAI-2 levels in plasma are normally below 
detection limits, however, intracellular (47 kDa form) and extracellular PAI-2 (60 
kDa form) seem to play physiological roles under certain conditions such as 
pregnancy, cancer, inflammation, diseases and in apoptosis (Dear and Medcalf, 
1995; Kruithof et al., 1995). 
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During pregnancy, plasma concentrations of PAI-2 increase from below 
detection limits to a maximum of 250 ng/ml at term (Kruithof et al., 1987; 
Lecander and Åstedt, 1987; Wright et al., 1988; Koh et al., 1992; Stegnar et al., 
1993; Halligan et al., 1994). Changes in PAI-2 concentration have been shown 
to occur in cases of pre-eclampsia and intrauterine growth retardation, 
indicating a role of PAI-2 in securing hemostasis during pregnancy (reviewed by 
Dear and Medcalf, 1995; Kruithof et al., 1995; Åstedt et al., 1998). This role may 
be related to regulation of uPA activity since PAI-2 cleaved at the reactive centre 
is observed in placental extracts (Kiso et al., 1991). PAI-2 levels are modulated 
during cancer and as discussed in later sections (see Section 1.7); elevated  
PAI-2 levels appear to be a marker of low metastatic activity and good prognosis 
in a few cancer models. Induction of PAI-2 expression by inflammatory 
mediators (e.g. phorbol esters) and down-regulation by anti-inflammatory 
agents (e.g. dexamethasone) suggest a role for PAI-2 in inflammation (Dear and 
Medcalf, 1995; Kruithof et al., 1995). The precise role of the predominant 
intracellular form of PAI-2 is still not clearly elucidated. PAI-2 seems to play a 
role in keratinocytes differentiation (Lavker et al., 1998; Risse et al., 1998; 
Williams et al., 1999; Risse et al., 2000), prevention of apoptosis (Kumar and 
Baglioni, 1991; Jensen et al., 1994; Dickinson et al., 1998; Jensen et al., 1999) 
and protection against viral or bacterial infections (Gan et al., 1995; Antalis et 
al., 1998; Shafren et al., 1999). Recently, a novel intracellular role of PAI-2 as a 
retinoblastoma protein (Rb)-binding protein was reported (Darnell et al., 2003). 
Rb is a ubiquitous regulator of transcription involved in activities such as cell 
cycle control, apoptosis, differentiation and tumour suppression (Harbour and 
Dean, 2000b, 2000a). Binding of PAI-2, via its unique C-D interhelical region, to 
Rb in the nucleus inhibits the turnover of Rb which leads to increase of Rb 
protein levels and activity (Darnell et al., 2003). These recent results provide 
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further insights to the mechanism by which intracellular PAI-2 may mediated 
its effects, however, further work is still required to elucidate the complete roles 
of intracellular PAI-2. 
1.5. THE UROKINASE PLASMINOGEN ACTIVATION PATHWAY: NON-
PROTEOLYTIC FUNCTIONS 
Members of the urokinase-plasminogen activation pathway of the 
plasminogen activation system are associated with other molecules present on 
the cell surface and/or the ECM, which appear to expand the functions of this 
pathway further than just generating proteolytic activity on the cell surface. 
This section addresses these other molecules which associate with this 
pathway. 
1.5.A. VITRONECTIN 
Vitronectin is a 78 kDa glycoprotein that contains a somatomedin B 
domain, an integrin-binding RGD (single-letter amino acid code) sequence, a 
collagen-binding region and two hemopexin-like domains (reviewed by Felding-
Habermann and Cheresh, 1993; Hess et al., 1995). This glycoprotein is 
primarily a circulatory plasma protein (plasma concentration of 4 µM) and it is 
deposited extravascularly in the ECM during injury and repair (Dvorak et al., 
1995; Hess et al., 1995). Plasma vitronectin is in the closed form (native, Figure 
10), while the extended form is believed to be the one deposited in the ECM 
(Hess et al., 1995). Cell-surface receptors of the integrin family (see Section 
1.5.B.), especially those containing αv chain (e.g. αvβ1, αvβ3, αvβ5), bind to the 
RGD sequence of vitronectin (Felding-Habermann and Cheresh, 1993; Schnapp 
et al., 1995). Interestingly, evidence suggests important functional binding 
between vitronectin and components of the urokinase plasminogen activation 
system. 
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Figure 10: Vitronectin structure 
The structures of native (right) closed vitronectin and the active extended vitronectin 
(left) are shown (modified from Andreasen et al., 1997). Abbreviations: Somatomedin B 
domain (SomB), integrin-binding Arginine-Glycine-Aspartic acid sequence (RGD), 
collagen-binding region connecting segment (Con.S) and two hemopexin-like domains 
(HPI and HPII). 
1.5.A.1. UPAR/VITRONECTIN INTERACTION 
uPAR is a high affinity receptor for the matrix (extended) form of 
vitronectin (Wei et al., 1994; Kanse et al., 1996). The vitronectin-binding site on 
uPAR is within domains 2 and 3 (Wei et al., 1994) while the uPAR-binding 
residues on vitronectin are located at the amino-terminal somatomedin B 
domain (Deng et al., 1996; Waltz et al., 1997). Vitronectin-uPAR binding is not 
blocked by RGD peptides, distinguishing this interaction from the known 
integrin–vitronectin interactions (Preissner et al., 1988). Intact uPAR is required 
for efficient vitronectin binding (Høyer-Hansen et al., 1997a) and this binding is 
enhanced by the presence of uPA on uPAR (Wei et al., 1994). This enhancement 
of the adhesion of uPAR to vitronectin is independent of the proteolytic activity 
of uPA (Chang et al., 1998; Sidenius et al., 2002). 
1.5.A.2. PAI-1/VITRONECTIN INTERACTION 
PAI-1 in its native form binds to vitronectin and this binding stabilises 
PAI-1 in active conformation (Reilly et al., 1992), thus protecting PAI-1 from 
converting into its latent form. The amino terminus of vitronectin (Somatomedin 
B domain) is involved in the PAI-1/vitronectin interaction and the binding site 
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for PAI-1 overlaps with those of uPAR and integrins (Seiffert and Loskutoff, 
1991; Royle et al., 2001). This is in agreement with data indicating that active 
PAI-1 blocks uPAR/vitronectin interaction (Deng et al., 1996; Kanse et al., 1996; 
Waltz et al., 1997; Loskutoff et al., 1999) and competition between PAI-1 and 
integrins for binding to vitronectin (Stefansson and Lawrence, 1996; Kjøller et 
al., 1997). 
The quantity of ECM-deposited PAI-1 correlates strongly with the 
availability of ECM-associated vitronectin (Mimuro et al., 1987; Declerck et al., 
1988; Mimuro and Loskutoff, 1989a, 1989b). Furthermore, the distribution of 
PAI-1 in the extracellular space is almost the same as that of vitronectin 
(Barnes et al., 1983; Hayman et al., 1983; Neyfakh et al., 1983). Thus, 
vitronectin appears to function as a ‘carpet’ for presenting active PAI-1 in the 
ECM. The vitronectin-PAI-1 complex dissociates simultaneously with the 
appearance of the inactive enzyme–PAI-1 product upon the reaction of 
vitronectin-associated PAI-1 with uPA or tPA (Declerck et al., 1988; Salonen et 
al., 1989; Hess et al., 1995; Deng et al., 1996). The significance and 
consequences of these interactions are discussed later (Section 1.6.). 
1.5.A.3. UPA/VITRONECTIN INTERACTION 
Moser et al. (1995) showed a concentration-dependent reversible binding 
of uPA to vitronectin in vitro (Kd approximately 97 nM). This binding involves the 
hemopexin domain fragment of vitronectin and the N-terminal fragment of uPA. 
PAI-1 does not compete with uPA for binding to vitronectin, suggesting that 
both molecules may co-localise on vitronectin (Moser et al., 1995). To date, 
functional consequences of uPA binding to vitronectin or co-localisation of uPA 




Integrins are heterodimeric transmembrane glycoprotein receptors 
composed of distinct α and β subunits, which bind to ECM proteins such as 
vitronectin, collagens, fibrin, laminin and fibronectin (Hynes, 1992; Chapman, 
1997). These receptors mediate adhesion of cells to the ECM via RGD moiety as 
well as non-RGD dependent interactions with intracellular signalling proteins 
and cytoskeletal elements (Hemler, 1998). Integrins undergo reversible 
activation upon binding to their ligands. This activation is characterised by 
conformational changes in the extracellular domains, reorganisation of 
intracytoplasmic connections (actin-cytoskeleton) and redistribution of integrins 
on the cell surface (Diamond and Springer, 1994; Yednock et al., 1995). 
A comprehensive study on the association of integrins with uPAR found 
that β1 integrins and uPAR co-localise with close proximity (7 nm) at focal 
contacts between carcinoma cells and fibronectin, laminin or vitronectin 
matrices (Xue et al., 1997). On the other hand, uPAR and β3 integrins co-localise 
only when cells attach to vitronectin. Furthermore, uPAR co-localises with α5 
integrins on cells attached to fibronectin, with α5 and αv integrins on cells 
attached to vitronectin and with α3 and α6 integrins on cells attached to laminin 
(Xue et al., 1997). The formation of complexes between uPAR and β1 integrins 
alters the phenotype (not the expression) of these integrins, thus affecting 
integrin functions (Wei et al., 1996; Wei et al., 2001). uPAR also interacts with 
the β2 integrin CD11b/CD18 (termed Mac-1) (Sitrin et al., 1996) and the 
interaction of β2 integrins with uPAR is essentially identical to that of β1 
integrins and uPAR (Wei et al., 1996). uPAR-dependent adhesion to immobilised 
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vitronectin is enhanced by uPAR-integrin-calveolin* multimeric complexes on 
the cell membranes (Wei et al., 1996; Chapman, 1997) and uPA/uPAR 
complexes are concentrated at these multimeric complexes (Stahl and Mueller, 
1995). 
The association of uPAR with various members of the integrin family and 
its ability to induce their activation indicate additional functions for the 
plasminogen activation pathway. As discussed in Section 1.6., uPAR may 
modulate integrin functions to focus proteolysis at specified sites and utilise the 
intracellular domains of integrins for signal transduction. 
1.5.C. LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) FAMILY 
Currently, there are more than six known mammalian members of the 
low-density lipoprotein receptor family of endocytosis (LDL receptors), which 
mediate the endocytosis of various types of ligands (Nykjær and Willnow, 2002; 
Strickland et al., 2002). Specifically, the α2-macroglobulin receptor/low density 
lipoprotein receptor-related protein (α2MR/LRP), the epithelial glycoprotein 330 
(megalin, gp330) and the very low-density lipoprotein receptor (VLDLR) of the 
LDLR family are known to mediate the endocytosis of components of the 
plasminogen activation system (reviewed by Andreasen et al., 1994; Andreasen 
et al., 1997; Strickland et al., 2002). 
Cell-surface uPAR-bound uPA/PAI-1 complex is rapidly internalised and 
degraded in lysosomes in a process mediated by α2MR/LRP (Cubellis et al., 
1990; Jensen et al., 1990; Nykjær and Willnow, 2002), gp330 (Moestrup et al., 
1993) and VLDLR (Argraves et al., 1995; Heegaard et al., 1995). Similarly, PAI-1 
mediates binding of tPA to α2MR/LRP (Owensby et al., 1989; Owensby et al., 
                                          
* Caveolae are plasma membrane structures that contain calveolin; a protein associated 
with intracellular signalling pathways and cytoskeletal elements. 
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1991; Bu et al., 1993; Grobmyer et al., 1993) and gp330 (Willnow et al., 1992) 
and these complexes are internalised and degraded. The uPA/PN-1 complex and 
the uPA/PCI complex are also endocytosed by α2MR/LRP and VLDLR (Conese et 
al., 1994). The endocytosis of uPA:PAI-2 complexes was only recently illustrated 
by definitive evidence (see Chapter 4, Al-Ejeh et al., 2004). The internalisation of 
uPA:PAI-2 complexes is mediated in part by members of the LDLR family; 
however, other mediators seem to play a role in this internalisation (see Chapter 
4 for more details). 
1.5.D. INTERACTION WITH SIGNALLING MOLECULES 
Studies indicate that uPAR transmits intracellular signals despite the 
lack of transmembrane structure in this extracellularly GPI-anchored receptor. 
The expression of uPAR and its ability to bind uPA are required for such 
signalling (Resnati et al., 1996) and uPA-mediated signalling is independent of 
its proteolytic activity (Sidenius et al., 2002; Liu et al., 2003). To date, molecular 
adaptors that may mediate uPAR signalling include integrins, calveolin and G-
protein-coupled receptor (GPCR) (reviewed by Ossowski and Aguirre-Ghiso, 
2000; Blasi and Carmeliet, 2002). Other less defined signal mediators have been 
proposed to mediate uPAR signalling such as α2MR/LRP and mannose-6-
phosphate/insulin-like growth factor II receptor (Blasi and Carmeliet, 2002). 
The uPA-uPAR/mediator association have been shown to modulate 
several signalling pathways. It is beyond the scope of this thesis to discuss the 
growing evidence of the signalling role of uPA/uPAR complexes (For more details 
see reviews by Conese and Blasi, 1995; Andreasen et al., 1997; Chapman, 1997; 
Dear and Medcalf, 1998; Konakova et al., 1998; Preissner et al., 2000; Blasi and 
Carmeliet, 2002). In brief, however, signalling pathways which are linked to 
uPA/uPAR include cytosolic kinase pathways (tyrosine kinases, 
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serine/threonine kinases and protein kinase C), focal adhesion kinase (FAK) 
pathway, extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) pathway, intracellular calcium mobilisation, Src (sarcoma) family 
kinases, Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) in addition to cytoskeletal elements such as vinculin and actin. 
These signalling pathways regulate the proteolytic as well as the non-proteolytic 
functions of the urokinase plasminogen pathway such as cellular adhesion, 
chemotaxis, proliferation, differentiation and LDLR-mediated endocytosis (see 
Section 1.6.). For example, FAK and ERK/MAPK signalling pathways are 
activated while the p38 MAPK pathway is down-regulated due to interaction 
between integrin and uPAR (Liu et al., 2002), thus affecting epidermal growth 
factor-receptor-dependent proliferation. Gradients of uPA, pro-uPA or the ATF of 
uPA display a chemotactic effect on cells which express uPAR (Resnati et al., 
1996) and a GPCR member is implied in transduction of signals for cytoskeletal 
adjustment required for this chemotactic activity (Fazioli et al., 1997; Degryse et 
al., 1999; Nguyen et al., 2000; Resnati et al., 2002). 
1.6. UROKINASE PLASMINOGEN ACTIVATION PATHWAY: THE OVERALL 
PICTURE 
The components of the urokinase-plasminogen activation pathway and 
their interactions which result in the generation and control of plasmin on the 
cell surface were introduced. However, studies indicate that the urokinase 
plasminogen activation pathway is more than just a provider of proteolytic 
activity required for ECM degradation. These studies improve the understanding 
of the role of this pathway in cell migration which emerges from 
characterisation of cross-talk between components of this pathway and other 
cellular components (e.g. integrins and signalling mediators) as well as 
components in the microenvironment (e.g. ECM components such as 
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vitronectin). Given these biochemical and physical interactions, the overall 
organisation and functions of the urokinase plasminogen activation pathway is 
discussed in this section. 
1.6.A. LOCALISED PROTEOLYSIS 
Localisation studies describe the accumulation of uPAR and  
pro-uPA/uPA [pro/uPA for abbreviation] at focal adhesion sites (cell-to-
substratum) and cell-to-cell contact sites (Pöllänen et al., 1987; Glass et al., 
1988; Hébert and Baker, 1988; Takahashi et al., 1990; Del Rosso et al., 1992; 
Jensen and Wheelock, 1992; Bastholm et al., 1994a; Bastholm et al., 1994b; 
Reinartz et al., 1995; Sitrin et al., 1996). Integrins also accumulate at these sites 
and their cytoplasmic domains interact with intracellular filaments (see reviews 
by Clark and Brugge, 1995). The accumulation of pro/uPA:uPAR at focal-
contacts occurs on specific ECM substrates, e.g. vitronectin (Ciambrone and 
McKeown-Longo, 1990; Nusrat and Chapman, 1991; Waltz and Chapman, 
1994; Wei et al., 1994; Wei et al., 1996). In vivo, only uPAR occupied with 
pro/uPA, but not unbound uPAR, accumulates at these specific sites on the cell 
surface (Myöhänen et al., 1993). The accumulation of pro/uPA:uPAR complexes 
at focal adhesion sites (see Figure 11) may be explained by uPAR/vitronectin 
and/or uPAR/integrin interactions described earlier (Section 1.5.). 
During cell migration, uPAR polarises to the leading edge of the cell in 
vitro (Estreicher et al., 1990; Okada et al., 1995) and in vivo (Del Vecchio et al., 
1993). Similarly, uPA also accumulates at the leading edge of cells (Pöllänen et 
al., 1987). The localisation of uPA/uPAR at focal adhesion sites and leading 
edges of migrating cells indicate the role of uPAR-bound uPA during phases of 
cell migration, invasion and tissue remodelling (Danø et al., 1985; Saksela and 
Rifkin, 1988; Gold et al., 1989). This role is convincingly related to the 
generation of plasmin on the cell surface since uPA-mediated plasminogen 
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activation occurs much faster in the presence of cells than their absence, both 
in vitro (Ellis et al., 1991) and in vivo (Quax et al., 1991b). The co-localisation of 
plasminogen with uPA at cell surfaces provides a mechanism for accelerated 
plasminogen activation by cells (Andronicos and Ranson, 2001). This is because 
binding leads to an activation susceptible conformation of glu-plasminogen; an 
important requirement for efficient generation of cell-surface plasmin (reviewed 
by Ranson and Andronicos, 2003). Plasmin generation on the cell surface is also 
dependant on binding of uPA to uPAR, since blocking uPAR/uPA binding 
inhibits it (Stephens et al., 1989; Ellis et al., 1991; Rønne et al., 1991) and 
accelerated cell-surface plasmin generation is not observed in uPAR-deficient 
mice (Bugge et al., 1995). Thus, cell-surface-associated plasmin generated by 
uPAR-bound uPA confers plasmin-dependent degradation of ECM (Bergman et 
al., 1986; Cajot et al., 1989; Schlechte et al., 1989; Cohen et al., 1991; Quax et 
al., 1991a; Quax et al., 1991b; Reiter et al., 1993). Conclusively, the correlation 
between plasmin-dependent proteolysis and uPA/uPAR binding in addition to 
the directed distribution of uPAR-bound uPA at focal adhesion sites on the cell 
surface indicate the conception of localised pericellular proteolysis at the 
invading fronts of migrating cells (see Figure 11). 
Plasmin bound to the cell surface is protected from inhibition by its 
efficient inhibitory serpin, α2AP (Stephens et al., 1989; Plow and Miles, 1990; 
Ellis et al., 1991; Duval-Jobe and Parmely, 1994; Falcone et al., 1994). Thus, 
control of plasmin activity on the cell-surface appears to be controlled by the 
level of plasmin generation rather than the activity of the generated plasmin. 
PAI-1 and PAI-2 can react with uPAR-bound uPA on the cell surface (Cubellis et 
al., 1989; Pöllänen et al., 1990). Although the reaction on the cell-surface may 
be slower than in fluid phase (Ellis et al., 1990), PAI-1 (Cajot et al., 1990; 
Shirasuna et al., 1993), PAI-2 (Laug et al., 1993) and PN-1 (Bergman et al., 
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Figure 11: The urokinase plasminogen activation pathway on the cell surface 
Accelerated plasmin generation on the cell-surface requires the co-localisation of 
receptor-bound plasminogen (plg) and binding of pro/uPA to uPAR. Interactions 
between uPAR with vitronectin and integrins and the interaction between vitronectin 
and integrins account for the accumulation of uPA/uPAR complexes at sites of focal 
adhesion. The accumulation of uPAR-bound pro/uPA at focal adhesion sites also leads 
to localised plasmin-dependent pericellular proteolysis at these sites. The generation of 
plasmin on the cell-surface allows the plasmin-mediated functions indicated in the 
Figure and discussed elsewhere in this review. Plasminogen activator inhibitors (PAIs) 
inhibit the uPA catalytic activity and thus control cell-surface plasminogen generation. 
uPAR/uPA:PAIs complexes are internalised by LDLRs. Intracellular signals which are 
mediated by various signal transduction adaptors may be initiated due to uPA/uPAR 
binding or during the internalisation of uPAR/uPA:PAIs. Note: Plasmin generated on the 
cell-surface remains bound to the cell-surface; this is not shown in the Figure for clearer 
presentation. 
As discussed earlier (Section 1.5.C.), serpin/uPA complexes are 
endocytosed readily after complex formation, thus clearing the cell surface of 
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inhibited uPA. Endocytosis of uPAR-bound uPA/serpin complexes is much 
faster than that of fluid-phase complexes (Olson et al., 1992; Conese et al., 
1994). Furthermore, the affinity of α2MR/LRP to uPA:PAI-1 complex is 
approximately 100-fold higher than the affinities for un-complexed components 
(Nykjær et al., 1994). This indicates preferential clearance of complexes when 
bound to cell-surface uPAR and suggests another control-point of the urokinase 
plasminogen activation pathway on the cell surface. However, in the case of PAI-
1, both uPAR and the α2MR/LRP are recycled to the cell surface (Nykjaer et al., 
1997). This recycling in addition to the binding properties of PAI-1 and uPAR to 
vitronectin, which have not been demonstrated for PAI-2, suggests that PAI-1 
may play as a switch molecule in the process of cell migration. 
1.6.B. FUNCTIONAL DUALITY 
Cell invasion through the ECM (see Section 1.3.) involves interplay of 
proteolytic and adhesive functions (detachment/attachment) at the leading and 
posterior ends of the cell. uPAR-bound uPA, which generates plasmin, is 
localised at focal adhesion sites, polarises to the leading edge of the cell and 
leads to degradation of the ECM in front of the cell. This proteolytic activity is 
inhibited when uPAR-bound uPA encounters active PAI-1 embedded on 
vitronectin. uPA:PAI-1 complexes are endocytosed and uPAR along with the 
endocytosis receptor are recycled back to the cell surface where uPAR may be 
able to bind to integrins and/or PAI-1-free vitronectin. Alternatively, the 
interaction of PAI-1 with vitronectin may also suppress integrin/vitronectin-
mediated adhesion independent of its serpin activity (Kjøller et al., 1997), thus 
modulating cellular adhesion. In the case of internalisation of uPA:PAI-1 
complex, binding of uPA to recycled uPAR may initiate another round of 
proteolysis and result in further ECM degradation and decrease in attachment. 
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This scenario implicates proteolytic/adhesive interplay through multiple 
interactions between uPA, uPAR, vitronectin, integrin and PAI-1. Similar 
proteolytic activity followed by detachment/attachment events at the posterior 
end of the cell may collectively lead to the migration and invasion of the cell 
through the ECM. 
Recent evidence indicates that PAI-1 can activate signalling systems and 
stimulate cell migration during chemotaxis, chemokinesis and wound healing 
assays (Degryse et al., 2004). These effects of PAI-1 are blocked when α2MR/LRP 
is blocked by antibodies or antagonist, suggesting that α2MR/LRP mediates the 
signalling activation and affects of PAI-1 in these assays (Degryse et al., 2004). 
These findings along with other growing evidence (Deng et al., 1996; Chapman, 
1997; Brooks et al., 2000), suggest that uPA and PAI-1 co-operate in the 
migratory process by facilitating attachment to and subsequent detachment 
from vitronectin in the extracellular matrix. Association of uPAR with 
integrins/vitronectin also links uPAR with intracellular signalling/cytoskeletal 
elements (Porter and Hogg, 1998; Chen et al., 2001; Kjøller and Hall, 2001) and 
facilitates cell migration and invasion (Yebra et al., 1996; Carriero et al., 1999; 
Yebra et al., 1999; Khatib et al., 2001; Prifti et al., 2002). Furthermore, these 
interactions even modulate the expression of uPAR/uPA/PAI-1 (Hapke et al., 
2001a; Hapke et al., 2001b) and plasminogen receptors (Kim et al., 1996). This 
dynamic organisation and interplay/cross-talk of plasminogen activation 
pathway components and other microenvironmental factors need intracellular 
signalling to orchestrate the organisation of the events (see Section 1.5.D.). As 
discussed in the previous section (Section 1.5.), signalling and other non-
proteolytic interactions of the urokinase plasminogen activation pathway 
provide further evidence for the critical involvement of this pathway in tumour 
cell invasion and metastasis. 
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1.7. UROKINASE PLASMINOGEN ACTIVATION PATHWAY: REGULATION 
AND CANCER 
Plasmin generation on the cell surface requires the presence of uPAR, 
uPA, plasminogen and plasminogen receptors. PAI-1 and PAI-2 are required for 
controlling uPA-mediated plasminogen activation. Thus, the first level of control 
of this pathway is the synthesis of these components, which can be regulated by 
a wide variety of factors including hormones, phorbol esters, growth factors, 
retinoids and cytokines (reviewed by Danø et al., 1985; Saksela and Rifkin, 
1988; Andreasen et al., 1990; Blasi et al., 1990; Besser et al., 1996). The control 
of expression of these components occurs at both transcriptional and 
posttranscriptional levels (Vassalli et al., 1991). In brief, under normal 
physiological conditions, complex regulation of plasminogen activators and PAIs 
synthesis allows this system to be precisely controlled in time and space and in 
a manner that depends upon hormones and growth factor balance and other 
microenvironmental conditions. 
In cancer, the precise regulation of the plasminogen activation system 
appears to be lost or modified. Early studies provided evidence for the particular 
involvement of uPA in the invasive and metastatic properties of malignant 
tumours. These include the close correlation between oncogene transformation 
and high increase in uPA synthesis (Unkeless et al., 1973; Unkeless et al., 
1974), the immunohistochemical localisation of uPA in invading areas of 
tumours (Skriver et al., 1984; Grøndahl-Hansen et al., 1991) and the inhibition 
of cellular invasion and metastasis by anti-catalytic antibodies to uPA in model 
systems (Ossowski and Reich, 1983; Mignatti et al., 1986; Hearing et al., 1988; 
Ossowski, 1988; Reich et al., 1988). During the last two decades, an 
overwhelming number of reports implicate the important role of the 
plasminogen activation pathway in cancer invasion and metastasis in vitro and 
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in vivo. In the space of this thesis, it is impossible to review all the available data 
to date which describe the effect of the different components of this pathway on 
cancer invasion and metastasis (for detailed reviews refer to Duffy et al., 1999; 
Murphy and Gavrilovic, 1999; Andreasen et al., 2000; Dunbar et al., 2000; 
Choong and Nadesapillai, 2003; Ranson and Andronicos, 2003; Reuning et al., 
2003a; Reuning et al., 2003b; Rosenberg, 2003; Sidenius and Blasi, 2003). In 
summary, in vitro evidence for the role of urokinase plasminogen activation 
pathway in cancer metastasis and invasion include: (1) correlation between 
metastatic and invasive potential of cancer cells and the expression of uPA, 
uPAR and plasminogen binding; (2) retardation of cancer cell migration and 
invasion by inhibiting the enzymatic activity of uPA or binding of uPA to uPAR; 
(3) increased migration and invasion when cells are transfected with uPAR or 
uPA cDNAs whereas migration decreased when uPAR- or uPA-overexpressing 
cancer cells are transfected with anti-sense cDNAs and (4) inhibition of invasion 
and metastasis when invasive cancer cells are treated with PAI-2 or transfected 
with PAI-2 cDNA. In vivo evidence for the role of this pathway in cancer invasion 
and metastasis include: (1) correlation between increased uPAR, uPA and PAI-1 
expression and plasmin generation with cancer metastasis in animal models; (2) 
inhibition of metastatic cancers in animal models when treated with anti-uPA 
antibodies or when pre-transfected with uPA anti-sense oligonucleotides; (3) 
decreased metastasis in animal models treated with uPA/uPAR binding 
antagonists and (4) suppression of tumour growth and invasion in animal 
models inoculated with PAI-2 or with invasive cancer cells transfected with PAI-
2 cDNA. 
The established role of the urokinase plasminogen activation pathway in 
cancer metastasis and invasion initiated the interest in evaluating its clinical 
significance in cancer patients. Early studies established that the level of uPA in 
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malignant tumours is significantly higher than that in the corresponding 
normal or benign tumours of the same tissue (for reviews see Duffy, 1993a; 
Duffy, 1996). A considerable number of studies have since evaluated the 
prognostic significance of uPA, uPAR, PAI-1 and PAI-2 in a wide variety of 
human cancers. Table I summarises the outcome of such studies undertaken 
between 1999 to date. For extensive reviews of studies prior to 1999 concerning 
this topic refer to Andreasen et al. (1997), Schmitt et al. (1997), Brunner et al. 
(1999), Duffy et al. (1999), Look and Foekens (1999) and Mazar et al. (1999). 
uPA and/or PAI-1, as evident in earlier reviews and Table I, appear to be 
the most common and best clinical and prognostic factors of the urokinase 
plasminogen activation pathways in many cancers including breast, prostate 
and colorectal cancers. In fact, the prognostic value of uPA/PAI-1 in axillary 
node-negative breast cancer patients was recently validated through 
randomised controlled trials (RCTs). RCTs ensure low risk of incorporating 
false-positive or false-negative results, thus uPA/PAI-1 were justified as strong 
prognostic markers in breast cancer patients by Level 1 of evidence (LOE-1 
which is highest level of evidence) (Duffy, 2004). Assay of uPA and PAI-1 may 
therefore help identify high risk node-negative breast cancer patients who would 
benefit from adjuvant chemotherapy (Duffy, 2004). 
 
Table I: Clinical significance of components of the plasminogen activation pathway in human cancers 
            Antigen 
Cancer uPA PAI-1 uPAR PAI-2 
Multiple myeloma 
● Marker of deeper myometrial 
invasion (Gerstein et al., 2003) 
(EI) 
 
● Soluble uPAR in plasma predicts 
extra-bone marrow involvement and 
poor prognosis (Rigolin et al., 2003) 
(IF) 
● High levels of soluble uPAR 
independent factor predicting worse 




● Urinary uPA has prognostic ability 
(Shariat et al., 2003a) 
(ELISA and EI) 
● Serum uPA level is an 
independent predictor of poor 
outcome (Shariat et al., 2003b) 
(ELISA) 
 
● uPAR has prognostic ability 
(Shariat et al., 2003a) 
(ELISA and EI) 
 
Pancreatic cancer 
● Potential prognostic indicator 
(Harvey et al., 2003) 
(IHC and ISH) 
 
● uPAR overexpression correlates 
with poorer survival (Harvey et al., 
2003) 
(IHC and ISH) 
 
Prostate cancer 
● Serum levels alone or with uPAR 
could be predictor of progression 
and prognosis (Miyake et al., 1999a; 
Miyake et al., 1999b) 
(ELISA) 
 
● Serum levels alone or with uPA 
could be predictor of progression 
and prognosis (Miyake et al., 1999a; 
Miyake et al., 1999b) 
(ELISA) 
● Serum levels of soluble uPAR is a 
possible diagnostic marker for early 
detection (McCabe et al., 2000) 
(ELISA) 
 
Table continues … 
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ 
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article) 
            Antigen 
Cancer uPA PAI-1 uPAR PAI-2 
Ovarian cancer 
● Strong prognostic relevance 
(Konecny et al., 2001) 
(ELISA) 
● Plasma levels correlate with 
presence of malignancy and higher 
stage of disease (Ho et al., 1999) 
(ELISA) 
● Statistically independent strong 
prognostic factor (Kuhn et al., 1999) 
(ELISA) 
● Predictor for overall survival 
(Tecimer et al., 2000) 
(ELISA) 
● Strong prognostic relevance 




● Provides significant additional 
prognostic information (Stabuc et al., 
2003) 
(ELISA) 
● Provides significant additional 





● uPA enzymatic activity is a 
prognostic factor (Okusa et al., 
1999) 
(EA and IHC) 
● Associated with a poor outcome 
(Kaneko et al., 2003) 
(IHC) 
● Correlated with tumour size, 
depth, lymph node involvement, 
differentiation and  vascular invasion 
(Kaneko et al., 2003) 
(IHC) 
● Correlated with tumour size, 
depth, lymph node involvement, 
differentiation and  vascular invasion 





● Increased and related to 
invasiveness, metastasis and poor 
prognosis (Zheng et al., 2000) 
(IHC and NB) 
● Contributes to the invasion, 
metastasis and prognosis (Zheng et 
al., 2000) 
(IHC and NB) 
● Increased and related to 
invasiveness, metastasis and poor 
prognosis (Zheng et al., 2000) 
(IHC and NB) 
 
Colon cancer 
● Increase in tumour and serum 
levels is associated with a worse 
prognosis (Berger, 2002) 
(VA) 
● Increase in tumour and serum 
levels is associated with a worse 
prognosis (Berger, 2002) 
(VA) 
● Increase in tumour and serum 
levels is associated with a worse 
prognosis (Berger, 2002) 
(VA) 
 
Table continues … 
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ 
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article) 
            Antigen 
Cancer uPA PAI-1 uPAR PAI-2 
Colorectal cancer 
● Combined analysis of uPA and 
PAI-1 is a useful prognostic factor 
(Fujii et al., 1999) 
(IHC and RT-PCR) 
● Major prognostic impact 
(Herszenyi et al., 1999) 
(ELISA) 
● Independent prognostic factors 
(Yang et al., 2000) 
(IHC) 
● Marker of late stages of this 
cancer (Papadopoulou et al., 2002) 
(ELISA and IHC) 
● PAI-1 level over uPAR or uPAR-
bound uPA associate with tumour 
progression (Abe et al., 1999) 
(ELISA) 
● Combined analysis of uPA and 
PAI-1 is a useful prognostic factor 
(Fujii et al., 1999) 
(IHC and RT-PCR) 
● Major prognostic impact 
(Herszenyi et al., 1999) 
(ELISA) 
● Marker of later stages 
(Papadopoulou et al., 2002) 
(ELISA and IHC) 
● PAI-1 genotype may be a useful 
prognostic marker (Loktionov et al., 
2003) 
(Genotyping) 
● Higher expression related to poor 
prognosis (Abe et al., 1999) 
(ELISA) 
● Plasma level of soluble uPAR 
independently predict survival 
(Stephens et al., 1999) 
(ELISA) 
● Independent prognostic factors 
(Yang et al., 2000) 
(IHC) 
● Soluble uPAR has an independent 
prognostic information in rectal 
cancer patients and high values 
associate with shorter survival 





● Elevated levels correlate with 
unfavourable prognosis (Taponeco 
et al., 2001; Tecimer et al., 2001) 
(ELISA and IHC) 
● High level correlates with un-
favourable prognosis (Gerstein et 
al., 2003) 
(EI) 
● Elevated levels appear correlated 
with unfavourable prognosis 
(Taponeco et al., 2001; Tecimer et 
al., 2001) 
(ELISA and IHC) 
● Useful prognostic marker for 
biologically aggressive forms 
(Memarzadeh et al., 2002) 
(IHC) 
● High tumour tissue concentration 
independent marker for shorter 
progression-free survival 




● Predictive of poor survival 
(Shiomi et al., 2000) 
(IHC and ISH) 
● Tumour and serum levels 
potentially predict survival 
probability (Strojan et al., 2000) 
(ELISA and IRA) 
● Parameter for prediction of 
prognosis (Sakakibara et al., 2004) 
(RT-PCR) 
● Elevated levels of soluble uPAR in 
plasma, but not significantly 
correlated to metastasis or 
recurrence (Schmidt and Hoppe, 
1999) 
(ELISA) 
● Expression of PAI-2 in fibroblasts 
surrounding these carcinomas is 
protective (Shiomi et al., 2000) 
(IHC and ISH) 
Table continues … 
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ 
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article) 
            Antigen 
Cancer uPA PAI-1 uPAR PAI-2 
Breast cancer 
● Prognostic role (de Witte et al., 
1999b) 
(ELISA) 
● Independent predictive factors of 
poor overall survival and relapse-
free survival (Foekens et al., 2000) 
(ELISA) 
● Clinical relevance and prognosis is 
best when combined with PAI-1 
(Harbeck et al., 2002a; Harbeck et 
al., 2002b) 
(ELISA) 
● High cytosolic levels correlate 
significantly with shorter disease- 
free survival (Levicar et al., 2002) 
(ELISA) 
● Independent prognostic value in 
primary breast cancer (Look et al., 
2002; Luqmani et al., 2002) 
(VA) 
● Cytosolic levels at diagnosis may 
be predictive of early relapse in 
primary cancer (Dazzi et al., 2003) 
(ELISA) 
● Prognostic marker validated by 
level-1-evidence for node-negative 
patients (Qin et al., 2003a; 
Thomssen et al., 2003; Duffy, 2004) 
(VA and ELISA for Qin et al.) 
● Prognostic role (de Witte et al., 
1999a; de Witte et al., 1999b) 
(ELISA) 
● Tumour-associated levels as 
independent prognostic information 
in a follow-up period of ~10 years 
(Harbeck et al., 1999a; Harbeck et 
al., 1999b; Harbeck et al., 2000) 
(EI and ELISA) 
● Independent predictive factors of a 
poor overall survival and relapse-
free survival (Foekens et al., 2000) 
● Patients with low levels of PAI-1 
have better disease-free survival 
(Borstnar et al., 2002) 
(ELISA) 
● Clinical relevance and prognosis is 
best when combined with uPA 
(Harbeck et al., 2002a; Harbeck et 
al., 2002b) 
● High cytosolic levels correlate 
significantly with shorter disease-
free survival (Levicar et al., 2002) 
● Independent prognostic value in 
primary cancer (Cufer et al., 2002; 
Look et al., 2002; Luqmani et al., 
2002) 
● Independent prognostic marker for 
recurrence-free survival in primary 
cancer (Hansen et al., 2003) 
(IHC and ELISA) 
● Prognostic marker validated by 
level-1-evidence for axillary node-
negative patients (Qin et al., 2003a; 
Qin et al., 2003b; Thomssen et al., 
2003; Duffy, 2004) 
(VA and ELISA for Qin et al.) 
● Elevated levels of cytosolic uPAR 
is an independent predictors of poor 
overall survival and relapse-free 
survival (de Witte et al., 2001) 
(ELISA) 
● Increased uPAR mRNA in primary 
cancer may be a predictor of poor 
overall survival (Pacheco et al., 
2001) 
(NB) 
● High level of age-dependent 
soluble uPAR in serum 
independently associate with poor 
outcome (Riisbro et al., 2002) 
(ELISA) 
● uPAR provides useful information 
for cancer diagnosis and prognosis 
(Qin et al., 2003a) 
(ELISA) 
● Intermediate and low levels show 
poor overall survival and relapse-
free survival (Foekens et al., 2000) 
(ELISA) 
● Patients with high levels of PAI-2 
have better disease-free survival 
(Borstnar et al., 2002) 
(ELISA) 
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ 
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article) 
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1.8. UROKINASE PLASMINOGEN ACTIVATION PATHWAY AND CANCER 
THERAPY 
The identification of strong tumour cell markers, especially to identify 
metastatic cells, is one of the main directives of cancer research. Since the 
leading cause of cancer-related mortality is the inability to control the spread of 
malignant tumours (Woodhouse et al., 1997), characterisation of strong 
tumour/malignancy markers is vital for therapeutic targeting purposes. It is 
beyond the scope of this thesis to review the efforts and the success of studies 
endeavouring to identify such markers (see review by Dubowchik and Walker, 
1999). As discussed in the previous section (Section 1.7.), uPA appears be a 
strong marker of cancer progression and metastasis and is currently validated 
by LEO-1 as a clinical and prognostic marker in breast cancer (Duffy, 2004) and 
may be validated for other human cancers in the near future. Modulation of 
uPA expression and the use of antagonist of the uPA/uPAR binding have shown 
success in regulating cancer metastasis and invasion (Crowley et al., 1993; 
Achbarou et al., 1994; Wilhelm et al., 1995; Min et al., 1996; Shapiro et al., 
1996). The therapeutic potential of modulating gene expression in humans is 
limited due to the requirement of cancer cell-specific gene delivery methods. 
Thus, antagonists of the uPA/uPAR binding or uPA inhibitors, natural (e.g. PAI-
2) or engineered (see review by Rockway et al., 2002), seem more feasible for 
clinical applications. Although such antagonists/inhibitors may be 
administered to inhibit tumour growth, migration or differentiation, tactics such 
as cytotoxins or toxic radiation for the killing and clearance of tumour cells 
present more valuable curative advantages. 
Several biological and chemical agents with different cytotoxic 
mechanisms are readily available for the targeted or non-targeted killing of cells. 
A particular targeted uPA-based anti-cancer strategy involves the production of 
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uPA-toxin conjugates. Examples of such successful strategies include uPA-
Pseudomonas exotoxin (PE) (Rajagopal and Kreitman, 2000), ATF-saporin (plant 
ribosome-inactivating protein) (Cavallaro et al., 1993; Fabbrini et al., 1997; 
Fabbrini et al., 2000), ATF-Diphtheria toxin (DT) (Vallera et al., 2002; 
Rustamzadeh et al., 2003) and PAI-1-(A-chain)Cholera toxin (Jankun, 1992) 
conjugates. Another example of uPA-based therapy is a recombinant fusion 
protein consisting of anthrax toxin lethal factor and Pseudomonas exotoxin 
which is engineered to be only cleaved and internalised by uPA-overexpressing 
cells (Liu et al., 2001; Ye et al., 2003). 
Alternatively, new hopes for cancer therapy arise from recent 
characterisation of radionuclides with favourable radiophysical states which are 
efficient for cytotoxic targeting. γ-emitting radionuclides are widely used for 
radioimaging; however, γ rays do not contribute significantly to therapeutic 
efficacy (Chatal and Hoefnagel, 1999). Isotopes emitting β particles are more 
often used for therapy (e.g. 131Iodine, 90Yttrium, 186Rhenium, and 67Copper) and 
are characterised by low linear energy transfer released over a relatively long 
distance, resulting in inefficient local killing of target cells coupled with toxicity 
to distant normal tissues (Waldmann, 1991; Bender et al., 1992; O'Donoghue et 
al., 1995; Griffiths et al., 1999). On the other hand, α-emitting radionuclides 
release high-energy emissions (6 - 9 Mega electron volts [MeV]; ten times as 
great as β- or γ-emitters) over a short distance (40 to 80 µm) (Waldmann, 1991; 
Behr et al., 1998; Behr et al., 1999; Chatal and Hoefnagel, 1999; Griffiths et al., 
1999). Thus, using α-emitters, much greater fraction of the total energy is 
deposited in the targeted cells and very few nuclear hits are required to kill 
these cells (Lloyd et al., 1979; Kassis et al., 1986). Monoclonal antibodies 
conjugated to metal chelators, such as cDTPA or its derivates, and labelled with 
α–emitting radionuclides (e.g. 213Bismuth and 211Astatine) are starting to show 
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promise in radio-immunotherapy. In preclinical studies, McDevitt et al. (2000) 
and Nikula et al. (1999) have proven the efficacy of 213Bismuth-labelled 
monoclonal antibodies for radio-immunotherapy of prostate cancer and 
leukaemia and are conducting a phase I trial for end stage leukaemia (Jurcic et 
al., 2002). 213Bismuth-labelled antibody has been validated for radio-
immunotherapy of multiple myeloma (bone marrow cancer) (Couturier et al., 
1999). 211Astatine-labelled antibodies have been used clinically in a phase I trial 
to treat malignant gliomas in humans (Zalutsky and Vaidyanathan, 2000). 
There are many other examples of the use of DTPA or its derivatives for 
chelating metals to agents used for imaging or targeting α-radiation to tumours 
(targeted alpha therapy, TAT) (Merlo et al., 1997; Boerman et al., 1999; Gruaz-
Guyon et al., 2001; Gulec et al., 2001; McDevitt et al., 2001; Wen et al., 2001). 
1.9. RATIONALE AND OBJECTIVES 
Given the functional duality (proteolytic and non-proteolytic functions) of 
the urokinase plasminogen activation pathway, it is not surprising that this 
pathway is critical in processes of cancer invasion and metastasis. Growing 
evidence suggest that uPA and PAI-1 co-operate in the migratory process by 
facilitating attachment to and subsequent detachment from vitronectin in the 
extracellular matrix (Deng et al., 1996; Chapman, 1997; Brooks et al., 2000; 
Degryse et al., 2004). In agreement, high levels of uPA and/or PAI-1 have shown 
a prognostic significance in many types of cancers (see Section 1.7.). This 
invites the clinical use of uPA as a target for therapeutic strategies against 
cancer. The low level of PAI-2 in metastatic cancers together with the good 
prognosis in cancer patients with high PAI-2 expression indicate the possible 
use of PAI-2 for the development of uPA-based targeted therapies. Exogenous 
PAI-2 (either as a free molecule or coupled to radionuclides) localises within 
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uPA-expressing colon carcinoma xenografts (Hang et al., 1998) and significantly 
reduces tumour growth and metastases with no evidence of toxicity (Shinkfield 
et al., 1992; Åstedt et al., 1995; Evans and Lin, 1995; Li et al., 2002; Allen et al., 
2003). Thus, despite the presence of PAI-1 in malignant tumours, it is apparent 
that uPA is accessible to exogenously administered PAI-2 within several tumour 
types in vivo. PAI-2 can specifically access and inhibit uPA while sparing 
thrombosis as suggested by the low second order inhibition rate constant 
towards tPA and that fibrin-bound tPA is protected from PAI-2 inhibition 
(Kruithof et al., 1995). Furthermore, unlike PAI-1 which is subject to oxidation 
(Baker et al., 1990b), stable cytotoxin-PAI-2 conjugates may be easily achieved 
in vitro (Ranson et al., 2002). 
The primary aim of this thesis was to provide further biological rationale 
for  the  preliminary success  of  the  anti-uPA  targeted  therapy  using  
PAI-2 linked to 213Bismuth reported by Li et al. (2002), Ranson et al. (2002) and 
Allen et al. (2003). This involved the direct in vitro determination of the 
inhibition kinetics of cell-surface uPA by PAI-2 on invasive and non-invasive 
breast cancer cells. The controversial fate of uPAR-bound uPA:PAI-2 complexes 
was also addressed as a part of these studies. An additional aim was to 
modulate uPAR-expression in breast cancer cells to assess the role of 
uPAR/uPA in the acquisition of metastatic phenotype and extend the analyses 
of PAI-2 binding to cells. Lastly, this thesis also aimed to optimising the protocol 
used for the preparation of PAI- 2-213Bismuth (α-PAI-2). This involved the 
development of standard operating procedures for the conjugation of PAI-2 to 
cDTPA and radiolabelling of the conjugate with 213Bismuth for radiotherapy. 
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Lipofectamine™ 2000, pcDNA3 plasmid, RPMI-1640 powder and T7- 
promoter primer were purchased from Invitrogen® Life Technologies, NSW, 
Australia. Foetal calf serum (FCS) was obtained from ThermoTrace®, VIC, 
Australia. Acetonitrile (100 %), ammonium persulfate, ammonium bicarbonate 
(NH4HCO3), ampicillin, bovine serum albumin (BSA fraction V), β-
mercaptoethanol, Brilliant Blue R250, bromophenol blue, chloroform, dimethyl 
sulfoxide (DMSO), ethidium bromide, ethyldiaminetriacetic acid (EDTA), Hank’s 
and phenol red-free Hank’s balanced salt powders, HEPES, hydroiodic acid (HI), 
insulin, lysozyme, nitric acid (HNO3), paraformaldehyde, pH strips (pH range 0 - 
14), phenol: chloroform, potassium phosphate (KH2PO4), propidium iodide, 
rabbit anti mouse IgG monoclonal antibody (IgG) conjugated to Cy3 or FITC, 
sodium monophosphate (Na2HPO4), TEMED, tranexamic acid (TA), Tris-HCl, 
trypsin-EDTA, urea and xylene cyanol were purchased from Sigma-Aldrich®, 
MO, USA. The colorimetric substrate for uPA Spectrozyme®-UK and mouse 
monocolonal antibodies raised against human A-chain uPA (#3921), B-chain 
uPA (#394), PAI-2 and uPAR (#3934) were all obtained from American 
Diagnostica Inc. (ADI), CT, USA. Another mouse monoclonal antibody raised 
against human uPAR (MAB807) was purchased from R&D Systems Inc., MN, USA. 
Rabbit anti-human uPAR polyclonal antibody was provided by David Croucher 
(School of Biological Sciences, University of Wollongong, Australia). Mouse 
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isotype control subclass IgG1 antibody was from Silenus, Sydney, NSW, 
Australia. Boric acid, calcium chloride (CaCl2), gelatine powder, glucose, glycine, 
magnesium chloride (MgCl2), magnesium sulphate (MgSO4), potassium acetate, 
potassium chloride (KCl), sodium acetate, sodium chloride (NaCl) and sodium 
dodecyl sulphate (SDS) were obtained from BDH Chemicals Australia Pty. Ltd., 
VIC, Australia. Absolute alcohol, citric acid, isopropanol, glacial acetic acid, 
hydrochloric acid (HCl), methanol and sodium hydroxide tablets (NaOH) were 
purchased from Ajax Chemicals, NSW, Australia. Agar, bactotryptone, trypton 
and yeast extract were obtained from Oxoid Australia Pty Ltd, VIC, Australia. 
Hind III, Not I, Pst I and Xho I restriction enzymes and their compatible 10 x 
buffers were purchased from Roche Applied Science, IN, USA. The Cy5 mono-
reactive dye pack, PD-10 columns (Sephadex G-25 columns), T4 DNA ligase and 
10 x ligation buffer were from Amersham Biosciences, Uppsala, Sweden. 
Qiagen® plasmid midi-prep kit and Superfect® transfection reagent were 
purchased from Qiagen Pty Ltd, VIC, Australia. BigDyeTM terminator mix v2.0 
was obtained from Applied Biosystems, CA, USA and PAGE-PLUSTM purchased 
from Amresco Inc., OH, USA. AG® 501-X8 resin, BioRad® DC protein 
concentration assay kit, broad range unstained and prestained markers and 
precision plus unstained marker were from BioRad Laboratories Inc., CA, USA. 
Prestained protein ladder marker (10 – 160 kDa) was obtained from Fermentas 
Inc., MD, USA. Agarose, glycerol and polyacrylamide were purchased from 
Progen Industries Limited, QLD, Australia. Human recombinant PAI-2 
(molecular weight 47 kDa) and Actisolv uPA were provided by PAI-2 Pty Ltd, 
Sydney, Australia. Iodo-beads were purchased from Pierce Chem. Co., IL, USA. 
Iodine-125 (125I) was obtained from PerkinElmerTM, MA, USA. Actinium-225 
(225Ac) and prepacked columns containing resin (AG® 50W-X4) were purchased 
from the Oak Ridge National Laboratory, United States Department of Energy, 
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USA. Whatman #1 filter paper was purchased from Whatman International Ltd., 
Kent, UK. Cyclic anhydride diethylenetriaminepentacetic acid (cDTPA) was 
purchased from MP Biomedicals Inc., formerly ICN Biomedicals, CA, USA. Glu-
Plasminogen was purified from human plasma and conjugated to FITC and Cy5 
as described earlier (Andronicos et al., 1997). uPA and the goat anti-human uPA 
polyclonal antibody were obtained from Chemicon® International, CA, USA. 
LysoTracker® Yellow DND-68 and transferrin-Alexa488 were purchased from 
Molecular Probes, Inc., OR, USA. Lambda (λ) DNA and the CellTitre 96® 
AQueous Non-Radioactive Cell Proliferation Assay were obtained from Promega® 
Corporation, WI, USA. Instant thin layer chromatography (ITLC-SG) strips were 
purchased from Gelman Science, MI, USA. The 0.22 µm sterile filter units and 
the 30 kDa cut-off microconcentrators were obtained from Millipore, MA, USA. 
Gamma (γ) counter tubes were purchased from Sarstedt®, NSW, Australia. 
AtomLab 200 dose calibrator was purchased from Pinestar Technology Inc., PA, 
USA. 
2.2. GENERAL METHODS† 
2.2.A. TISSUE CULTURE AND ANALYSIS 
2.2.A.1. CELL LINES 
The human breast cancer cell lines - MDA-MB-231, T-47D and MCF-7 
(American Type Culture Collection, ATCC®, VA, USA) - were routinely cultured 
at 37oC in a Heracell incubator (Kendro® Laboratory Products, Langenselbold, 
Germany) in atmospheric air containing humidified 5 % CO2. Cells were grown 
in culture media [10.4 g/l of RPMI-1640 and 2 g/l sodium bicarbonate; solution 
was adjusted to pH 7.2 and filter-sterilised using 0.22 µm sterile filters units]. 
                                          
† All buffers and solutions in this thesis are described in alphabetical order in Appendix 
4 (Section 7.4.) 
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Culture media was supplemented with 5 % (v/v) foetal calf serum (FCS) and  
T-47D cells were also supplemented with 0.26 units/ml insulin. Cells were 
routinely passaged at confluency using Trypsin-EDTA. The MDA-MB-231 cell 
line has been shown previously to display a metastatic phenotype (high uPA, 
uPAR and plasminogen binding and activation capacity) and metastasise in 
nude mouse models (Andronicos et al., 1997; Ranson et al., 1998; Li et al., 
2002). The T-47D and MCF-7 cells display a non-metastatic phenotype (low 
uPA, uPAR, plasminogen binding and activation capacity) (Ranson et al., 1998). 
All cell experiments were performed using cells cultured for 48 – 72 h 
without a change of media. Cells were detached using sterile 1 x phosphate 
buffered saline (PBS) containing 5 mM EDTA [PBS: 8 g/l NaCl, 0.2 g/l KCl, 1.44 
g/l Na2HPO4, 0.24 g/l KH2PO4; pH adjusted to 7.4; then EDTA was added at 5 
mM final concentration]. Detached cells were centrifuged at 652 x g for 3 min at 
4oC and cell pellets were washed and resuspended at 1 x 106 cells/ml in ice-cold 
binding buffer [Hank’s buffered saline solution: 9.5 g/l Hank’s powder, 1 mM 
HEPES and 0.1 % w/v bovine serum albumin (BSA); 1 mM CaCl2 and 1 mM 
MgCl2; pH 7.4]. Cell and viability were assessed by trypan blue exclusion and 
visualisation in hemocytometer. Unless specified otherwise, all surface pro-uPA 
was activated by incubation of cells at 1 x 106 cells/ml for 5 min at room 
temperature (RT) with 5 µg/ml plasminogen solution in RPMI-1640, washed 
then resuspended at 1 x 106 cells/ml in binding buffer for further 
experimentation. 
2.2.A.2. FLOW CYTOMETRY 
Cell-surface antigens were detected by indirect immunofluorescence 
staining as previously described (Ranson et al., 1998). The concentration and 
the specificity of the primary and secondary antibodies used are specified in the 
Figure legends. Plasminogen binding was detected directly using 50 µg/ml 
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plasminogen-FITC conjugate in the absence or presence of 1 mM tranexamic 
acid (TA, a lysine analogue) as described by Ranson et al. (1998). Plasminogen 
was purified from human plasma and conjugated with FITC as described by 
Andronicos et al. (1997). After the direct and indirect staining, cells were 
washed and resuspended in PBS containing 1 mM CaCl2 and 1 mM MgCl2 and 
the vital fluorescent stain propidium iodide (PI) at 5 µg/ml. Flow data was 
acquired using the Becton-Dickinson FACSCalibur™ flow cytometry system (BD 
Biosciences, CA, USA) and the instrument calibrated with reference settings for 
each cell line. Cell-associated fluorescence was measured by dual-colour flow 
cytometry which allows a differentiation between cell-surface and total 
fluorescence (Ranson et al., 1998). Briefly, PI positive cells (non-viable) were 
excluded from the remaining cells which were intact (PI negative) and hence 
indicate cell-surface detection. Flow cytometry data was analysed using WinMDI 
v2.8 (Scripps Research Institute, CA, USA) and only viable cell-associated 
fluorescence are reported. 
2.2.A.3. CONFOCAL MICROSCOPY 
Confocal microscopy was used to visualise the distribution and 
localisation of cell-surface and internalised antigens. For assays on attached 
cells, these cells were cultured for 48 – 72 h on sterile glass-slide cover slips, 
washed and blocked for 1 h at room temperature with phenol red-free binding 
buffer [prepared as for normal binding buffer however using phenol red-free 
Hank’s powder]. Cells were gently washed using ice cold PBS containing 1 mM 
CaCl2 and 1 mM MgCl2 before staining. For assays with suspension cells, 48 h-
cultures were detached with EDTA and washed with ice cold PBS containing 1 
mM CaCl2 and 1 mM MgCl2 before staining. Staining assays were performed 
using antibodies or fluorochrome-conjugated antigens which are specified for 
each assay. Generally, in staining assays involving plasminogen binding, cells 
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were first incubated with 50 µg/ml plasminogen-Cy5 [prepared as described by 
Andronicos and Ranson (2001)] for 1 h on ice in the absence or presence of 5 
mM TA. Cells were then washed 3 x 5 min incubation in ice-cold phenol red-free 
binding buffer. For double staining assays, cells were then incubated for 30 min 
on ice in 20 µg/ml of primary antibody, washed three times as described earlier 
and then incubated for 30 min on ice in 1:50 dilution of secondary antibody 
(anti-immunoglobulin antibodies conjugated to FITC or Cy3) in phenol red-free 
binding buffer. Cells were washed and cover slips were air-dried and mounted 
on glass slide using mounting buffer [1 x PBS containing 1 mM CaCl2 and 1 mM 
MgCl2 and 10 % glycerol]. Cells were not fixed prior staining as earlier assays 
found cell-fixing (using paraformaldehyde) resulted in disruption of cell-surface 
and reduced cell viability (data not shown), thus slides were analysed 
immediately. 
All confocal laser scanning microscopy images were acquired using a 
Leica TCS SP system and the UV 63x1.32 NA oil PLAPO immersion objective 
lens (Leica, Heidlberg, Germany). FITC and Cy3 fluorochromes were excited 
using the 488 nm and the 583 nm spectral lines of the Argon ion laser, 
respectively. Cy5 fluorochrome was excited with the 633 nm spectral line of the 
Helium-Neon laser. The emissions of Cy3, FITC and Cy5 were collected at 525-
540 nm, 545-560 nm, and greater than 650 nm, respectively. Furthermore, 
transferrin-Alexa488 and LysoTracker® Yellow DND-68 were excited using the 
488 nm spectral line of the Argon ion laser and their emissions were collected at 
510-530 and 545-560 nm, respectively. The signal from each of the 
fluorchromes used did not leak into the channels used for detection of the other 
fluorochromes. All confocal images were analysed and manipulated using the 
softwares Volocity (version 2.0.1 Build 85, Improvision Ltd., MA, USA) and 
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Confocal Assistant (version 4.02 Build 101, developed by Todd Clark Brelje, 
University of Minnesota, MN, USA). 
2.2.A.4. CELL PROLIFERATION/CYTOTOXICITY ASSAYS 
Cell proliferation was determined using the colorimetric CellTitre 96® 
AQueous Non-Radioactive Cell Proliferation Assay (Promega® Corporation, WI, 
USA). This assay is based on the conversion of the substrate  
3-(4,5–dimethylthiazol–2-yl)-5-(3-carboxymethoxyphenyl)–2-(4-sulfophenyl)-2H- 
tetrazolium/phenazine methosulfate (MTS/PMS) to a coloured product by 
metabolically active cells. The effect of various agents on cell proliferation was 
also determined using this assay since cytotoxic or proliferative agents result in 
modulation of metabolism. 
In order to establish the relationship between cell number and 
absorbance of the product produced from the substrate of this assay, increasing 
number of cells was transferred in triplicate to 96-wells plate in a final 100 µl of 
phenol red-free binding buffer containing 5 % (v/v) FCS. The assay substrate, 
MTS/PMS (20 µl), was added to cell solutions in addition to control triplicate 
wells containing 100 µl of phenol red-free binding buffer only. The plate was 
incubated at 37oC in the humidified 5 % CO2 incubator for 3 h and then the 
absorbance at 490 nm was measured using the Spectramax® 250 UV plate 
reader (Molecular Devices Corporation, CA, USA). A standard curve for the 
relationship between cell number and absorbance was constructed after 
blanking all values to the absorbance reading of control wells. Further cell 
proliferation assays were performed using the number of cells which falls in the 
linear range of the correlation between cell number and the absorbance of the 





2.2.B. PROTEIN ANALYSIS METHODS 
2.2.B.1. PROTEIN CONCENTRATION ASSAY 
The BioRad® DC protein concentration assay kit was used to determine 
the concentration of protein samples against standard BSA solutions. Aliquots 
(5 µl) of standard BSA solutions (0 - 1 mg/ml in PBS) and protein samples were 
added in duplicates to 96-wells plate. For each well, 25 µl of Reagent A from the 
kit was added and then two 100 µl volumes of Reagent B were mixed. The plate 
was stored on ice for 5 min for maximal colour development and the absorbance 
of all wells was measures at 750 nm using the Spectramax® 250 plate reader. 
The concentrations of protein samples were interpolated using the curve 
constructed from the standard BSA solutions and their absorbencies. 
2.2.B.2. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
PAGE, unless otherwise specified, was performed using gels composed of 
4 % stacking gel and 12 % resolving gels as per Laemmli (1970). Briefly, 
resolving gel [12 % v/v of liquid 40 % acrylamide, 0.1 % w/v sodium dodecyl 
sulphate (SDS), 375 mM Tris-HCl pH 8.8, 0.1 % v/v TEMED and 0.05 % w/v 
ammonium persulphate (APS)] was poured and set. Stacking gel [4 % v/v of 
liquid 40 % acrylamide; 126 mM Tris-HCl pH 6.8; 0.1 % w/v SDS; 0.1 % v/v 
TEMED and 0.05 % w/v APS] was poured on top of stacking gel and a comb 
was inserted to form wells. Samples for PAGE were prepared in a 20 µl final 
volume and 5 µl of 5 x non-reducing sample buffer was added [60 mM Tris-HCl; 
2 % w/v SDS; 10 % v/v glycerol; 0.01 % w/v bromophenol blue]. For reducing 
conditions 5 µl of 5 x reducing sample buffer [non-reducing sample buffer but 
including 5 % w/v 2-β-mercaptoethanol] was added and samples were boiled for 
5 min. Electrophoresis was carried out for 1 h at 150 volts against 15 µl of SDS-
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PAGE markers (specified for each gel) using 1 x running buffer [3.03 g/l Tris, 
14.4 g/l glycine and 1 g/l SDS]. Gels were stained overnight in Coomassie blue 
stain [0.1 % w/v Brilliant Blue R250, 40 % v/v methanol and 10 % v/v glacial 
acetic acid]. Gels were destained in destain buffer [40 % methanol and 10% 
glacial acetic acid] and documented using the Novex® Gel Document System 
(Novel Experimental Technology, CA, USA). Gels were analysed by the software 
LabImage® (version 2.62, Labsoft Diagnostics AG, Germany). Standard curves 
were constructed for the relationship between the size of bands in the molecular 
marker lane and the distance travelled by these bands. The molecular weights 
of bands observed on the gel were interpolated from these standard curves. 
2.2.B.3. RADIO- AND FLUORO-IMAGING OF SDS-PAGE GELS 
The Storm® scanner (Molecular Dynamics, Amersham Biosciences, 
Uppsala, Sweden) was used to acquire images of SDS-PAGE gels used to 
analyse radiolabelled or fluorochrome-conjugated proteins. In the case of 
radiolabelled proteins, the SDS-PAGE gel was exposed to a phosphor screen 
(Molecular Dynamics, Amersham Biosciences, Uppsala, Sweden) for 3 h prior to 
Coomassie blue staining. The phosphor screen was scanned at 100 micron 
resolution using the phosphor imager scanner-head. In the case of 
fluorochrome conjugated-proteins (Cy5), the gel was scanned using the red 
fluorescence/chemiluminescence scanner-head at 100 micron resolution and 
800 volts photomultiplier. Images obtained after scanning were processed with 
the associated software (ImageQuantTM, Molecular Dynamics, Amersham 
Biosciences, Uppsala, Sweden). SDS-PAGE gels were stained in Coomassie blue 
stain solution and destained as described above (Section 2.2.B.2.) then 




2.2.B.4. CONFIRMATION OF MODIFIED PAI-2 ACTIVITY 
The effect of PAI-2 modification on its biological function was determined 
by two methods; complex formation with uPA and inhibition of the activity of 
uPA. The ability of modified PAI-2 to form SDS-stable complexes with uPA was 
compared to unmodified PAI-2 as previously described (Hang et al., 1998; 
Ranson et al., 2002). Briefly, modified and unmodified PAI-2 were incubated for 
90 min at 37oC with equimolar amount of uPA in a final 20 µl of 1 x PBS, then 
fractionated by SDS-PAGE under reducing conditions (see Section 2.2.B.2.). 
The activity of modified PAI-2 was investigated by its ability to inhibit 
active uPA from acting on the synthetic colorimetric uPA substrate, 
Spectrozyme®-UK. Assays were performed in triplicate in 96-wells plate with 150 
µl final volume in each well and all solutions were prepared in 0.1 % gelatine 
buffer [0.1 g gelatine dissolved in 100 ml of dH2O containing 150 mM NaCl, 20 
mM Tris-HCl and adjusted to pH 8.4]. Unmodified and modified PAI-2 or BSA 
(negative control) at 2, 1 or 0.1 µg/ml were mixed with 20 IU uPA (100 µl of 200 
IU/ml actisolv uPA stock) in a final 150 µl of buffer. Standard curve was 
prepared by 1:2 serial dilutions of 20 IU uPA in a final 150 µl of buffer (see 
Appendix 3 for example, Section 7.3.). Reactions were incubated at 37oC for 30 
min. The Spectrozyme®-UK substrate (50 mM stock in DMSO) was prepared at 2 
mM in 0.1 % gelatine buffer and 50 µl aliquots were added to all wells including 
a triplicate blank wells (150 µl buffer only). The appearance of coloured product 
was assayed kinetically at 37oC for 10 min measuring absorbance at 405 nm 
every 15 sec using the Spectramax® plate reader. 
2.2.B.5. INSTANT THIN LAYER CHROMATOGRAPHY (ITLC) 
Instant thin layer chromatography was generally used for assessing 
percentage incorporation of radionuclide by protein or the purity of radiolabelled 
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protein from free contaminating radioisotope. Marks were placed 1 cm from 
both the bottom and top edges and at the middle of the 1 x 9 cm ITLC-SG strips. 
Sample (1 - 2 µl) was applied at the bottom 1 cm-mark and the strip was placed 
vertically in a minimal volume of mobile phase (0.1 M citrate pH 5.5, unless 
specified otherwise). Chromatography was performed until the solvent reached 
the top 1 cm-mark then the strip was cut into two pieces at the middle mark. 
The two pieces of each strip were placed in separate gamma counter tubes and 
radioactivity was measured. Since protein movement is retarded on these strips, 
radionuclide incorporation on the protein or purity was calculated as the 
percentage of activity at the bottom section (origin, Ori) over the sum of the 
activity at the bottom and top (solvent front, SF) sections. 
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Chapter 3: MODULATION OF THE EXPRESSION OF 
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR 






Expression levels of urokinase plasminogen activator (uPA) and its 
receptor (uPAR) strongly correlate with a malignant tumour cell phenotype 
(Andreasen et al., 1997; Wang, 2001). The role of uPAR as an integral 
membrane protein that specifically binds uPA has been long established. More 
recently, data suggests that uPA/uPAR may have two complementary 
functions; the established role as an activator of the proteolytic cascade on the 
surface of cancer cells (reviews by Mignatti and Rifkin, 1993; Andreasen et al., 
1997) and another non-proteolytic role as a component of a signal transducing 
assembly and cell adhesion factor (Busso et al., 1994; Chapman, 1997; Fazioli 
et al., 1997). 
Expression of the various components of the plasminogen activation 
system is under regulation by hormones, cytokines and growth factors both 
under normal physiological conditions and during cancer. For example, the 
cytokines interleukin-2 (IL-2) and interleukin-1β (IL-1β) up-regulate both uPA 
and uPAR (Ogura et al., 2001; Al-Atrash et al., 2002). Basic fibroblast growth 
factor (bFGF) or transforming growth factor (TGF)-alpha increase invasion 
activity and associate with increases in cellular mRNA levels of uPA and uPAR 
(Mori et al., 2000). The upregulation of uPA and uPAR by these, and other 
factors, is mediated largely by classical mitogenic signalling pathways (Aguirre 
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Ghiso et al., 1999a). Evidence suggests that upon experimental oncogenic 
transformation or in spontaneous human cancers, mitogenesis and expression 
of uPA and uPAR are activated through common signalling complexes and 
pathways (Aguirre Ghiso et al., 1999a). Interestingly, several examples of these 
mitogenic signalling pathways have been shown to be activated by uPA 
binding to uPAR and/or the interaction of uPAR with integrins and/or 
vitronectin and mediate the role of uPA/uPAR in cancer invasion and 
metastasis. The activation of these pathways have been described by the 
interaction of several adaptors such as integrins, calveolin and G-protein-
coupled receptor (GPCR) with uPAR (reviewed by Ossowski and Aguirre-Ghiso, 
2000; Blasi and Carmeliet, 2002). 
The ability to modulate the expression of physiologically important 
proteins in cultured mammalian cells after delivering the encoding cDNA or 
mRNAs (transfection) have important applications for analysing their in vivo 
functions. Utilising these techniques, early in vitro and in vivo studies 
investigated the role of uPA/uPAR in cancer invasion and metastasis. For 
example, uPAR downregulation via anti-sense transfection techniques - 
delivery of anti-sense cDNA or mRNA - renders many human cancers dormant 
(Kook et al., 1994; Mohanam et al., 1997; Yu et al., 1997; Mohan et al., 1999; 
Lakka et al., 2001; Liao et al., 2001; Wang et al., 2001). Such studies showed 
that, as an activator of the proteolytic cascade, uPA/uPAR enhances local 
invasion, intravasation and metastasis formation (for more details and 
examples see Andreasen et al., 1997). While these early studies addressed the 
end-point result on cancer invasion and metastasis, a growing number of 
investigations are interested in understanding the mechanisms underlying the 
effects of modulating the expression of uPA/uPAR. For example, evidence 
suggests that uPAR downregulation leads to abolishment of 
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uPA/uPAR/integrin(α5β1)–dependent signal transduction; reducing the 
extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) pathway activation (Aguirre Ghiso et al., 1999b) or focal adhesion 
kinase (FAK) mitogenic signalling (Aguirre Ghiso, 2002) and resulting in 
cancer cell dormancy. In contrast, overexpression of uPAR through its 
interaction with integrins is responsible for generating a feedback loop where 
ERK activity increases and this feeds back by increasing the expression of 
uPAR (Aguirre-Ghiso et al., 2001). A similar positive feedback loop is also 
activated by the binding of uPA to uPAR that activates ERK signalling which in 
turn increases uPAR on the cell surface (Ma et al., 2001). In addition to 
activation of ERK proteins, binding of uPA to uPAR activates myosin light 
chain kinase (MLCK) thus affecting cell motility (Nguyen et al., 1999). The level 
of uPAR occupancy affects cysteine- and metallo-protease expression during 
macrophage differentiation (Rao et al., 1995) which is mediated by activation 
of FAK and MAPK following the occupancy of uPAR by uPA (Tang et al., 1998). 
Given the crosstalk between uPA/uPAR and other cell-surface adaptors (e.g. 
integrins), extracellular proteins (e.g. vitronectin) and intracellular signalling 
pathways, modulation of uPAR expression is expected to affect various cell-
surface markers and cell behaviour including the ability to bind uPA-inhibitors 
e.g. PAI-2. 
3.1.A. RATIONALE AND AIMS 
The aim of this chapter was to modulate the expression of uPAR on 
invasive and non-invasive breast cancer cell lines using transfection 
methodology. This involved the cloning of uPAR cDNA in sense and antisense 
orientations into an expression vector and then extensive optimisation of 
transfection protocols for the different cell lines used. The transfected cells were 
used for PAI-2 binding studies (see Chapter 4) and also provided materials for 
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studies concerning the relationship between uPA/uPAR overexpression and 
plasminogen binding capacity on cancer cells (Stillfried, G., Al-Ejeh, F. and 
Ranson, M., manuscript in preparation). 
3.2. METHODS 
3.2.A. BIOINFORMATICS TOOLS 
The sequence of human uPAR cDNA (ID: X51675 Roldan et al., 1990), 
and pBSM13+ were obtained from the National Centre for Biotechnology 
Information (NCBI). Sequence alignments were performed using ClustalW® 
(version 1.7, Thompson et al., 1994). Restriction enzyme sites on DNA stretches 
were detected using the software pDRAW32 (the DNA analysis software version 
1.1.61 by AcaClone® software). The software pDRAW32 was also used for 
drawing maps of plasmids and genes based on their sequences. 
3.2.B. PRODUCTION OF PLASMID CONSTRUCTS AND ANALYSIS 
3.2.B.1. AGAROSE GEL ELECTROPHORESIS 
Electrophoresis was performed using specified volumes of DNA with DNA 
sample buffer [5 x concentration: 30 % glycerol; 0.125 % w/v xylene cyanol, 
0.125 % w/v bromophenol blue]. The molecular weight marker, λDNA digested 
with Hind III restriction enzyme (lab preparation at 37 ng/µl), was mixed (5 µl) 
with 1 µl of 5 x DNA sample buffer.  Solutions were loaded onto a set agarose gel 
[1.2 % w/v agarose dissolved in 1 x Tris-Borate-EDTA (TBE) buffer]. 
Electrophoresis was performed at 70 volts for 1 h in 1 x TBE [10 x buffer 
prepared at 108 g/l Tris-HCl; 55 g/l boric acid, 40 mM EDTA pH 8.0 and 
diluted 1 in 10 for use at 1 x concentration]. Gels were stained in 1 µg/ml 
ethidium bromide solution for 30 min, destain in distilled water (dH2O) for 30 
min or more (as required) then visualised and documented using the Novex® gel 
document system. 
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All gels were analysed using Gel-Pro Analyzer™ software (version 3.1, 
Media Cybernetics, MD, USA). A standard curve was constructed for the 
relationship between the distance travelled and the molecular weight of the 
bands in the molecular weight marker lane. The sizes of bands in samples 
loaded were interpolated from this standard curve. Similarly, a standard 
calibration curve was constructed for the relationship between the amount of 
bands in the molecular weight marker and the intensity of their staining. The 
amount of DNA in loaded samples was calculated based on these calibration 
curves. Spectrophotometry was used to determine the purity of DNA 
preparation expressed as the ratio of absorbance at 260 nm (DNA) to the 
absorbance at 280 nm (protein) as per Maniatis et al. (1989). 
3.2.B.2. RESTRICTION ENZYME DIGESTION 
Analytical restriction enzyme digestions were performed using 2 µg of 
DNA, 2 µl of the compatible 10 x restriction enzyme buffer and 1 µl restriction 
enzyme (approximately 1000 units) diluted with dH2O to final volume of 20 µl 
and mixed gently. The reaction was spot-centrifuged and incubated at 37oC for 
3 h or overnight prior to agarose gel electrophoresis (Section 3.2.B.1.). For 
preparative restriction enzyme digestion, the volumes and amounts were 
increased and incubated at 37oC for 24 h. 
3.2.B.3. ELECTROELUTION OF DNA FROM AGAROSE 
This was performed as described by Maniatis et al. (1989). Briefly, DNA of 
interest was separated using agarose gel electrophoresis followed by ethidium 
bromide staining (Section 3.2.B.1.). Stained DNA fragments were visualised 
using a hand-held ultra-violet lamp and the bands of interest were excised 
using a razor blade. One end of a washed dialysis tube (prepared by boiling in 1 
mM EDTA (pH 8.0) for 10 min and then washed in water) was sealed and the 
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slice of agarose containing the band of interest was transferred into the tube. 
Approximately 350 µl of 1 x TBE buffer was added, enough to keep the excised 
agarose in constant contact with buffer. The other end of the dialysis tube was 
sealed forming a bag. The bag was immersed in 1 x TBE buffer and 
electrophoresis was performed. The hand-held ultra-violet light was used to 
visualise the movement of the DNA fragments out of the gel piece and 
electrophoresis was stopped. The buffer containing the DNA fragments were 
collected and phenol/chloroform extractions followed by ethanol precipitation 
with 0.3 M sodium acetate (pH 5.5) were performed as described by Maniatis et 
al. (1989). 
3.2.B.4. CDNA LIGATION 
A mixture was prepared in a final 8.5 µl of dH2O containing 50:1 mass-
ratio mixture of insert (uPAR cDNA): linearised cloning vector (pcDNA3) and was 
incubated at 45oC for 5 min. The DNA mix was cooled on ice and 1 µl of 10 x 
ligation buffer and T4 DNA ligase (0.5 µl of 400 U/µl) were added. Reaction was 
incubated at room temperature overnight and then frozen for further use. 
3.2.B.5. DYE TERMINATOR CYCLE SEQUENCING 
DNA strands were sequenced using an automated ABI 377 sequencer 
(Applied Biosystems, CA, USA). Cycle sequencing reactions were carried out as 
per manufacturer’s instructions (Applied Biosystems, CA, USA) in final 10 µl 
volumes containing 3.5 µl of BigDyeTM terminator mix v2.0, 3.2 µM of primer for 
the universal promoter T7, 3 % v/v DMSO and 200 - 300 ng of plasmid DNA. 
Thermocycling conditions were one cycle at 95°C for 3 min, followed by 28 
cycles at 95°C for 15 sec and 3.5 min at 60°C. Reactions were precipitated by 
the addition of 2 µl of DNA precipitation buffer (1.5 M sodium acetate pH 8; 250 
mM EDTA) and 10 µl of dH2O. Ice-cold 100 % ethanol was added at five-volumes 
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of the reactions and the samples incubated on ice for 5 min. These were 
centrifuged at 12500 g for 15 min, supernatant discarded and pellets washed 
once with ice-cold 70 % ethanol before air-drying. Reactions were resuspended 
in 3.5 µl DNA loading buffer and denatured at 90°C for 3 min before plunging 
on ice until running sequencing gel. Sequencing gels were prepared in a final 50 
ml volume of dH2O containing 1 x TBE buffer, 6 M Urea and 4.8 % PAGE-
PLUSTM both deionized with AG® 501-X8 resin. Solutions were filtered using 
0.22 µm filters and the gel was polymerized with 35 µl TEMED and 350 µl of 10 
% APS. 
3.2.B.6. REPARATION OF UPAR SENSE AND ANTISENSE EXPRESSION 
VECTORS: RATIONALE OF CDNA CLONING 
The pcDNA3 plasmid was used as an expression vector as it contains the 
high efficiency Human cytomegalovirus immediate-early (CMV) promoter for 
high-level expression in a wide range of mammalian cells (Invitrogen® Life 
Technologies, NSW, Australia). The uPAR cDNA insert (Roldan et al., 1990) was 
provided as pBluescriptM13+/uPAR+ (pBSM13+/uPAR+) by Professor E. Kruithof 
(Geneva). The uPAR cDNA was cloned in the sense orientation into the plasmid 
pcDNA3 (Figure 12) (Ranson M., unpublished data). This plasmid, designated 
pcDNA3/uPAR+, was confirmed to contain the uPAR cDNA in the sense 
orientation by restriction enzyme analysis (Figure 12). In order to clone the 
cDNA in the antisense orientation into pcDNA3 plasmid (designated 
pcDNA3/uPAR-), uPAR cDNA was released from pBSM13+/uPAR+ plasmid using 
Not I and Hind III restriction enzyme digestion and the pcDNA3 plasmid was 
linearised using the same restriction enzyme combination (Figure 13). The uPAR 
cDNA and linearised pcDNA3 plasmid were purified by electroelution and DNA 
extraction/precipitation as described earlier (Section 3.2.B.3.). cDNA was ligated 
into the linearised pcDNA3 as described in Section 3.2.B.4. to produce the 
pcDNA3/uPAR- plasmid. The presence of the uPAR cDNA in the antisense 
orientation was confirmed by restriction enzyme analysis (Figure 13). 
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Figure 12: Confirmation of uPAR cDNA inserted into pcDNA3 in sense direction 
The ~ 1150 kb uPAR cDNA was excised from pBSM13+/uPAR+ by restriction with Not I 
and Xho I, as confirmed by agarose gel electrophoresis. Excised uPAR cDNA was ligated 
with Not I/Xho I digested pcDNA3 mammalian expression vector. The produced plasmid 
(pcDNA3/uPAR+, prepared by Ranson M., unpublished data) was confirmed to contain 
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Figure 13: uPAR cDNA cloning in antisense orientation into pcDNA3 vector 
The ~ 1150 kb uPAR cDNA was excised from pBSM13+/uPAR+ by restriction with Not I 
and Hind III, as confirmed by agarose gel electrophoresis. The pcDNA3 mammalian 
expression vector was also digested with Not I and Hind III. Digested pcDNA3 and uPAR 
cDNA were electroeluted from agarose gel then ligated to produce pcDNA3/uPAR- 
plasmid which was confirmed to contain the uPAR cDNA in the antisense orientation by 
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3.2.B.7. TRANSFORMATION OF COMPETENT ESCHERICHIA COLI 
Luria Broth [LB 100 ml: 10 g/l trypton, 5 g/l yeast extract and 10 g/l 
NaCl] was inoculated with 2 ml of freshly prepared overnight culture of 
Escherichia coli (E. coli). The inoculated medium was incubated at 37oC with 
shaking at 180 rpm until the optical density at 600 nm wavelength reached 0.5 
(OD600 nm = 0.5 approximately after 3 h using LB as a blank). Grown bacteria 
were centrifuged at 3020 x g for 10 min at 4oC. The pellet was incubated on ice 
for 10 min and then resuspended in 50 ml of ice-cold 0.1 M MgCl2. The solution 
was centrifuged at 3020 x g for 10 min at 4oC and the pellet was resuspended in 
5 ml of ice-cold 0.1 M CaCl2. Solution was divided to 1 ml aliquots and the 
competent E. coli was stored 4oC until further use (maximum 7 days storage). 
Plasmids constructs (5 µl, ~ 5 µg) were mixed with 100 µl of competent  
E. coli cells and incubated on ice for 30 min. Transformation reaction was heat-
shocked at 42oC for 45 seconds and then placed on ice for 2 min. SOC medium 
[900 µl sterile solution containing: 2 % w/v Bactotryptone, 0.5 % w/v yeast 
extract; 10 mM NaCl; 2.5 mM KCl; 20 mM MgCl2; 10 mM MgSO4 and 20 mM 
Glucose] was added and the reaction was incubated at 37oC with 180 rpm 
shaking for 1 h. Aliquots (10, 100 and 890 µl) of the transformation reaction 
were spread onto three separate Z-agar plates [sterile 1.5 % w/v agar in LB] 
containing 100 µg/ml ampicillin (Amp) antibiotic. Plates were incubated at 37oC 
overnight and colonies were randomly selected and screened for the presence of 
plasmid containing the uPAR cDNA in the designated orientations. Briefly, 
single colonies were used to inoculate separate 3 ml aliquots of LB media 
containing 100 µg/ml Amp for plasmid mini-preparations as described by 
Maniatis et al. (1989). Isolated plasmids were analysed by restriction enzyme 
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mapping to confirm the presence and orientation of uPAR cDNA (Section 
3.2.B.2.). 
3.2.B.8. PLASMID MIDI-PREPARATION 
Colonies containing the pcDNA3 plasmid with the insert uPAR cDNA in 
the desired orientations were used to make overnight starting cultures which 
were then used to inoculate 50 ml of LB media containing 100 µg/ml Amp. After 
overnight incubation at 37oC with constant 180 rpm shaking, samples of the 
cells (100 µl) were used to prepare glycerol: cells (7:1 v:v) stocks for storage at –
80oC. The remainder of the bacterial cell culture was centrifuged at 6000 x g for 
15 min at 4oC. Plasmid midi-preparations were then performed to extract the 
DNA from bacterial cells as per manufacturer’s instructions using the Qiagen® 
plasmid midi-prep kit. The DNA pellet produced was resuspended in water, then 
chloroform/phenol extractions and ethanol precipitation were performed as 
described by Maniatis et al. (1989). The precipitated plasmids were sterilised by 
rinsing in 100 % ethanol in a biohazard sterile hood, the final sterile extracted 
DNA solution was resuspended in sterile TE buffer [10 mM Tris-HCl, pH 7.4; 1 
mM EDTA] and frozen at -20oC until further use. The DNA concentration was 
determined specifically for each plasmid preparation from standard curves 
constructed from the molecular weight marker for the relationship between the 
amount of DNA and intensity of ethidium bromide staining. The absorbance at 
260 nm (DNA) and 280 nm (protein) measured for plasmid solutions allowed 
measurement of the purity of DNA. 
The concentration of plasmid DNA solutions ranged between 0.8 and 1.2 
µg/µl and were in the range of pure DNA preparation (A260/A280 = 1.8 - 2) (data 
not shown, see Section 7.2 - Appendix 2 for example). Dye terminator cycle 
sequencing (Section 3.2.B.5.) of the plasmid constructs using T7 promoter-
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primer confirmed the presence of the uPAR cDNA in the sense (Figure 14) and 
antisense (Figure 15) orientations. 
GAGCTGnCCTCnCCnACATGGGTnACCCGTCGCTGCTGCCGTTGnnGTTGCCTGnTCnAC 97 
































 || |   |||| ||| |||||||  || ||||||| ||||||||| ||| ||||| ||| 
GATCCAGGAAGGTGAAGAAGGGCGTCCAAAGGATGA-CCGCCACCTCCGT-GGCTG-TGG 583 
                                                   
nTACCTTCCCnGCTGnCCGGGCTTTCCAATGGTTTCCAC 616 
 ||||||||| |||| ||||||  ||||||||||||||| 
CTACCTTCCCGGCTGCCCGGGC--TCCAATGGTTTCCAC 620 
  
Figure 14: Alignment of sequence from pcDNA3/uPAR+ and Human uPAR gene 
The sequence from the chromatogram produced from the ABI prism cycle sequencer 
(black) was exported and aligned with human uPAR gene sequence (red, NCBI accession 
#: X51675, Roldan et al., 1990) using the ClustalW® program. Matched pairs are 
marked by ( | ) and the sequence shows almost complete homology to the uPAR cDNA 



















































|||| ||||||| ||||| ||||| ||||  ||||||| |||||||||||| 
CACAGGAAATGCATTCGAGGTAACGGCTT--CGGGAAT-AGGTGACAGCCC 388  
Figure 15: Alignment of sequence from pcDNA3/uPAR- and human uPAR gene 
The sequence produced from the ABI prism cycle sequencer (black) was aligned with 
human uPAR gene sequence (red, NCBI accession #: X51675, Roldan et al., 1990) using 
the ClustalW® program. Matched pairs are marked by ( | ) and the sequence shows 
almost complete homology to the uPAR cDNA gene when aligned in the opposite  
orientation (3’  5’) (antisense). 
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3.2.C. TRANSIENT TRANSFECTION OF CANCER CELLS WITH UPAR CDNA 
Transient transfection of mammalian cells was optimised using the 
Lipofectamine™ 2000 and Superfect® transfection reagents. The pcDNA3/uPAR 
sense (pcDNA3/uPAR+) plasmid was used with MCF-7 and T-47D cell lines and 
pcDNA3/uPAR antisense (pcDNA3/uPAR-) plasmid with the MDA-MB-231 cell 
line. Transfection was performed as per manufacturer’s instruction as follows. 
Cells cultured for 48 h were detached using Trypsin-EDTA and resuspended at 
1 x 106 cells/ml in RPMI-1640 containing 5 % FCS. Cells were seeded into 6-
wells plates containing 2 – 2.5 ml RPMI-1640 containing 5 % FCS in order to 
achieve subconfluent culture after overnight incubation at 37oC. After this 
incubation complexes between plasmid DNA and reagent for each well were 
formed by incubating together in 200 µl RPMI-1640 for 20 min at RT after 
which 300 µl of RPMI-1640 containing 5 % FCS was added to the plasmid DNA: 
reagent complexes. Control treatments were prepared identically either in the 
absence of reagent (plasmid DNA only control), absence of plasmid DNA (reagent 
only control) or in the absence of both plasmid DNA and reagent (negative 
control). While the manufacturer’s instructions recommend the addition of the 
final 500 µl transfection solution directly to the 2 – 2.5 ml cell culture media, it 
was found that removal of culture media and incubation of cells only with the 
transfection solution overnight then supplementing the cells with 2 ml of 
culture media significantly increased the transfection efficiency (data not 
shown). 
Transfection optimisation in terms of cell-surface uPAR levels as 
detected by flow cytometry involved variation in the number of cells, amount of 




3.3.A. OPTIMISATION OF TRANSIENT TRANSFECTION OF CANCER CELLS 
Initial transfection experiments using the Superfect® reagent in the 
absence or presence of pcDNA3/uPAR- showed this reagent to be cytotoxic to all 




Figure 16: Cytotoxic effect of Superfect® reagent and plasmid DNA on  
MDA-MB-231 cells 
Density plots showing fluorescence of propidium iodide (PI) detected by FL-2 detector on 
Y-axis plotted against forwards scatter (FSC) on the X-axis. Cell viability of transfected 
cells was assessed in comparison to a gate established for viable population (excluding 
PI) of untreated cells (region R1).Cell populations presented were identically treated 
during the transfection procedure where an overnight culture of 5 x 105 MDA-MB-231 
cells per well in 6-wells plates were seeded overnight then incubated overnight with 
transfection solution: (A) in the absence of pcDNA3/uPAR- plasmid and Superfect 
reagent, (B) presence of 7.5 µl reagent alone, (C) 1.5 µg DNA with 3 µl Superfect, (D) 1.5 
µg DNA with 4.5 µl Superfect or (E) 1.5 µg DNA with 7.5 µl Superfect. Cells were 
supplemented with 2 ml of culture media, incubated for further 24 h and viability was 
assessed (i.e. 48 h after transfection) by the incorporation of propidium iodide (PI) dye. 
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Treatment of cells with the Superfect® reagent alone showed a slight 
toxicity in comparison to untreated cells. However, fluorescence due to 
incorporation of PI dye significantly increased when cells were transfected using 
the same amount of DNA with increasing volumes of the Superfect® reagent 
(Figure 16). This observed toxicity due to transfection with the Superfect® 
reagent was also seen with the other cell lines (data not shown), thus the 
Superfect® reagent was abandoned. 
3.3.A.1. TRANSIENT TRANSFECTION OF MDA-MB-231 CELLS 
Initial transfection experiments of MDA-MB-231 cells with 
LipofectamineTM-2000 transfection reagent showed that 24 h after addition of  
1 µg pcDNA3/uPAR- plasmid DNA and 2 µl of reagent, uPAR expression 
significantly decreased by 30 % in comparison to that with non-transfected 
MDA-MB-231 cells (Figure 17 - A, p < 0.05, n = 4). The cell-surface expression 
of uPAR on cells transfected using the 1:2 ratio was significantly different from 
all other reagent-treated cells (Figure 17 – A, p < 0.05, n = 4). Treatment of cells 
with the 1:2 plasmid DNA to reagent ratio displayed the lowest PI incorporation, 
indicating lower toxicity compared to the other treatments (data not shown). 
Finally, the expression of uPAR on the surface of cells treated with other 
plasmid DNA to reagent ratios or reagent alone was not significantly different 
from that of control MDA-MB-231 cells (Figure 17 - A, p > 0.05, n = 4). For 
further optimisation, the 1:2 pcDNA3/uPAR- plasmid (µg): LipofectamineTM-2000 
(µl) ratio was kept constant but the amounts was increased in addition to 
increasing the transfection time from 24 h to 48 h. Control MDA-MB-231 cells 
assayed at 48 h past transfection (Figure 17 – B) showed higher uPAR 
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Figure 17: The effect of LipofectamineTM-2000 on MDA-MB-231 cell-transfection 
MDA-MB-231 cells (5 x 105 cells/well in 2.5 ml of RPMI-1640 + 5 % FCS) were added to 
6-wells plate, incubated overnight and attached cells were washed and treated as 
follows. (A) Cells were incubated in transfection solution for 24 h and then assayed by 
flow cytometry. Transfection solutions were prepared using 1 µg pcDNA3/uPAR- in the 
absence (DNA only control) or presence of different volumes of LipofectamineTM-2000 
(LF) reagent. For the reagent control (LF only control), transfection solution was 
prepared using 4 µl of LipofectamineTM-2000 in the absence of plasmid DNA. (B) Cells 
were incubated in transfection solution for 24 h then supplemented with 2 ml of RPMI-
1640 + 5 % FCS and incubated for another 24 h then assayed by flow cytometry (i.e. 48 
h after transfection). Transfection solutions were prepared using 1 µg pcDNA3/uPAR- in 
the absence LipofectamineTM-2000 reagent (DNA only control) or using 1, 1.5, 2 and 2.5 
µg of pcDNA3/uPAR- complexed with 2, 3, 4 and 5 µl of LipofectamineTM-2000 reagent, 
respectively. uPAR expression was determined using the #3934 antibody (5 µg/ml) and 
data shown is the MFI ± SEM (n = 4). In order to measure cell-surface uPAR, only values 
from viable cells (excluded PI) were used and the asterisks denote statistically significant 
differences between cell-surface uPAR levels in comparison to the DNA control treatment 
(p < 0.05, n = 4). 
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The expression of uPAR at 48 h on MDA-MB-231 cells transfected at 
each of the pcDNA3/uPAR- plasmid concentration was significantly lower from 
control cells (p < 0.05, n = 4) (Figure 17 – B). The maximal decrease in uPAR 
expression was observed using 1.5 µg pcDNA3/uPAR- plasmid and 3 µl reagent 
(62 % decrease compared to control MDA-MB-231 cells; p < 0.05, n = 4). uPAR 
expression on cells transfected with 1 µg of pcDNA3/uPAR- plasmid and 2 µl 
reagent was higher at 48 h than that at 24 h (compare Figure 17 – A and B). 
The decrease in uPAR expression using the 1:2 plasmid DNA (µg) to 
LipofectamineTM-2000 (µl) ratio was not associated with significant cell death as 
assessed by PI incorporation (Figure 18). 
   
  
Figure 18: Viability of MDA-MB-231 cells transfected with increasing 
pcDNA3/uPAR-: LipofectamineTM-2000 amounts 
Cell populations were identically treated during the transfection procedure described 
earlier (Figure 17 – B). Cells were either incubated (A) in the absence of plasmid DNA 
and LipofectamineTM-2000 (LF) reagent, or with (B) 1.0 µg DNA: 2 µl LF, (C) 1.5 µg DNA: 
3 µl LF, (D) 2 µg DNA: 4 µl LF, (E) 2.5 µg DNA: 5 µl LF or (F) reagent (5 µl) alone. Viability 
was assessed by the exclusion of PI dye (R1 gate). 
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3.3.A.2. TRANSIENT TRANSFECTION OF T-47D CELLS 
Adopting the transient transfection procedure optimised for MDA-MB-
231 cells, uPAR expression in T-47D cells was significantly increased using 
different amounts and ratios of pcDNA3/uPAR+ plasmid: LipofectamineTM-2000 
reagent compared to cells treated with LipofectamineTM-2000 reagent alone 
(Figure 19, p < 0.05, n > 3). Transfection of T-47D cells with 1.5 µg 
pcDNA3/uPAR+ and 4.5 µl LipofectamineTM-2000 resulted in 2.0-fold increase in 
cell surface uPAR compared to cells treated with LipofectamineTM-2000 alone. 
Consistent high transfection efficiency and cell viability were obtained when  
5 x 105 of T-47D cells were transfected using 2 µg of pcDNA3/uPAR+ and 6 µl of 
LipofectamineTM-2000 reagent (data not shown). 
LF only control
1 DNA: 2 LF
1.5 DNA : 1.5 LF
1.5 DNA: 3 LF
1.5 DNA: 4.5 LF
























Figure 19: Transfection of T-47D cells with different amounts of pcDNA3/uPAR+: 
LipofectamineTM-2000 complexes 
T-47D cells were used to inoculate 6-wells plate at 5 x 105 cells per well in 2 ml of RPMI-
1640 + 5 % FCS the day before transfection procedure. Cells were transfected according 
to optimised protocol using specified pcDNA3/uPAR+ plasmid (µg): of LF reagent (µl). 48 
h past transfection, cells were detached and assayed for uPAR expression using the 
MAB807 anti-uPAR monoclonal antibody (10 µg/ml). Data shown is the MFI ± SEM (n ≥ 
3) for cell-surface uPAR detection. Asterisks mark significantly different uPAR levels in 
comparison to control treatment (no DNA control, 0 µg DNA: 4.5 µl LF) (p < 0.05, n ≥ 3). 
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Given that conditions were optimised in terms of cell-viability and uPAR 
expression, mock transfections were also performed using the a 1:3 ratio (2 µg: 
6 µl) of pcDNA3 plasmid: LipofectamineTM-2000 reagent for 48 h incubation in 
order to determine whether the increase of cell-surface uPAR was specifically 
due to the presence of uPAR cDNA expression. As shown in Figure 20 - A, 
transfection of T-47D cells with pcDNA3 plasmid did not affect cell-surface 
uPAR levels at all. In contrast, transfection of these cells with pcDNA3/uPAR+ 
plasmid significantly increased cell-surface uPAR compared to both control and 
mock-transfected T-47D cells (p < 0.05, n = 3) as detected by flow cytometry 
(Figure 20 – A) and confocal microscopy (Figure 20 – B). 
 
3.3.B. THE EFFECT OF UPAR OVEREXPRESSION 
The effect of increasing uPAR expression via transfection was investigated 
with respect to cell-surface expression of the components of the plasminogen 
activation pathway and cell morphology. Flow cytometry and confocal 
microscopy techniques (see Section 2.2.A.) were used to compare control and 
transfected cells. 
3.3.B.1. CELL-SURFACE ANTIGEN CHANGES 
The upregulation of uPAR on the surface of T-47D cells was found to be 
associated with significantly increased levels of endogenous cell-surface uPA 
and increased lysine-dependent binding of plasminogen (Table II). The values 
were obtained from five different transfection experiments performed 




















Figure 20: Increased cell-surface 
uPAR is due transfection with uPAR 
cDNA 
(A) Cell-surface uPAR level was 
determined on DNA only control (2 µg 
pcDNA3/uPAR+: 0 µl LF, clear bars), 
mock-transfected (2 µg pcDNA3: 6 µl 
LF, light grey) and pcDNA3/uPAR+-
transfected (2 µg pcDNA3/uPAR+: 6 µl 
LF, dark grey) T-47D cells using the 
MAB807 antibody. Data presented are 
the MFI ± SEM (n = 3) and the viability 
of cell population in all assays was 
higher than 70%. The levels on 
pcDNA3/uPAR+-transfected cells were 
significantly different compared to both 
control and mock-transfected cells  
(p < 0.05). (B) Mock-transfected (I and 
II) and pcDNA3/uPAR+-transfected  
(III – VI) T-47D cells were analysed by  
B 
                Mock Transfected                                    pcDNA3/uPAR+ transfected 
   
   
confocal microscopy. Mock- and pcDNA3/uPAR+-transfected cells were incubated with polyclonal anti-uPAR 
antibody (I - IV, 20 µg/ml). pcDNA3/uPAR+-transfected cells were alternatively incubated with isotype control 
(rabbit serum, V and VI, 20 µg/ml). Cells were then incubated with anti-rabbit IgG FITC-conjugated 
antibody, washed and analysed by confocal microscopy. Top panels are transmission images of basal 
sections and the scale bars represent 10 µm of actual length. Bottom panels are the corresponding fluoro-




Table II: The effect of uPAR overexpression on uPA levels and plasminogen 
binding on T-47D cells 
uPAR  uPA  Plg Experiment 
number Mean SEM  Mean SEM  Mean SEM
1 3.0 0.3  2.5 0.1  1.4 0.1 
2 2.2 0.1  1.9 0.1  1.8 0.1 
3 1.8 0.3  1.5 0.2  1.4 0.5 
4 1.2 0.2  1.3 0.4  1.5 0.6 
5 1.6 0.2  1.3 0.0  2.4 0.3 
T-47D cells were transfected according to the optimised transfection protocol where 5 x 
105 cells were seeded in 2 ml of RPMI-1640 + 5 % FCS per well in 6-wells plate, 
incubated overnight, washed and incubated for 24 h with transfection solution 
containing preformed complexes (20 min at RT) of 2 µg pcDNA3/uPAR+ and 6 µl 
LipofectamineTM-2000 in 200 µl RPMI-1640 then 300 µl RPMI-1640 + 5 % FCS was 
added. Cells incubated with the 500 µl transfection solution were supplemented with 2 
ml or RPMI-1640 + 5 % FCS and incubated for another 24 h before flow cytometry 
assays using MAB807 anti-uPAR and #392 anti-uPA antibodies for cell-surface uPAR 
and uPA, respectively. Lysine-dependent plasminogen binding was also determined by 
flow cytometry using plasminogen-FITC incubated with cells in the absence or presence 
of TA. Controls were either no treatment, LipofectamineTM-2000 reagent alone or mock-
transfected (2 µg pcDNA3 complexed with 6 µl LipofectamineTM-2000) which showed no 
difference in uPAR expression. Values presented are the mean fold-increase of cell-
surface parameter on transfected cells compared to control T-47D cells. There was a 
significant difference between the levels of each parameter on control and 
pcDNA3/uPAR+-transfected T-47D cells in all cases (p < 0.05, n ≥ 3). Values shown were 
obtained from viable cells only (excluded PI) and thus represent cell-surface levels. 
A linear correlation (r2 = 0.95) described the relationship between the 
fold-increase of endogenous cell-surface uPA and the fold-increase of cell-
surface uPAR shown in Table II (Figure 21). This indicated that the significant 
increase in cell-surface expression of uPAR on T-47D cells was directly 
associated with increased uPA levels on the cell-surface. Cell-surface uPA 
completely co-localised with cell-surface uPAR on pcDNA3/uPAR+-transfected  
T-47D cells (Figure 22), emphasising the role of uPAR to localise uPA on the 
cell-surface. Nevertheless, areas of unoccupied uPAR were evident in the 
overlays, indicating incomplete occupancy of cell-surface uPAR. 
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As suggested in Table II, the increase of lysine-dependent binding of 
plasminogen, whilst significant, failed to directly correlate to either the increase 
of cell-surface uPAR or the resulting increase of endogenous cell-surface uPA 
(data not shown). Mock-transfected T-47D cells did not show any significant 
changes in cell-surface uPA and lysine-dependent plasminogen binding in 
comparison to untreated T-47D cells (p < 0.05, n = 3) (data not shown). 























Figure 21: Correlation between increased surface uPAR and uPA on transfected 
T-47D cells 
The fold-increase of cell-surface uPA on transfected T-47D cells compared to control 
cells was directly correlated to the fold-increase of cell-surface uPAR. Data points are 
the mean of triplicate determination for both control and transfected T-47D cells. Error 
bars are the SEM and data were obtained from independent assays performed at 
different times. The bold line represents the linear correlation with a regression (r2) of 




Figure 22: Distribution of cell-surface uPA and uPAR on T-47D cells transfected 
with uPAR cDNA 
Transiently transfected T-47D cells were stained with mouse anti-human B-chain uPA 
then goat anti-mouse IgG Cy3-conjugated antibody. Cells were washed and then 
incubated with rabbit anti-human uPAR polyclonal antibody (provided by David 
Croucher, University of Wollongong) then goat anti-rabbit IgG FITC-conjugated 
antibody. There was no leakage between the FITC and Cy3 channels and addition of 
secondary antibodies alone did not produce any staining (data not shown). Furthermore, 
according to manufacturer’s specifications, the goat anti-mouse IgG Cy3-conjugated and 
the goat anti-rabbit IgG FITC conjugated antibodies do not show cross reactivity. Co-
localisation of uPAR (green, panel II) and uPA (blue, panel III) is shown in the overlay 
and appear in cyan colour (panel IV). The image shown is a representative sample 
obtained from basal sections and the scale bar in the transmission image (panel I) 
represents 10 µm. 
The optimised transfection procedure was utilised to modulate uPAR 
expression on MCF-7 cells. This cell line did not resist manipulation as cell 
viability was generally low when cells were assayed by flow cytometry (50 – 70 % 
viability). This reduced viability was consistently observed with experiments on 
both control and transfected MCF-7 cells. Despite this resistance to 
manipulation, a small but significant increase in uPAR expression was observed 




but significant increase in cell-surface uPA (Figure 23). However, this was not 
accompanied by a significant increase in the lysine-dependent binding of 
plasminogen possibly due to the low increase in cell-surface uPAR/uPA on 
MCF-7 cells or that the overexpression of uPAR/uPA on T-47D and MCF-7 cells 
























Figure 23: The effect of uPAR overexpression on MCF-7 cells 
MCF-7 cells were transfected with pcDNA3/uPAR+ plasmid and cell-surface uPAR 
(#3934 antibody), uPA (#392 antibody) and lysine-dependent plasminogen binding were 
compared between DNA only control (empty bars) and transfected (grey bars) cells. Data 
are the MFI ± SEM (n = 3) and cell viability in all assays ranged between 65 – 75 %. Only 
the lysine-dependent plasminogen binding was not significantly different between 
control and transfected cells (p > 0.05). Data presented are from one representative 
experiment and similar data were observed in other experiments. 
3.3.B.2. SPATIAL AND MORPHOLOGICAL CHANGES 
Control and T-47D cells transiently transfected with pcDNA3/uPAR+ 
plasmid were analysed for the localisation of uPAR, uPA and plasminogen 
binding on the cell-surface by confocal microscopy. Cell-surface uPA and 
plasminogen binding on control T-47D cells was very low (Figure 24 – A) 
compared to pcDNA3/uPAR+-transfected T-47D cells (Figure 24 – B and C). 
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Plasminogen binding was greatly reduced in the presence of the lysine analogue 
TA (Figure 24 – D), indicating that lysine-dependent binding dominated the total 
plasminogen binding to transfected cells. Thus, confocal microscopy analysis 
emphasised the success of the transfection procedure and showed that 
endogenous cell-surface uPA levels and plasminogen binding were increased in 
association with overexpression of uPAR on these cells. 
Control incubations with antibody isotypes (e.g. Figure 24 – E), 
secondary antibodies alone (data not shown) or in the presence of TA (Figure 24 
– D) confirmed the lack of signal leakage between the different channels used for 
the detection of the different fluorochrome-emissions by the confocal 
microscope. Therefore, overlays of images were a bona fide evidence of co-
localisation not artefacts of staining procedure. uPA and plasminogen binding 
had a higher distribution on the cell surface at basal and transverse sections 
(Figure 24) compared to the apical surfaces (data not shown) of attached 
transfected T-47D cells. Plasminogen binding and uPA displayed a punctuate 
distribution and co-localised almost completely on transfected T-47D cells. 
Nevertheless, small areas on the cell surface of the transfected cells did not bind 
plasminogen although uPA appeared in these areas. 
Control T-47D cells displayed a general cuboidal (spherical) shape as 
seen in the transmission images in Figure 24. The overexpression of uPAR 
affected the morphology of these cells where transfected cells appeared to 
display a more elongated (fibroblastic) shape compared to control cells. This was 
seen in most transmission images of transfected T-47D cells; however it was 
most apparent in the transmission images displayed in Figure 24 – B and C 
compared to Figure 24 - A. 
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Figure 24: Confocal microscopy of control and T-47D cells transiently transfected with pcDNA3/uPAR+ plasmid 
T-47D cells cultured on glass slide cover-slips were transfected as per optimised protocol and subjected to double staining procedure then analysed by 
confocal microscopy. Cells in Panels I - IV were incubated with pcDNA3/uPAR+ plasmid only (control T-47D cells) whereas in Panels V - XX were 
incubated with pcDNA3/uPAR+: LipofectamineTM-2000 complexes (pcDNA3/uPAR+-transfected T-47D cells). Cells in Panels I – XII were incubated with 
plasminogen-Cy5, washed and incubated with anti-B-chain uPA monoclonal antibody (#394, 20 µg/ml) then with anti-mouse IgG FITC-conjugated 
antibody. Cells in Panels XIII- XVI were incubated with plasminogen-Cy5 in the presence of TA, washed and incubated with anti-B-chain uPA 
monoclonal antibody (#394, 20 µg/ml) then with anti-mouse IgG FITC-conjugated antibody. Cells in panels XVII – XX were incubated with 
plasminogen-Cy5 then with mouse isotype IgG1 followed with anti-mouse IgG FITC-conjugated antibody. The lack of signal in XV when cells incubated 
with TA compared to VII and XI when cells incubated in the absence of TA indicate that plasminogen binding is completely lysine dependent on these 
cells and that the signal from uPA staining (green, VI, X and XIV) did not leak into the plasminogen channel (red, VII, XI and XV). On the other hand, 
the lack of signal in XVIII indicates that staining with anti-uPA antibody is specific (no staining seen with isotype) and that the signal from plasminogen-
Cy5 (VII, XI, and XIX) does not leak into the uPA channel (VI, X, and XVIII). Images in I, V, IX, XIII and XVII are transmission images and the scale bars 
represent 10 µm of actual length. Overlays of uPA and plasminogen staining are shown in IV, VIII, XII, XVI and XX and co-localisation appears in 
orange/yellow. All images shown in Figure were obtained from basal sections of the attached cells (i.e. sections at the site of attachments to the cover 
slip) except for Panels IX - XII. Images in Panels IX - XII were obtained from transverse section (i.e. section between the basal [attachment site] and 
apical [opposite side] sections of attached cells). Transverse sections were selected where the cells are largest and the membrane is highest in focus. 
Images shown in the Figure are representative samples of several assays each performed in replicates (> 3 images per assay). 
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3.3.C. COMPARISON BETWEEN T-47D AND MDA-MB-231 CELLS 
The previous results showed that the overexpression of uPAR resulted in 
increase of uPA and lysine-dependent plasminogen binding on the surface of  
T-47D cells (Table II and Figure 24). Taken together, the overexpression of 
uPAR/uPA and increased plasminogen binding on T-47D cells appeared to 
manifest a more metastatic phenotype (Ranson et al., 1998). To further 
characterise the effect of uPAR-overexpression on T-47D cells, these cells were 
directly compared to the metastatic MDA-MB-231 cells. 
3.3.C.1. CO-LOCALISATION OF UPA AND PLASMINOGEN 
The lysine-dependent binding of plasminogen on the surface MDA-MB-
231 cells was independent from the pattern of uPA distribution at both the 
basal (Figure 25) and transverse sections (data not shown). Cell-surface uPA 
displayed a punctuate distribution while diffused plasminogen binding was 
observed on MDA-MB-231 cells. These patterns were previously reported on this 
cell line by Andronicos and Ranson (2001). In comparison to MDA-MB-231 
cells, transiently uPAR-overexpressing T-47D cells displayed punctuate 
distribution and very high co-localisation of both uPA and plasminogen (Figure 
24). Cell-surface uPA and plasminogen binding on MDA-MB-231 cells was more 
than 5- to 10-fold higher than that on uPAR-overexpressing T-47D cells. This 
indicated that MDA-MB-231 cells still showed a more malignant phenotype, 
however, in order to allow spatial comparison, the signals detected in Figure 24 
and Figure 25 were normalised to the same level. 
3.3.C.2. THE EFFECT OF EXOGENOUS UPA BINDING ON PLASMINOGEN BINDING 
Incubation of MDA-MB-231 cells with exogenous uPA showed a 
significant increase (1.5-fold) of cell-surface uPA compared to control cells (p < 
0.05, n = 3, Figure 26 - A). This indicated that majority, but not all, of cell-
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surface uPAR was occupied with uPA (69 % in the representative Figure 26 - A) 
prior to addition of exogenous uPA. The level of uPA and the occupancy of uPAR 
on the surface of MDA-MB-231 cells were much higher than control or 
transfected T-47D cells. Furthermore, in contrast to T-47D cells (Figure 26 - B), 
lysine-dependent binding of plasminogen on MDA-MB-231 cells was not 
significantly different before and after incubation with exogenous uPA (p > 0.05, 
n = 3, Figure 26 - A). 
The incubation of T-47D cells with exogenous uPA showed a significant 
increase (2.3-fold) of cell-surface uPA compared to control T-47D cells (p < 0.05, 
n = 3, Figure 26 - B). This indicated that only a fraction (44 % in the 
representative Figure 26 - B) of cell-surface uPAR was occupied with uPA prior 
to addition of exogenous uPA. Lysine-dependent binding of plasminogen also 
significantly increased (2.2-fold) on cells incubated with exogenous uPA 
compared to control T-47D cells (p < 0.05, n = 3, Figure 26 - B). It should be 
noted that uPAR occupancy was not significantly different between transfected 
and control T-47D cells, 44 ± 6 % and 36 ± 2 % respectively (p > 0.05 from 
experiments repeated 3 times in triplicate, data not shown). 
3.3.C.3. EFFECT OF UPA OR UPAR BLOCKING ON PLASMINOGEN BINDING 
Lysine-dependent plasminogen binding was not significantly different 
between cells blocked with anti-uPA or anti-uPAR antibodies and cells blocked 
with isotype antibody (p > 0.05, n = 3 in two identical assays) (data not shown). 
This indicated that blocking of uPA or uPAR on transfected T-47D cells did not 
specifically affect plasminogen binding. The lysine-dependent binding of 
plasminogen to the invasive MDA-MB-231 cells also was not significantly 
affected by conditions leading to the blocking of uPA or uPAR (p > 0.05, n = 3 in 
two identical assays) (data not shown). 
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Figure 25: Distribution of uPA and plasminogen binding on MDA-MB-231 cells 
Cells cultured on glass slide cover-slips were subjected to double staining procedure, mounted onto glass slides and analysed immediately by confocal 
microscope. Scale bars in all images represent 20 µm and only images from basal sections are presented. Top panel: Cells incubated with 
plasminogen-Cy5 followed by indirect immunostaining for uPA using anti-B-chain uPA antibody (#394) then by rabbit anti-mouse IgG FITC conjugated 
antibody. Bottom panel: Cells incubated with plasminogen-Cy5 in the presence of 5 mM TA followed by uPA staining. The lack of signal in the 
plasminogen channel when cells incubated in the presence of TA indicate that plasminogen binding was lysine-dependent and that signal from uPA 


































































Figure 26: Effect of exogenous uPA on plasminogen binding to the cell-surface 
Cell-surface uPA (using the #394 antibody) and lysine-dependent binding of 
plasminogen (using plasminogen-FITC) to (A) MDA-MB-231 cells and (B) T-47D cells 
were determined by flow cytometry before and after the incubation of cells with 
exogenous uPA (50 nM). Data presented are the MFI ± SEM (n = 3) and cell-viability was 
higher than 70 % and 90 % in all assays for T-47D and MDA-MB-231 cells, respectively. 
One asterisk denotes significant differences in cell-surface uPA level before and after 
incubation with exogenous uPA (p < 0.05). Two asterisks denote significant differences 
in the lysine-dependent binding of plasminogen to the cell-surface before and after 
incubation with exogenous uPA (p < 0.05). 
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3.4. DISCUSSION 
A transient transfection procedure was successfully optimised using the 
LipofectamineTM-2000 transfection reagent and uPAR cDNA for the modulation 
of cell-surface expression of uPAR in breast cancer cell lines. Consistent 
significant increases (1.5- to 3-fold) of cell-surface uPAR were observed by 
transfection of T-47D cells with pcDNA3/uPAR+ plasmid using LipofectamineTM-
2000 reagent. 
The increase of cell-surface uPAR on T-47D cells was associated with 
increased cell-surface levels of uPA and plasminogen binding. Mock 
transfection, using null pcDNA3 plasmid, confirmed that this increase of cell-
surface markers was specifically due to transfection of these cells with the uPAR 
cDNA. The increase of cell-surface uPA and plasminogen binding observed may 
be due to concurrent increased secretion of uPA and overexpression of
plasminogen receptors with the overexpression of uPAR in T-47D cells. The
direct correlation between the increase of cell-surface uPA and the increase of 
cell-surface uPAR on transfected T-47D cells supported this. Kariko et al. 
(1993) reported that transfection of human osteosarcoma cell line (HOS) with 
uPAR cDNA showed a 2-fold increase in the surface expression of uPAR 
associated with 2-fold increase in receptor-bound uPA-mediated plasmin 
generation. In contrasting experiments, antisense inhibition of the cell surface 
expression of uPAR not only suppresses ERK/MAPK signalling activity but was 
also associated with inhibition of adhesion, suppression of uPA secretion and 
inhibition of pro-MMP-9 secretion (Ahmed et al., 2003a). In fact, proteomic 
analysis of uPAR-antisense-clones compared to wild-type and mock-
transfected control colon cancer cell line (HCT116) cells shows the loss of 
approximately 200 proteins and quantitative differences in the expression of 
141 other proteins (Ahmed et al., 2003b). Thus, evidence in the literature supports 
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the notion that transfection of T-47D cells with uPAR cDNA may have affected 
the secretion of uPA and expression of plasminogen receptors on the cell 
surface along with that of cell-surface uPAR. 
The low occupancy (44 %) of cell-surface uPAR on control untransfected 
T-47D cells indicated that free uPAR was available for uPA binding prior to 
transfection. The increase of cell-surface uPA on transfected T-47D cells is due 
to concurrent upregulation of uPA expression and secretion in these cells, 
which allowed more uPA to the increased cell-surface uPAR. Interestingly, 
despite the increase of both cell-surface uPA and uPAR, overall uPAR occupancy 
on transfected T-47D cells (~ 50 %) was not significantly different from that on 
control T-47D cells. This was also reflected by the fact that there was a direct 
correlation between the increase of cell-surface levels of uPAR and uPA, thus 
the occupancy rates of uPAR on the cell-surface was not affected. In other 
words, these cells appear to dynamically maintain a proportion of receptor 
unoccupied despite transfection procedures. The significance of maintenance of 
unoccupied receptors on these cells prior to and after transfection may be 
related to the newly characterised functions of unoccupied uPAR. The clustering 
of unoccupied uPAR has been implicated in cell signalling leading to changes in 
adhesion and migration (Koshelnick et al., 1997; Sitrin et al., 2000; Gellert et 
al., 2003; Sitrin et al., 2004) via association with lipid rafts or caveolae (Wei et 
al., 1999) and integrins (Tarui et al., 2001). Since the binding of uPA restricts 
the lateral mobility of uPAR (Myöhänen et al., 1993), reserving unoccupied 
receptor may be a tactic used by cells to allow the movement of uPAR to focal 
adhesion contact points where it may cluster and accumulate with caveolae 
(Wei et al., 1999) and integrins before being occupied by uPA and being 
restricted to these areas. 
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While there was not a direct correlation, the increase in uPAR/uPA on 
transfected T-47D cells corresponded to an increase in plasminogen binding 
capacity. Furthermore, plasminogen binding was co-localised with cell-surface 
uPA when analysed by confocal microscopy. On both MDA-MB-231 and uPAR-
overexpressing T-47D cells, uPA preferentially distributed to basal sections of 
attached cells. This was in agreement with previous studies which documented 
the high concentration of uPA/uPAR at focal adhesion sites (see review by 
Andreasen et al., 1997). Areas of co-localisation of uPA and plasminogen were 
confirmed on cell-surface of MDA-MB-231 cells as previously shown by 
Andronicos and Ranson (2001). However, the overall distribution of 
plasminogen was different on transfected T-47D cells compared to MDA-MB-
231 cells. MDA-MB-231 cells showed a broader diffuse staining for plasminogen 
and not all co-localised with uPA (as per Andronicos and Ranson, 2001). The 
large colocalisation of uPA and plasminogen on transfected T-47D cells in 
addition to the increased plasminogen binding observed on control T-47D cells 
when incubated with exogenous uPA suggests that uPA may act as a receptor 
for plasminogen. In support of this suggestion, a novel non-active-site 
interaction between uPA and plasminogen is necessary for the assembly and 
efficiency of cell-surface plasminogen activation complexes (Ellis et al., 1999). 
The inability to reduce the binding of glu-plasminogen when T-47D cells where 
blocked with anti B-chain uPA monoclonal antibody confirmed that bound 
plasminogen was independent of the active site of uPA. Similarly, this antibody 
did not alter the co-localisation of glu-plasminogen and uPA detected by 
confocal microscopy of MDA-MB-231 cells (Andronicos and Ranson, 2001). The 
anti A-chain uPA monoclonal antibody also did not affect plasminogen binding 
on transfected T-47D cells or MDA-MB-231 cells. This antibody is raised against 
a different epitope in the A-chain of uPA deduced by Ellis et al. (1999) for the 
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binding of glu-plasminogen, thus the possibility of uPA acting as a site for 
plasminogen binding cannot be confidently excluded. 
All together, the underlying reason for the co-localisation of glu-
plasminogen and uPA on the cell surface is to efficiently generate plasmin on 
the cell surface (Andronicos and Ranson, 2001). However, other potential 
receptors responsible for the co-localisation of plasminogen at close proximity to 
cell-surface uPA are not known. Furthermore, comparison of transfected T-47D 
cells to transfected MCF-7 cells complicates the scenario since both transfected 
cell-lines displayed increased cell-surface uPAR and uPA, whereas only T-47D 
cells showed increased plasminogen binding upon transfection with uPAR 
cDNA. Similarly, while plasminogen binding increased on T-47D cells incubated 
with exogenous uPA, plasminogen binding was not affected on MDA-MB-231 
after the binding of exogenous uPA to these cells. These differences may reflect 
cell line differences related to the expression of different plasminogen receptors. 
In order to provide an explanation to these findings, two models are 
proposed. First, intracellular signals initiated from increased uPAR and/or 
increased uPA binding to uPAR may increase the expression of plasminogen 
receptors on the cell surface. Intracellular signalling pathways initiated by 
uPAR/uPA are indicated to regulate the proteolytic as well as the non-
proteolytic functions of the urokinase plasminogen pathway such as cellular 
adhesion, chemotaxis, cell proliferation, expression, differentiation and 
endocytosis (see reviews by Conese and Blasi, 1995; Andreasen et al., 1997; 
Chapman, 1997; Dear and Medcalf, 1998; Konakova et al., 1998; Preissner et 
al., 2000; Blasi and Carmeliet, 2002). Increased plasmin generation, which 
would require increased plasminogen binding, has been described for uPAR 
cDNA transfected human osteosarcoma (HOS) cells (Kariko et al., 1993). In the 
case of control untransfected T-47D cells incubated with exogenous uPA, 
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intracellular signals are initiated simply due to the binding of uPA to 
unoccupied cell-surface uPAR (Figure 27). Sufficient evidence exists to suggest 
that intracellular signalling due to uPAR/uPA overexpression and/or the 
addition of exogenous uPA was responsible for increased plasminogen binding 
in T-47D cells. This appeared not to be the case for transfected MCF-7 cells 
possibly due to inefficient increase in cell-surface uPAR/uPA. 
The second proposed model which may explain the increased 
plasminogen binding on uPAR/uPA overexpressing T-47D cells or uPA-
incubated control T-47D cells may relate to proteolytic activity on the cell 
surface (Figure 27). The increased proteolytic activity of plasmin on the cell-
surface may have caused the exposure of new lysine residues nearby and 
resulted in increased plasminogen binding and the apparent co-localisation of 
uPA and plasminogen on transfected T-47D cells. This was not observed on 
MDA-MB-231 cells incubated with exogenous uPA since the cell-surface may 
have been already maximally activated for plasminogen binding on these 
invasive cells. In the case of transfected MCF-7 cells the small increase in cell-
surface uPAR/uPA may have not substantially increased plasmin activity on the 
cell-surface. Candidates receptors for plasminogen include actin, annexin II, 
cytokeratin 8, α-enolase, megalin and tetranectin (reviewed by Félez, 1998; 
Ranson and Andronicos, 2003). While only cytokeratin 8 and α-enolase display 
a C-terminal lysine residue required for the lysine-dependent binding of glu-
plasminogen, the other plasminogen receptors may be considered as latent 
receptors which require plasmin modification for glu-plasminogen binding 
(Félez, 1998; Ranson and Andronicos, 2003). Thus, increased cell-surface uPA 
on transfected T-47D cells and control T-47D cells incubated with exogenous 
uPA as well as increased plasminogen receptors may result in increased 
plasmin activity which may in turn activate latent plasminogen receptors. 
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Finally, the overexpression of uPAR affected the morphology of 
transfected T-47D cells where the cells adopted a less epithelial (round) shape 
and more fibroblastic (elongated) shape, similar to MDA-MB-231 cells, in 
comparison to control T-47D cells. This observation is supported by data 
showing that, in contrast, antisense uPAR-transfected human glioma cell line 
(SNB19) adopt larger and more round morphology, fail to form an organised 
actin cytoskeleton and do not spread efficiently when plated over ECM 
substrates in comparison to control cells (Chintala et al., 1997). Thus, 
modulation of uPAR-expression appears to affect cell differentiation/expression 
and morphology relating to the malignant phenotype of cancer cells. 
In summary, transient overexpression of uPAR cDNA in T-47D cells 
affected the level of cell-surface uPA and plasminogen binding. Transient uPAR-
overexpressing T-47D cells, as discussed in the next chapter were used to 
assess PAI-2 binding in comparison to other breast cancer cell lines. uPAR-
overexpressing T-47D cells were also useful to elucidate some molecular details 
regarding the effect of uPAR expression on invasiveness. Increased lysine 
dependent plasminogen binding due to increased cell-surface uPA on uPAR-
overexpressing T-47D cells or control T-47D cells incubated with exogenous 
uPA suggests a role for uPA/uPAR in plasminogen binding. Two models for this 
effect were proposed, illustrated in Figure 27, which describe possible molecular 
details for increased invasiveness due to uPAR overexpression however; future 
work is required to provide definitive evidence for these conclusions or other 
explanations. 
 
Figure 27: Proposed model for increased plasminogen binding due to increased cell-surface uPA/uPAR 
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Chapter 4: KINETIC ANALYSIS OF UPA:PAI-2 COMPLEX 
FORMATION AND SUBSEQUENT INTERNALISATION BY 





Binding of uPA to its receptor significantly increases the rate of uPA-
mediated plasminogen activation in vitro (Ellis et al., 1991) and in vivo (Quax et 
al., 1991b). The co-localisation of plasminogen with uPA at cell surfaces 
provides a mechanism for accelerated plasminogen activation by cells 
(Andronicos and Ranson, 2001). Receptor-bound plasmin is protected from 
inactivation by circulating inhibitors (Hall et al., 1991) and thus promotes the 
remodelling of the local extracellular environment by either directly degrading 
basement membranes and extracellular matrix (ECM) or by activating pro-
metalloproteases (Andreasen et al., 1997). Plasmin is also responsible for the 
release of latent growth/angiogenic factors from ECM (Bass and Ellis, 2002; 
Rakic et al., 2003). 
The proteolytic activity of soluble and uPAR-bound uPA is efficiently 
inhibited by PAI-1 and PAI-2 (see Section 1.4.D. for details, Cubellis et al., 1989; 
Ellis et al., 1990; Pöllänen et al., 1990). The crystal structures and inhibitory 
mechanism of both PAI-1 (Nar et al., 2000) and PAI-2 (Jankova et al., 2001; 
Saunders et al., 2001) are well defined (see Section 1.4.D.1). Both act as classic 
serpins and form SDS-stable 1:1 stoichiometric complexes with the catalytic site 
on their target protease (Kruithof et al., 1995; Huntington et al., 2000; Nar et al., 
2000; Jankova et al., 2001; Saunders et al., 2001). 
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Although the PAI-2 inhibitory mechanism is well characterised in vitro, to 
date only indirect quantitative analyses of cell-bound uPA inhibition by PAI-2 
have been made by monitoring plasminogen activation using a coupled 
colorimetric assay (Ellis et al., 1990; McGowen et al., 2000). Using such an 
assay, Ellis et al. (1990) derived the second order association rate constant 
value of 3.3 x 105 M-1s-1 on U937 cells, thus were the first to describe the rapid 
and efficient inhibition of cell surface uPAR-bound uPA by PAI-2. However, 
insights into the serpin inhibitory mechanism gained since this study was 
published (Kruithof et al., 1995; Jankova et al., 2001; Saunders et al., 2001) 
cast some doubt on the parameters used to measure inhibition. Silverman 
(1996) states that as serpins are ‘mechanism-based enzyme inactivators’, in 
that they irreversibly inhibit their target protease by forming a covalent bond 
with the protease (Huntington et al., 2000), the two principal parameters for 
describing this class of inhibitors are the inactivation rate constant (kinact) and 
the inactivation constant (KI). As PAI-2 has been shown to be a classic serpin 
(Jankova et al., 2001; Saunders et al., 2001), kinact and KI are more appropriate 
parameters for measuring inhibition by PAI-2. The irreversible formation of the 
complex between PAI-2 and uPA reflects the complete inhibition of uPA activity. 
Therefore, the level of PAI-2 binding to cells would provide a direct measure for 
the inhibition of cell-surface uPA. While Estreicher et al. (1990) investigated the 
kinetics of complex formation between receptor-bound uPA on the THP-1 
monocytic cell line and PAI-2, this was a semi-quantitative and indirect analysis 
of PAI-2 binding as 125I-uPA was used as the means of detection. Thus, the 
inactivation constants for PAI-2 inhibition of uPA (kinact and/or KI) have not been 
previously reported. 
There is also very little direct data regarding the fate of PAI-2 after 
inactivation of uPAR-bound uPA. In contrast, PAI-1, either added to uPAR-
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bound uPA or as a preformed complex with uPA, has been definitively shown to 
induce the rapid cellular internalisation and degradation of the complex. This 
internalisation process requires uPAR and one or more of the members of the 
low density lipoprotein receptor (LDLR) family of endocytosis receptors such as 
α2-macroglobulin receptor/low-density lipoprotein receptor-related protein 
(α2MR/LRP) (see reviews by Andreasen et al., 1997; Loskutoff et al., 1999). 
Estreicher et al. (1990) reported that 125I-uPA:PAI-2 complexes are rapidly 
cleared from the cell surface of THP-1 cells following the formation of a cell-
surface bound 70 kDa degradation intermediate. The identity of the cleavage 
site or product was not ascertained. Jensen et al. (1990) reported that PAI-2 
mediated about 40 % degradation of uPAR-bound 125I-uPA on human 
choriocarcinoma cells. Both authors speculated that like PAI-1, PAI-2 mediates 
the endocytosis of uPAR-bound uPA whereupon both uPA and PAI-2 are 
degraded in lysosomes. However, neither study provided data supporting these 
claims. Ragno et al. (1995), also using THP-1 cells, found that the 125I-uPA:PAI-2 
complex is cleaved into a 70 kDa fragment (comprising the uPA B chain 
complexed to PAI-2) as well as a 22 kDa fragment (mostly uPA A chain) after 
binding to uPAR. These authors concluded that neither the 22 nor 70 kDa 
fragments are internalised but rather that the 70 kDa fragment is released into 
the cell medium while the 22 kDa fragment remains cell-surface bound. It 
should be noted that a 70 kDa fragment (Saunders et al., 1998: See Figure 5) as 
well as a 22 kDa fragment (Croucher et al., unpublished data) can also be 
obtained in solution by incubating excess 55 kDa uPA with PAI-2. This suggests 
that the intermediary formation of these fragments may not necessarily be a 
step related to uPAR binding of uPA:PAI-2 but to an undefined cleavage step in 
solution. Despite these apparent contradictions and lack of any direct evidence, 
it has become accepted in the literature that PAI-2, unlike PAI-1 and other 
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serpins, is not internalised after inhibiting uPAR-bound uPA on cells (Andreasen 
et al., 1997; Andreasen et al., 2000; Schmitt et al., 2000). 
 
4.1.A. RATIONALE AND AIMS 
The inhibition kinetics of PAI-2 towards cell-surface uPA were measured 
using coupled assays which utilised uPA-mediated plasmin generation as an 
indicator of PAI-2 inhibition of uPA. The aim of this chapter was to develop 
binding assays to measure uPA:PAI-2 complex formation on the cell surface which
would directly reflect PAI-2 inhibitory kinetics on the cell-surface. Due to the 
controversial fate of cell-bound uPA:PAI-2 complexes, it was also the aim to 




4.2.A. PREPARATION OF 125I-PAI-2 FOR RADIOLIGAND BINDING STUDIES 
Radio-iodination of PAI-2 was performed as per manufacturer’s 
instructions (Pierce Chem. Co., IL, USA) and as previously described (Hang et 
al., 1998). Briefly three iodo-beads were washed three times with 3 ml of  
1 x PBS (pH 7.2) at room temperature and dried on Whatman #1 filter paper. 
Washed beads were transferred to a reaction tube containing 0.5 milli-Curies 
(mCi) of iodine-125 radioisotope (125I) diluted in a final 500 µl volume of 1 x PBS. 
After 5 min incubation at room temperature, 50 µg of PAI-2 was added to the 
reaction vessel, mixed gently and incubated 15 min at room temperature. 
Radiolabelled PAI-2 was immediately separated from free 125I by size 
exclusion chromatography where PD-10 columns were equilibrated with 15 ml 
of freshly prepared elution buffer [1 x PBS, 0.1 % w/v BSA, pH 7.4]. The 
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radiolabelling reaction was allowed to pass through the column followed by two 
0.2 ml aliquots of elution buffer. Ten to twelve 0.5 ml-fractions of the eluant 
were collected during the continuous addition of elution buffer. Aliquots (10 µl) 
from eluted fractions were counted using normalised‡ Cobra 5005R gamma (γ)-
counter (Packard Instruments Co., CT, USA). The fraction(s) corresponding to 
the first high radioactivity peak were collected. This represented radiolabelled 




















Figure 28: Representative purification profile of 125I-PAI-2 
Radiolabelling and purification of 125I-PAI-2 were performed as described earlier. The 
radioactivity of 10 µl aliquots from the 0.5 ml fractions collected was measured and 
plotted (Y-axis) against the elution volume required to obtain that fraction (X-axis). The 
first peak (i.e. fraction 4) represents purified 125I-PAI-2 whereas the second peak 
represents free 125I. 
                                          
‡ See Appendix 1 (Section 7.1.) for normalisation procedure of the Cobra® γ-counter 
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The percentage of free 125I in the purified 125I-PAI-2 solution was 
determined by instant thin layer chromatography (Section 2.2.B.5.). The purity 
of 125I-PAI-2 was generally more than 95 % (97 ± 1 %, n = 4) indicating that the 
majority of free 125I was removed from 125I-PAI-2. 
4.2.A.1. DETERMINATION OF SPECIFIC RADIOACTIVITY 
The specific radioactivity of 125I-PAI-2 was determined using two 
methods; autoradiography of SDS-PAGE fractionation and utilising the data 
from PD-10 column purification (Bolton, 1977). This was done due to the 
contaminating presence of BSA in the preparations as 0.1 % BSA (fraction V§) 
was used in the PD-10 column purification. 
In the first method, both 125I-PAI-2 and 125I-uPA:PAI-2 complexes were 
fractionated on the same gel as PAI-2 standards of known protein amounts 
(Figure 29 – A). Autoradiogram of this showed that all of the 125I-PAI-2 was 
complexed with uPA, thus the 98 kDa band (Lane 2 Figure 29 – B) contains all 
the 125I-PAI-2 added to the reaction. This indicated that some of the protein in 
the 47 kDa band (Lane 1 Figure 29 – A) was due to the contaminating presence 
of BSA which mostly fractionated at around this molecular weight (data not 
shown). Since uPA:PAI-2 form 1:1 complexes, then 50 % of the protein in the 98 
kDa band (Lane 2 Figure 29 – A) is due to PAI-2. The amount of 125I-PAI-2 in the 
aliquot (10 µl) used was interpolated by comparison of the intensity of the 98 
kDa band (Lane 2 Figure 29 – A) to the standard curve constructed for the 
relationship between amounts of PAI-2 protein standards (Lanes 3 – 6 Figure 29 
– A) and staining intensity (data not shown). 
                                          
§ BSA was used in PD-10 purification in order to minimise the non-specific binding of 
the small amounts of PAI-2 used to the column bed or plastic. 
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Figure 29: Representative SDS-PAGE and autoradiogram of 125I-PAI-2 
125I-uPA:PAI-2 complexes were generated as described in Section 2.2.B.4 except that a 
molar excess of uPA was used. (A) Samples were fractionated by reducing 12 % SDS-
PAGE, (B) the gel was exposed to phosphor screen for 3 h and the screen was scanned, 
then the gel was stained with Coomassie blue, destained and documented. Lane 1: 125I-
PAI-2, lane 2: 125I-uPA:PAI-2. Equivalent amount of 125I-PAI-2 (10 µl) was used for lanes 
1 and 2. Lanes 3 – 6: PAI-2 standard solutions - 0.1, 0.4, 0.8 and 1.0 µg respectively. 
The position and size of bands (in kDa) of the molecular weight marker are shown at the 
right. SDS-PAGE and autoradiography produced the amount of 125I-uPA:PAI-2 complex 
(98 kDa). This was converted to the amount of 125I-PAI-2 using molar equivalence since 
1 mole of complex is equivalent to 1 mole of PAI-2. 
The second method for determination of protein concentration utilised 
the data from PD-10 column purification (Bolton, 1977). Briefly, the difference 
between the total radioactivity used and the activity eluted as free 125I was 
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calculated to represent PAI-2-bound radioactivity (data not shown). The 
radioactivity of the selected purified fraction over the total bound radioactivity 
represented the percentage recovery of protein in the purified fraction (e.g. 6.3 
% for preparation shown in Figure 28). The amount of PAI-2 in the purified 
fractions was calculated by the percentage recovery and the total amount of 
PAI-2 used (6.3 µg for preparation in Figure 28). The estimated protein 
concentration of 125I-PAI-2 preparations was almost identical using the two 
different methods and the average was used (Table III). Thus, specific 
radioactivity (s.a.) could be calculated and this was based on the average 
protein concentration derived using the above two methods, radioactivity in 
each sample and the purity of 125I-PAI-2 preparations (Table III). 
4.2.B. PREPARATION OF PAI-2-CY5 FOR INTERNALISATION STUDIES 
PAI-2 was labelled with Cy5 fluorochromes as per manufacturer’s 
instructions of the Cy5 mono-reactive dye pack (Amersham Biosciences, 
Uppsala, Sweden). PAI-2-Cy5 was separated from free Cy5 by size-exclusion 
chromatography (see Section 4.2.B.1.); however BSA was not included in the 
equilibrium or elution buffer since large amounts of PAI-2 were used for the 
conjugation reactions. Purified PAI-2-Cy5 was stored in the dark at 4oC until 
further use. The protein concentration and the dye/protein ratio (D/P) for PAI-
2-Cy5 preparation were calculated as per manufacturer instructions**. PAI-2-
Cy5 retained the ability to form SDS-stable complexes with uPA (data not 
shown). 
 
                                          
** D/P = [Cy5]/[PAI-2] = (A650 / εCy5)/(A280 – (0.05 x A650)/ εPAI-2) 
Concentration is in molar units, A: is the absorbance and ε is the extinction 
coefficient (M-1 cm-1) 
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1 15 14 1.44 x 105 99.4% 1.28 x 107 6.01 x 108 
2 1.5 1.6 5.03 x 104 96.3% 4.07 x 107 1.91 x 109 
3 2.0 2.1 7.20 x 104 96.7% 4.35 x 107 2.05 x 109 
PAI-2 concentration was determined by (a) SDS-PAGE and autoradiography method or (b) PD-10 column-based method. Radioactivity was determined 
by counting the radioactivity of a known volume of 125I-PAI-2 solution. The specific radioactivity was calculated as the radioactivity concentration 
(corrected to 80 % counting efficiency of detector) multiplied by the percentage purity (bound activity) and divided by the average protein concentration. 
The specific activity was converted from units of cpm/µg to cpm/nmole using the molecular weight of PAI-2. 
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4.2.C. RADIOLIGAND BINDING STUDIES USING 125I-PAI-2 
The formation of complexes between 125I-PAI-2 and cell-surface uPA in 
terms of PAI-2 binding reflects the inhibition of uPA activity and can be used to 
analyse inhibitory kinetics of PAI-2 at the cell surface. Radioligand binding 
studies were performed using 125I-PAI-2 of known concentration and specific 
activity. Metastatic and non-metastatic breast carcinoma cell lines were 
prepared and resuspended in binding buffer as described earlier (Section 
2.2.A.1.). 
Initial binding experiments were performed in order to estimate the time 
required for saturation binding and establish a linear correlation between 
binding and cell number. Cells were incubated at 4oC with 125I-PAI-2 (~ 5 x 105 
cpm/ml) in the presence or absence of unlabelled PAI-2. Triplicate aliquots (200 
µl) were removed at the specified time point and cells were processed for 
radioactivity counting as described below. The relation between cell number and 
binding of 125I-PAI-2 was established by the incubation of increasing cell 
numbers at 4oC for the time required to reach saturation with 5 x 105 cpm/ml 
of 125I-PAI-2 in the absence or presence of unlabelled PAI-2. The amount of  
PAI-2 bound was plotted against the number of cells. Further binding 
experiments were performed using the time required to reach saturation and 
number of cells which falls in a linear correlation in the relationship between 
the amounts of bound PAI-2. 
Generally, after binding of 125I-PAI-2 to cells, cells were processed for 
radioactivity counting and analysis as follows. Cells were washed using ice-cold 
1 x PBS containing 1 mM CaCl2 and 1 mM MgCl2, lysed using 200 µl of 0.1 M 
NaOH and counted using the γ-counter normalised for 125I counting. The total 
binding of PAI-2 was measured as the binding of 125I-PAI-2 in the absence of any 
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inhibitors, whereas the non-specific binding was measured as the binding of 
125I-PAI-2 to cells in the presence of 100-fold molar excess of unlabelled PAI-2. 
The specific binding in all assays was calculated as the difference between the 
total and non-specific binding. Binding was initially measured in units of 
radioactivity relative to the number of cells used (i.e. cpm per million cells). This 
binding was converted to be expressed in units of femtomole (fmole) per million 
cells using the specific activity of 125I-PAI-2 used (cpm/mole). Data from all 
binding experiments was analysed using the functions specified in the 
radioligand binding analysis software, GraphPad® prism (v 3.03). 
 
4.2.D. INTERNALISATION STUDIES USING PAI-2-CY5 
PAI-2-Cy5 and confocal microscopy were used to detect the fate of PAI-2 
on MDA-MB-231 and T-47D cells either detached or attached to cover slips. For 
detached cells, cells were prepared as described earlier (Section 2.2.A.1.), 
washed and resuspended in ice-cold phenol red-free binding buffer at 1 x 106 
cells/ml. The cell solution was adjusted to 37oC and PAI-2-Cy5 was added at a 
final concentration of 100 nM. Samples were removed at specified time points 
and diluted 1:25 in ice-cold phenol red-free binding buffer in order to stop the 
reaction. Samples were centrifuged at 652 x g for 3 min at 4oC and pellets were 
washed with ice-cold PBS containing 1 mM CaCl2 and 1 mM MgCl2 and 
analysed immediately by confocal microscopy (as described in Section 2.2.A.3.). 
For attached cells, cells grown for 48 h on cover slips in 6-wells plates were 
washed and activated with plasminogen (5 µg/ml in RPMI-1640 for 5 min at 
RT). Cells were washed four times using PBS containing 1 mM CaCl2 and 1 mM 
MgCl2, temperature was adjusted to 37oC and pre-warmed phenol red-free 
binding buffer containing 100 nM PAI-2-Cy5 was added. At specified time 
points, ice-cold phenol red-free binding buffer was added to dilute PAI-2-Cy5 
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solution then the total volume was immediately removed. Cells were washed 
gently 5 times with ice-cold 1 x PBS containing 1 mM CaCl2 and 1 mM MgCl2, 
cover slip mounted on glass slide and analysed immediately by confocal 
microscopy. In addition, internalisation was compared between cells before and 
after blocking of uPA by pre-incubation of cells with 20 µg/ml anti-B-chain uPA 
monoclonal antibody at 4oC. Cells pre-incubated with exogenous uPA (100 nM 
at 4oC for 30 min) were also compared to control cells. 
Endosomal and lysosomal markers conjugated with fluorochromes were 
utilised in order to detect whether PAI-2-Cy5 localised into these organelles. 
Cells were incubated for 20 min in ice-cold phenol red-free binding buffer 
containing 100 nM of PAI-2-Cy5 and 50 µg/ml transferrin-Alexa488 (endosomal 
marker Van Dam et al., 2002). Cells were washed with PBS containing 1 mM 
CaCl2 and 1 mM MgCl2 at room temperature and then resuspended in 37oC-
prewarmed phenol red-free binding buffer containing 75 nM LysoTracker® 
Yellow DND-68 (lysosomal marker). Samples were removed at specified time 
points, washed with ice-cold PBS containing 1 mM CaCl2 and 1 mM MgCl2 and 
analysed immediately by confocal microscopy. 
In order to confirm lysosomal degradation of any internalised uPA:PAI-2 
complexes, lysates of MDA-MB-231 cells pre-incubated with 100 nM PAI-2-Cy5 
at 37oC for specified periods of time were fractionated by 12 % SDS-PAGE under 
reducing conditions. The resulting gel was scanned using the red fluorescence 
scanner then Coomassie blue stained (as described in Sections 2.2.B.2. and 
2.2.B.3.) The acquired Cy5 fluoro-image was superimposed onto the Coomassie 
blue stained gel and the molecular weight of the observed bands in the Cy5 
scan was calculated using the standard molecular weight marker in the 
Coomassie blue stained gel. 
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4.2.E. EFFECT OF PAI-2 ON CELL-SURFACE UPA/UPAR LEVELS 
The effect of PAI-2 binding to cell-surface uPA on uPA/uPAR was 
analysed by flow cytometry. MDA-MB-231 cells pre-activated with plasminogen 
were incubated in the absence or presence of 100 nM of PAI-2 in binding buffer 
at 37oC. At specified time points, samples were removed, washed and then 
subjected to indirect immunofluorescence detection of cell-surface uPA and 
uPAR as described earlier (Section 2.2.A.2.). Anti human A-chain uPA 
monoclonal antibody was used since PAI-2 inhibits uPA by interaction at the 
uPA B-chain which may sterically hinder anti-B chain antibody access hence 
inhibit detection by flow cytometry. In order to test dose-dependency of the 
effect of PAI-2 on cell-surface uPA, this assay was performed using different 
concentrations of PAI-2 (1, 10 and 100 nM). 
The effect of PAI-2 on the total capacity of cells to bind uPA was assayed 
by incubation of cells with 100 nM of PAI-2 at 37oC and samples were removed 
at specified time points. The cells were adjusted to 4oC to inhibit any further 
possible endocytosis then incubated in the absence (endogenous uPA) or 
presence of 100 nM exogenous uPA (total maximal uPA) for 30 min on ice prior 
to analysis of cell-surface uPA by flow cytometry. The difference between the 
total maximal uPA and the endogenous uPA levels was used to represent the 
binding of exogenous uPA (i.e. unoccupied uPAR) under the effect PAI-2
internalisation over time. 
Finally, the effect of uPAR occupancy on the effect of PAI-2 on cell-
surface uPA was assayed on cells pre-incubated with 100 nM of exogenous uPA 
in binding buffer at 4oC (i.e. saturated cells) then incubated with 100 nM of PAI-
2 in binding buffer at 37oC. Samples were removed and washed and cell-surface 




4.3.A. QUANTIFICATION OF 125I-PAI-2 BINDING TO CELL-SURFACE 
UPAR-BOUND UPA 
4.3.A.1. JUSTIFICATION FOR PERFORMING BINDING EXPERIMENTS AT 4OC 
The use of uPA colorimetric substrates was not suitable to assay cell-
surface uPA activity since cell-viability was greatly reduced (> 90 % dead) within 
few minutes of incubation (data not shown). To the best of my knowledge,  
uPA:PAI-2 complex formation at 4oC over short periods of time has not been 
shown previously. Since cell binding experiments with 125I-PAI-2 required 
incubation at 4oC to prevent possible endocytosis, confirmation of complex 
formation at 4oC was essential in order to reflect complete inhibition of uPA 
activity. Incubation of molar excess of PAI-2 with uPA in fluid phase, to mimic 
cell binding studies where saturating amount of PAI-2 would be added to cells, 
showed that SDS-stable complexes between PAI-2 and uPA formed after 15 min 
at 4oC (Figure 30). The conversion of the synthetic colorimetric uPA substrate, 
Spectrozyme®-UK, was entirely inhibited when equimolar amounts of PAI-2 were 
incubated for 15 min with uPA in solution at 4oC (data not shown). Thus, 
complex formation between 125I-PAI-2 and cell-surface uPA at 4oC should occur 
and would reflect the inhibition of uPA activity. 
Initial binding experiments showed that complex formation on the 
metastatic MDA-MB-231 cells reached equilibrium by 30 min of incubation at 
4oC using 1.5 nM 125I-PAI-2 (data not shown). As only a small fraction of the 
total 125I-PAI-2 added was bound to cells, this indicated that PAI-2 ligand 
was not depleted in the assay (Motulsky and Christopoulos, 2004). Using this 
concentration of 125I-PAI-2 and 2 h incubation time, a linear correlation was 
established between the amount of PAI-2 bound and cell concentration (1 – 5 x 
106 cells/ml) (data not shown). Thus, subsequent experiments were performed 
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using ~ 1.5 nM 125I-PAI-2 and 1 - 4 x 106 cells/ml and 1 – 2 h incubation. 
Furthermore, 125I-PAI-2 binding assays did not affect cell viability as judged by 
trypan blue staining compared to control cells (incubated in the absence of PAI-

















Figure 30: Formation of uPA:PAI-2 complexes at 4oC in fluid phase 
A 4-fold molar excess of PAI-2 was incubated with uPA (containing both high [55 kDa] 
and low [33 kDa] molecular weight forms) at 4oC. Equal aliquots were removed after  
15 min (Lane 3), 30 min (Lane 4), 45 min (lane 5), 60 min (Lane 6) and 120 min (Lane 
7) and fractionated by reducing 12 % SDS-PAGE. PAI-2 alone (4 µg, Lane 2), uPA alone 
(1 µg, Lane 1) and 4-fold molar excess PAI-2 incubated with uPA for 120 min at 37oC 
(Lane 8) were also fractionated as controls. 
A series of 125I-PAI-2 binding experiments confirmed that PAI-2 binding 
capacity is directly related to the amount of cell-surface uPA which indicate that 
125I-PAI-2 binding to the cell-surface was reflective of uPA inhibition and that 
uPA is the only specific cell-surface protease inhibited by PAI-2 on human 
breast carcinoma cell lines. First, the specific 125I-PAI-2 binding on high uPA 
expressing MDA-MB-231 cells was significantly higher (~ 10-fold) than that on 
low uPA-expressing MCF-7 and T-47D cells (p < 0.05 n =3, Figure 31). 
Furthermore, for each cell line PAI-2 binding was significantly enhanced by 
plasminogen pre-treatment (to activate any receptor-bound pro-uPA) (Figure 
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31). These data also indicated that a proportion of the total endogenous cell 







































Figure 31: 125I-PAI-2 binding to metastatic and non-metastatic breast cancer cells 
MDA-MB-231, MCF-7 and T-47D cells were incubated in the absence (clear bars) or 
presence (filled bars) of 5 µg/ml plasminogen at room temperature. Cells were washed 
and incubated with 1.5 nM 125I-PAI-2 at 4oC for 2 h in the absence (total) or presence 
(non-specific) of 150 nM of unlabelled PAI-2. Specific binding was calculated and data 
presented are the mean ± SEM (n = 3). One asterisk denotes significant difference in 
PAI-2 binding to the same cell line under different treatment, whereas two asterisks 
denote significant difference between different cell lines subjected to the same treatment 
(p < 0.05). 
Secondly, when cell-surface uPA was either pre-blocked using a 
neutralizing monoclonal antibody, or a uPA specific active-site alkylating agent 
(EGR-CMK) or acid-stripped prior to 125I-PAI-2 incubation, the total 125I-PAI-2 
binding to MDA-MB-231 cells was reduced to the same levels obtained in the 
presence of excess unlabelled PAI-2 (i.e. non-specific binding, approximately 
25% of total binding) (Figure 32). These data indicate that all of the specific 
binding of PAI-2 to these cells can be attributed to cell surface uPAR-bound uPA 
and that there may be some non-specific binding sites for PAI-2. Similar results 
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were obtained using HCT116 colorectal (Hang et al., 1998) and PC-3 prostate 
(Al-Ejeh et al., 2004) carcinoma cells. This indicates that these treatments 
sufficiently decreased binding to non-specific binding levels and indicate that 
uPA is the only specific target for PAI-2 on breast, colorectal and prostate 
carcinoma cells. When surface-stripped cells were then incubated with 
exogenous uPA prior to 125I-PAI-2 incubation, total 125I-PAI-2 binding was 
enhanced by 2.3-fold compared to control cells (Figure 32). These data also 














































Figure 32: 125I-PAI-2 binding to MDA-MB-231 cells under different treatments 
MDA-MB-231 cells pre-activated with plasminogen were incubated in the absence 
(control) or presence of anti-B-chain uPA (10 µg/ml of the #394 monoclonal antibody) or 
the active-site alkylating agent (EGR-CMK, 0.5 mM) for 30 min at 4oC. Other cells were 
incubated for 5 min in acid wash solution (acid strip: 100 mM NaCl, 50 mM glycine, pH 
2.8, Stoppelli et al., 1986). All cells were diluted 1:10 in binding buffer to neutralise the 
incubation condition and washed with PBS. Stripped cells were incubated in the 
absence of presence of 100 nM uPA for 30 min at 4oC and then washed. Treated cells 
were incubated with 1.5 nM 125I-PAI-2 for 2 h at 4oC whereas control cells were similarly 
incubated with 125I-PAI-2, however in the absence (control) or presence of 150 nM 
unlabelled PAI-2 (excess unlabelled). Cells were washed and lysed for radioactivity 
counting. Asterisks denote significant differences in amounts of PAI-2 bound compared 
to control MDA-MB-231 cells (p < 0.05, n = 3). 
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Cell-surface endogenous uPA levels were significantly enhanced (2-fold, 
Figure 33 – A) on uPAR overexpressing T-47D cells (2-fold increase in uPAR, 
data not shown) compared to controls (i.e. untreated or mock-transfected cells, 
as described in Section 3.3.B.1). Concomitantly, a significant increase in PAI-2 
binding capacity was also observed on uPAR-transfected T-47D cells compared 






































Figure 33: Specific binding of 125I-PAI-2 to control and transiently uPAR-
overexpressing T-47D cells 
T-47D cells were transiently transfected with pcDNA3/uPAR+ plasmid as per optimised 
method (Section 3.3.A.). (A) Control and transfected T-47D cells (T-47D/uPAR+) were 
assayed for uPA expression by flow cytometry using the #394 anti-uPA monoclonal 
antibody. Data are presented as the mean fluorescence intensity (MFI) ± SEM (n =3). (B) 
Control and transfected T-47D cells were incubated with 1.5 nM 125I-PAI-2 in the 
absence or presence of 150 nM of unlabelled PAI-2. The specific binding was calculated 
and data presented are the mean ± SEM (n = 3). Asterisks denote significant differences 
between control and transfected T-47D cells (p < 0.05). Transfected cells showed 2-fold 
increase in cell-surface uPAR (data not shown). 
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Finally, when simultaneous assays for 125I-PAI-2 binding and 
immunofluorescent detection of uPA were performed, a linear correlation was 
observed between PAI-2 binding capacity and cell-surface uPA levels on the 
various cancer cell lines (Figure 34). This was expected since PAI-2 complexes to 
uPA at 1:1 molar stoichiometric ratio. 
































Figure 34: Correlation between cell-surface uPA and 125I-PAI-2 binding 
The specific 125I-PAI-2 binding on cultured breast cancer cells was plotted against the 
cell-surface uPA simultaneously assayed for the same cell line. Data are presented as 
mean ± SEM (n = 3) for PAI-2 binding and MFI ± SEM (n = 3) for cell-surface uPA level. 
The r2 for the linear correlation was 0.99 and the data did not deviate from the fitted line 
as judged by runs test (degrees of freedom = 28). Asterisks mark significant differences 
in cell-surface uPA and PAI-2 binding level compared between the different cell lines 
used. There was no significant difference between MCF-7 and T-47D cells for cell-
surface uPA or PAI-2 binding level. 
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4.3.A.2. PAI-2 INHIBITION PARAMETERS AT THE CELL SURFACE 
Saturation assays showed that PAI-2 bound in a saturable and specific 
manner to MDA-MB-231 cells (representative saturation curve shown in Figure 
35). As expected, saturation binding best fitted a single-binding site model since 
PAI-2 inhibits uPA by forming an irreversible 1:1 stoichiometric covalent 
complex with the protease. The maximal amount of PAI-2 complexed with uPA 
and the concentration PAI-2 required for half-inactivation†† (inhibition constant, 
KI) of uPA on the surface MDA-MB-231 cells were calculated by the fitted model 
from three separate experiments and summarised in Table IV. The average 
maximal binding was calculated to be 5.0 ± 0.2 fmoles of 125I-PAI-2 per million 
cells and the average KI was 81 ± 9 pM. 
Maximal binding of PAI-2 was significantly different between one of the 
assays compared to the other two assays (5.9 ± 0.2 compared to 4.6 ± 0.1 and 
4.5 ± 0.1 fmoles per million cells, p < 0.05). In assay 1, cells were cultured for 72 
h compared to 48 h for assays 2 and 3. This is explained by the fact that cell-
surface uPA levels are higher after 72 h in culture without passage compared to 
48 h and that PAI-2 binding capacity is directly correlated to cell-surface uPA 
(Figure 34). Nevertheless, the KI was not significantly different between the three 
assays (p > 0.05), indicating that inhibition was mechanism-dependent rather 
than uPA-level dependent. As further proof to the independency of KI from cell-
surface uPA levels, saturation analysis of the non-metastatic, low cell-surface 
uPA expressing T-47D cells which bind less PAI-2 (Section 4.3.A.1) also 
produced a similar KI to that reported for MDA-MB-231 cells (83 ± 3 pM, Figure 
36). 
                                          
†† KI = concentration of PAI-2 required to reach half the maximal amount of PAI-2 
complexed with cell-surface uPA. Since complex formation is reflective of inhibition 
then KI = the concentration of PAI-2 required to inhibit half of cell-surface uPA 
(Silverman, 1996). 
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Figure 35: Saturation binding of 125I-PAI-2 to MDA-MB-231 cells at 4oC 
125I-PAI-2 was measured in the absence (▼, total binding) or presence (●, non-specific 
binding) of a 100-fold molar excess of unlabeled PAI-2 at each concentration. Specific 
binding ( ) was calculated by the subtraction of non-specific binding from the total 
binding. Data was fitted best to a one binding site hyperbolic model (r2 = 0.97) from 
which the concentration of 125I-PAI-2 required to achieve half-maximal binding (KI) as 
well as the maximal binding was calculated. Irreversible binding of 125I-PAI-2 directly 
reflects the inactivation of uPAR-bound uPA. Each data point represents the mean ± 
standard error of the mean (SEM, n = 3). 







1 81 ± 4 5.9 ± 0.2* 
2 83 ± 6 4.6 ± 0.1 
3 79 ± 5 4.5 ± 0.1 
Mean ± 
SEM 81 ± 9 5.0 ± 0.2 
Saturation assays were performed using three different preparations of 125I-PAI-2. Data 
were fitted to one-binding site hyperbolic function as per Figure 35. None of the data 
deviated from the fitted model (r2 = 0.93 – 0.97) as judged by the runs test performed by 
GraphPad® (degrees of freedom = 18 – 21). The average KI and average maximal binding 
and their respective SEM from the three experiments are shown. Asterisk denote 
significant difference of maximal binding in assay 1 compared to assay 2 and 3 (p < 




































Figure 36: Saturation binding of 125I-PAI-2 to T-47D cells at 4oC 
T-47D cells (2 x 106 cells/ml) pre-incubated with 5 µg/ml plasminogen (at room 
temperature for 5 min) were incubated in triplicate with increasing concentration of 125I-
PAI-2 in the absence or presence of 100-fold molar excess of unlabelled PAI-2. After 2 h 
incubation, cells washed with PBS and lysed for activity counting. The specific binding 
was calculated and data presented are the mean ± SEM. Data was fitted to one-binding 
site hyperbolic curve (r2 = 0.95) and did not deviate from the fitted model as judged by 
the runs test (degrees of freedom = 17). 
The kinetics of formation of 125I-PAI-2 complexes with cell-surface uPA 
was assayed at both 4oC and 37oC (Figure 37). The rate of complex formation 
was reflective of the rate of inhibition (kinact) of cell-surface uPA and was 
calculated to be 0.32 ± 0.03 and 0.48 ± 0.04 min-1 at 4oC and 37oC, respectively. 
Based on the equation which describes the kinetics of mechanism-based 
enzyme inactivators‡‡ the time required to reach half inhibition (t1/2) was 
                                          
‡‡ t1/2 =   In 2  +  In 2•KI     Where t1/2 is the time for half inactivation, [I] concentration of 
               kinact     kinact•[I]    the inactivator, KI is the inactivation constant ([I] required for 
                                           half inactivation) and kinact is the rate of inactivation. The 
                                         term inhibition is used here instead of inactivation to  
                                         avoid confusion as PAI-2 is described as uPA inhibitor 
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calculated to be 2.3 ± 0.1 and 1.5 ± 0.1 min at 4oC and 37oC, respectively. These 
differences in kinact/t1/2 inhibition at 4oC compared to 37oC indicated that 
inhibition of cell-surface uPA was faster at 37oC than that at 4oC. The maximal 
amount of bound 125I-PAI-2 were not significantly different between cells 
incubated at 4oC and 37oC, indicating that the total amount of complexes 
formed was temperature independent. 
 





































Figure 37: Kinetics of 125I-PAI-2 association to MDA-MB-231 cells 
MDA-MB-231 cells (1 x 106 cells/ml) pre-activated with plasminogen were incubated 
with 1.5 nM of 125I-PAI-2 in the absence or presence of 150 nM unlabelled PAI-2 at 4oC 
(○) and 37oC (▲). At the specified time points aliquots were removed for radioactivity 
counting. The specific binding of 125I-PAI-2 (fmoles/106 million cells) was calculated and 
data presented are the mean ± SEM (n = 3). Data was fitted to one-phase exponential 
association function (r2 > 0.96) and the curves did not deviate from the model. Only the 
rate of complex was found to be significantly different (p < 0.05). 
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4.3.B. THE FATE OF CELL-BOUND PAI-2 
As shown in Figure 37, maximal PAI-2 binding to MDA-MB-231 cells 
occurs within 15 min at 4oC. As incubation at 4oC prevents any endocytosis 
that might occur, the majority of bound PAI-2 should be at the cell surface. This 
was confirmed using PAI-2-Cy5 as the ligand for analysis of PAI-2 binding by 
confocal microscopy (Figure 38). That binding was uPA-dependent was further 
confirmed by pre-blocking cells with anti-B-chain uPA monoclonal antibody 
(Figure 38). Pre-incubation of cells with exogenous 100 nM uPA, which 
saturates all cell-surface uPAR (Stillfried G., manuscript in preparation), lead to 
an increase in cell-surface associated PAI-2-Cy5 (Figure 38). 
Confocal microscopy analysis of MDA-MB-231 cells incubated with PAI-
2-Cy5 at 37oC showed that PAI-2 was mainly localised in intracellular vesicles 
after 15 min (Figure 39 - B). Internalisation of PAI-2-Cy5 at 37oC was specific 
and selective since incubation of cells with BSA-Cy5 did not show any cell-
associated fluorescence (Figure 39 – C). Indeed, pre-blocking of cell-surface uPA 
on MDA-MB-231 cells with the anti-B chain uPA (#394) monoclonal antibody 
not only inhibited the binding of PAI-2 (see Figure 38) but also the 
internalisation of PAI-2-Cy5 (Figure 40). In contrast, when cells were pre-
incubated with exogenous uPA in order to saturate cell-surface uPAR there was 
a significant increase in PAI-2-Cy5 detected in the cytoplasm (Figure 40). This 
suggests that PAI-2 not only binds in a uPAR-bound uPA-dependent manner 
(see Figure 38) but is also internalised via a uPA-dependent pathway. 
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Figure 38: Binding of PAI-2-Cy5 to MDA-MB-231 cells at 4oC 
MDA-MB-231 cells (1 x 106 cells) pre-activated with plasminogen were incubated in the absence (control: I, V, and IX) or presence of 20 
µg/ml mouse IgG1 (isotype: II, VI and X), 20 µg/ml anti-B-chain uPA (#394) monoclonal antibody (anti-uPA: III, VII and XI), or 100 nM 
of exogenous uPA for 30 min at 4oC (exogenous uPA: IV, VIII, and XII). Cells were washed and incubated with 5 µg/ml of PAI-2-Cy5 at 
4oC for 15 min then washed with PBS and analysed immediately by confocal microscopy. Samples were analysed using the same 
settings for photomultiplier voltage and pinhole (2.8) except for cells incubated with exogenous uPA where the pinhole was reduced to 
half pinhole value (1.4) of other treatments due to the high intensity of the signal. Only a representative image is shown for each 
treatment selected from > 10 images obtained from assays (> 2) repeated independently. The scale bars in all transmission images (I – 
IV) and overlays of PAI-2-Cy5 signal with the transmission images (IX – XII) represent 10 µm and cell viability was higher than 95 % in 
all samples as determined by trypan blue stain. 







Figure 39: Internalisation of PAI-2-Cy5 by MDA-MB-231 cells at 37oC 
MDA-MB-231 cells (1 x 106 cells/ml) pre-activated with plasminogen were incubated 
with 5 µg/ml of PAI-2-Cy5 at 37oC for (A) 0 min or (B) 15 min. (C) Cells pre-activated 
with plasminogen were also incubated with 5 µg/ml BSA-Cy5 at 37oC for 15 min. 
Aliquots were removed, washed with ice-cold PBS and analysed immediately by confocal 
microscopy. This assay was repeated twice using different cultures of cells and only a 
representative image is shown from > 10 images obtained in each assay. The scale bars 
in all transmission images represent 5 µm and cell viability was higher than 95 % in all 
samples as detected by trypan blue stain. 
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Figure 40: Effect of uPA modulation on the internalisation of PAI-2-Cy5 
MDA-MB-231 cells (1 x 106 cells) pre-activated with plasminogen were incubated in 
the absence (control) or presence of 20 µg/ml anti-B-chain uPA (#394) monoclonal 
antibody (anti-uPA) or 100 nM of exogenous uPA for 30 min at 4oC (exogenous uPA). 
Cells were washed and incubated 5 µg/ml of PAI-2-Cy5 for 15 min at 37oC. Samples 
were washed with ice-cold PBS and analysed immediately by confocal microscopy. 
Samples were analysed using the same settings for photomultiplier voltage and pinhole 
except for cells incubated with exogenous uPA where the pinhole was reduced to half 
the value for pinhole of other treatments due to the high intensity of the signal. The 
scale bars in all transmission images represent 5 µm and cell viability was higher than 
95 % in all samples as detected by trypan blue stain. Samples shown are from two 




4.3.B.1. COMPARTMENTATION AND DEGRADATION OF INTERNALISED PAI-2 
Transferrin-Alexa488 (endosomal marker) and LysoTracker® Yellow DND-
68 (lysosomal marker) were used for the visualisation of these compartments in 
T-47D and MDA-MB-231 cells incubated with PAI-2-Cy5. Co-localisation of the 
endosomal and lysosomal markers after 15 min at 37oC showed three different 
areas of compartmentation in T-47D cells (Figure 41- A). There were areas 
where only endosomal marker was observed and areas where only lysosomal 
marker was observed, explained by early endosomes and lysosomes, 
respectively. Finally, endosomes co-localised with lysosomes at some areas of 
the cytoplasm of these cells, suggesting the fusion of late endosomes and 
lysosomes at these areas. In the case of MDA-MB-231 cells, transferrin-Alexa488 
always co-localised with LysoTracker® Yellow DND-68 after 15 min at 37oC 
(Figure 41 – B). Since differentiation between the these two markers was 
possible in the case of T-47D cells, the co-localisation of transferrin and 
LysoTracker® in MDA-MB-231 cells may be due to inability of these cells to 
shuttle transferrin-Alexa488 from endosomes to the cell exterior which is a 
requirement for detecting early endosomes (Van Dam et al., 2002). Thus, co-
localisation of internalised PAI-2-Cy5 with transferrin-Alexa488 in MDA-MB-231 
was not informative as endosomal compartmentation was not clear. 
As shown in Figure 41 – A, T-47D cells did not bind or internalise 
detectable amounts of PAI-2-Cy5 when analysed by confocal microscopy 
although PAI-2 binding was measured using 125I-PAI-2 on these cells (see Figure 
36). This may be due to lower detection limit of fluorescent confocal microscopy 
compared to radio-detection methods in addition to the fact that T-47D cells 
express very little of uPA on the cell-surface. While a large proportion of 
internalised PAI-2-Cy5 co-localised with the lysosomal marker by 15 min of 
incubation at 37oC, a small amount of intracellular PAI-2-Cy5 was not localised 
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in lysosomes (Figure 41 – B). This non-lysosomal intracellular PAI-2-Cy5 at 15 
min incubation was presumably in endosomes as after 45 min incubation all 
PAI-2-Cy5 localised in lysosomes (Figure 41 – C). The presumed endosomal and 
the evident lysosomal compartmentation of internalised PAI-2-Cy5 indicated the 
endocytosis of bound PAI-2 on metastatic MDA-MB-231 cells. As little PAI-2 
bound to and is hence internalised by the non-metastatic low uPA-expressing T-
47D cells, this further confirmed the uPAR-bound uPA-dependent pathway of 
PAI-2 internalisation. 
Lysates of MDA-MB-231 cells incubated with PAI-2-Cy5 showed the 
presence of degradation fragments with a molecular weight less than 37 kDa 
the intensities of which increased over time (Lanes 3 - 5 Figure 42). The 
intensity of these degradation fragments was significantly lower for lysates 
prepared from MDA-MB-231 cells pre-treated with anti-B chain uPA monoclonal 
antibody before incubation with PAI-2-Cy5 (lane 2 in Figure 42). Thus, the 
presence of uPA:PAI-2 fluorescent degradation products further confirmed the 
localisation of internalised PAI-2-Cy5 in lysosomes. 
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Figure 41: Compartmentation of internalised PAI-2-Cy5 
Cells incubated with PAI-2-Cy5 and transferrin-Alexa488 for 20 min at 4oC were washed and incubated at 37oC with LysoTracker® Yellow 
DND-68. Cells were then washed at the specified times and analysed by confocal microscopy obtaining images sequentially using detectors 
for Cy5, Alexa488 and LysoTracker® fluorescence. (A) T-47D cells after 15 min incubation at 37oC, (B) MDA-MB-231 cells after 15 min 
incubation at 37oC and (C) MDA-MB-231 cells after 45 min incubation at 37oC. For (A) 6 panels are shown, which are Transferrin-Alexa488 
(green), LysoTracker® (blue), PAI-2-Cy5 (red), Transferrin-Alexa488/LysoTracker® overlay, transmission image and Transferrin-
Alexa488/LysoTracker®/PAI-2-Cy5 overlay superimposed on the transmission image (scale bars represents 10 µm). For each (B) and (C), 6 
panels are shown, which are Transferrin-Alexa488 (green), LysoTracker® (blue), PAI-2-Cy5 (red), Transferrin-Alexa488/PAI-2-Cy5 overlay, 
LysoTracker®/PAI-2-Cy5 overlay and Transferrin-Alexa488/LysoTracker®/PAI-2-Cy5 overlay superimposed on the transmission image 
(scale bars represents 10 µm). Co-localisation of Transferrin-Alexa488 and PAI-2-Cy5 appears in yellow/orange, co-localisation of 
LysoTracker® and PAI-2-Cy5 appears in pink, co-localisation of Transferrin-Alexa488 and LysoTracker® appears in cyan and the co-
localisation of Transferrin-Alexa488/LysoTracker®/PAI-2-Cy5 appears in white. Cell viability was higher then 95 % for all cells and only 
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Figure 42: Degradation of internalised PAI-2-Cy5 
MDA-MB-231 cells pre-incubated with plasminogen were incubated with PAI-2-Cy5 at 
37oC for 5 (Lane 3), 10 (lane 4) and 15 (lane 5) min prior to washing and lysing in 
reducing sample buffer and fractionation by 12 % SDS-PAGE. MDA-MB-231 cells pre-
incubated with plasminogen were pre-blocked with 10 µg/ml anti-B chain uPA 
monoclonal antibody for 30 min at 4oC prior to incubation with PAI-2-Cy5 for 15 min at 
37oC (Lane 2) and PAI-2-Cy5 (0.33 µg, 7.5 fmoles) (Lane 1) were also fractionated as 
controls. (A) The SDS-PAGE was stained in Coomassie blue stain, destained and 
documented after (B) being scanned using the red fluorescence detector of the Storm® 
scanner. The Coomassie blue stained gel was superimposed on the fluorescence scan 
and the molecular weight marker bands (kDa) were marked on the scan. 
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4.3.C. FURTHER INSIGHTS INTO THE MECHANISM OF PAI-2 
ENDOCYTOSIS 
4.3.C.1. CLEARANCE OF CELL-SURFACE UPA 
At 37oC in the absence of PAI-2, endogenous cell-surface uPA levels on 
MDA-MB-231 cells slowly decreased over the observation period (~10 % loss by 
60 min), indicating slow endogenous uPA clearance from the cell surface (Figure 
43). A similarly slow turnover of cell-associated exogenous uPA has been shown 
for monocytic cells that do not produce any detectable PAIs (THP-1 cells) 
(Estreicher et al., 1990). Since (1) endogenous cell surface PAIs are also not 
detectable on breast carcinoma cells used in this study (Gillian Stillfried, 
personal communications), (2) PAI-2 is internalised via a uPA/uPAR dependent 
pathway; and (3) PAIs affect cell-associated uPA clearance via uPAR endocytosis 
(Cubellis et al., 1990; Estreicher et al., 1990; Jensen et al., 1990), then 
exogenous PAI-2 should influence uPA disappearance. Indeed, the addition of 
100 nM PAI-2 significantly accelerated the loss of cell surface endogenous uPA 
(Figure 43). This effect was most apparent within the first 10 min (t1/2 = 1.14 ± 
0.06 min in the presence of 100 nM PAI-2 vs. t1/2 = 787 ± 37 min in the absence 
of PAI-2) and was dose-dependent (t1/2 = 1.52 ± 0.06 and 3.07 ± 0.04 min in the 
presence of 10 and 1 nM PAI-2, respectively). The rate of PAI-2 mediated uPA 
loss from the cell surface was appreciably slower after 10 min in the presence of 
PAI-2 and, by 60 min in the presence of 100 nM PAI-2, approximately 30 % of 
the total cell-surface endogenous uPA disappeared from the cell surface (Figure 
43). This apparent stabilisation of cell-surface uPA levels at approximately 70 - 
80 % of initial cell-surface levels, even in the presence of high PAI-2 
concentrations (i.e. 100 nM), appears to be at odds with the uPA-dependent 
endocytosis of the majority of cell-bound PAI-2 (refer to Figure 41). This 
suggested additional complex concurrent processes during endocytosis of the 
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uPA:PAI-2 complex involving uPAR occupancy levels, potential uPAR recycling 
and uPA secretion, which must lead to replenishment of cell-surface uPA, 
resulting in the apparent stabilisation of relatively high uPA levels. 

























Figure 43: PAI-2-mediated clearance of cell-surface uPA 
MDA-MB-231 cells pre-treated with plasminogen were incubated in the absence (●) or 
presence of 1 (■), 10 (▲) or 100 (▼) nM of PAI-2 at 37oC. Samples were removed at the 
specified time points, washed and analysed by flow cytometry for cell-surface uPA. Only 
fluorescence associated with viable cells was used and the data are displayed as the 
percentage of MFI over the maximal MFI observed at time zero (absence of PAI-2). Data 
points, % MFI ± SEM (n ≥ 3), were fitted to one-phase exponential decay curve and did 
not deviate from the fitted model as judged by runs test (degrees of freedom > 18). 
4.3.C.2. EFFECT OF PAI-2 ON CELL-SURFACE UPAR 
The effect of uPAR/uPA:PAI-2 complex formation and endocytosis on 
potential uPAR recycling and occupancy levels was assessed using two different 
methods. Firstly, endogenous levels of cell surface uPAR were directly measured 
by immunofluorescence and flow cytometry. During the first 10 min of 
incubation with PAI-2 the total cell-surface uPAR level decreased rapidly to ~ 
40% of the maximal uPAR levels (i.e. at zero min in the presence of PAI-2) 
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(Figure 44). Between 10 and 15 min after incubation with PAI-2, uPAR cell-
surface levels were restored to 86 % of the maximal level. 






















Figure 44: PAI-2-mediated clearance of cell-surface uPAR 
MDA-MB-231 cells pre-treated with plasminogen were incubated with 100 nM of PAI-2 
at 37oC. At the specified time points cell-surface uPAR was measured using the #3934 
antibody by flow cytometry. Only fluorescence associated with viable cells was used and 
the data are displayed as percentage of MFI over the maximal MFI observed at time zero 
(% MFI ± SEM, n = 3). 
This result indicated that some uPAR recycling must take place. Given 
that not all uPAR disappeared from the cell surface, this further indicates that 
only a proportion of uPAR is occupied with endogenous uPA on this cell (refer to 
Figure 32). Thus, it appears that the effect of PAI-2 incubation is to cause 
internalisation of existing occupied uPAR and presumably recycling of 
unoccupied receptor to the cell surface. As suggested above, any uPA secretion 
that may occur as a result of complex endocytosis could bind to unoccupied 
uPAR (either pre-existing or recycled). Thus, the difference between the amount 
of endogenous uPA and the total amount of uPA the cells could potentially bind 
to the cell surface (i.e. measured after the addition of exogenous uPA) gives an 
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indication of the amount of unoccupied uPAR at any time after incubation with 
PAI-2. In agreement with previous experiments (refer to Figure 43), the 
endogenous cell-surface uPA level decreased by 30 % by 10 min of incubation 
with 100 nM PAI-2, after which time it stabilised at this level (Figure 45 – A). 
Total uPA levels (endogenous uPA plus bound exogenous uPA) decreased to 65 
% by 10 min after incubation with PAI-2. However, unlike the endogenous uPA 
levels, total uPA levels were restored to 90 % of the maximal levels (i.e. at zero 
min in the presence of PAI-2) between 10 and 30 min after incubation with  
PAI-2 (Figure 45 – B). Unoccupied uPAR was then calculated and represented 
graphically, and found to initially decrease by 40 % in the first 10 min after 
incubation with PAI-2 (Figure 45 – C). By 30 min after incubation with PAI-2, 
unoccupied uPAR levels increased to 130 % of that at time zero of incubation 
with PAI-2. 
Assuming that unoccupied uPAR remains on the cell surface, the data 
suggests that while the majority of cell-surface uPAR/uPA:PAI-2 is internalised, 
cells may replenish cell-surface uPA from intracellular reservoir resulting in the 
decrease of unoccupied cell-surface uPAR and an overall stabilisation of cell 
surface uPA levels. After the first 10 min of internalisation, uPAR recycling may 
result in the observed restoration of cell-surface uPAR and the marked increase 
in unoccupied cell-surface uPAR between 10 and 30 min. Indeed, when 
unoccupied cell-surface uPAR was saturated with uPA by incubation with 
exogenous uPA prior to incubation with PAI-2, the clearance of cell-surface uPA 
was slower but greater percentage was cleared in comparison to previous uPA 
clearance data. As shown in Figure 46, cell-surface uPA continued to decrease 
rapidly after 10 min of incubation with PAI-2 (t1/2 = 9.1 ± 0.4 min). Stabilisation 
of cell-surface uPA occurred between 30 and 60 min where unoccupied uPAR 
would have been made available by recycling in order to bind secreted uPA. 
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Figure 45: Total cell-surface uPA capacity and endogenous cell-surface uPA 
during PAI-2 endocytosis 
MDA-MB-231 cells pre-treated with plasminogen were incubated with 100 nM of PAI-2 
at 37oC. At the specified time points samples were removed and processed as follows.  
(A) Cells were analysed for cell-surface uPA by flow cytometry (i.e. endogenous cell-
surface uPA). (B) Cells were incubated with 100 nM exogenous uPA for 30 min at 4oC 
then analysed for cell-surface uPA by flow cytometry (i.e. total cell-surface uPA 
capacity).(C) The difference between B and A was calculated to represent the binding of 
exogenous uPA (i.e. unoccupied cell-surface uPAR). Only fluorescence associated with 
viable cells was used and the data are displayed as absolute MFI units ± SEM (n = 3). 
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Figure 46: The effect of uPAR saturation on PAI-2-mediated clearance of  
cell-surface uPA 
MDA-MB-231 cells pre-treated with plasminogen were incubated with exogenous uPA 
(30 min at 4oC), washed then incubated with 100 nM of PAI-2 at 37oC. Samples were 
removed at the specified time points, washed and analysed by flow cytometry for cell-
surface uPA. Only fluorescence associated with viable cells was used and the data are 
displayed as the percentage of MFI over the maximal MFI observed at time zero (absence 
of PAI-2). The MFI for cells incubated with exogenous uPA was 2-fold higher than 
normal cells indicating 50 % of cell-surface uPAR was unoccupied (data not shown). 
Data points, % MFI ± SEM (n ≥ 3), were fitted to one-phase exponential decay curve and 
did not deviate from the fitted model as judged by runs test (degrees of freedom > 18). 
4.4. DISCUSSION 
The results presented in this chapter describe the irreversible inhibitory 
kinetics and fate of PAI-2 bound to the surface of human carcinoma cells and 
provides definitive evidence of uPAR-bound uPA mediated endocytosis of PAI-2. 
In order to investigate the cellular fate of PAI-2, it was essential to quantify the 
irreversible binding of PAI-2 to cell-surface uPAR-bound uPA and perform 
internalisation assays under saturating conditions. PAI-2 is known to be an 
efficient inhibitor of uPA activity (Ellis et al., 1990) and can form 1:1 SDS-stable 
complexes with 125I-uPA on the cell surface (Estreicher et al., 1990). Therefore, 
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the amount of PAI-2 bound to cells and the concentration of PAI-2 required to 
saturate uPAR-bound uPA are directly reflective of the irreversible inhibition 
constant KI. The very low KI value described here confirms the efficient and 
potent inhibition of cell surface uPAR-bound uPA by PAI-2 and falls in the range 
of the most potent antiviral drugs. For example, anti-HIV cyclic urea drugs, 
which are also mechanism-based protease inactivators, have KI values in the 
range of 18 - 88 pM (De Lucca et al., 1998). The kinact value measured for PAI-2 
is in the range of typical reported values (0.001 – 1 min-1) and describes a 
relatively rapid inhibitory mechanism (Silverman, 1996). 
That uPAR-bound uPA is the only specific site for PAI-2 binding on 
human carcinoma cells is supported by the following evidence. Firstly, the one-
binding site model best fitted the specific PAI-2 binding data thus indicating the 
presence of a single population of high-specificity target for PAI-2. Secondly, the 
specific binding of PAI-2 to cells on which the uPA active site was either 
specifically blocked or inactivated was completely inhibited. Thirdly, a linear 
correlation exists between cell-surface uPA levels and the PAI-2 binding 
capacity. Given that uPA was the only determinant for 125I-PAI-2 binding to 
breast cancer cells, the inhibition parameters derived in this study represents 
specific targeting of cell surface uPA by PAI-2. It should be noted, however, that 
a small proportion of the total binding could not be competed by excess PAI-2 
(refer to Figure 32), suggesting the presence of non-specific, uPA-independent 
PAI-2 binding moiety/ies. The nature of this interaction has yet to be 
characterised. 
The uPA-dependent binding of PAI-2 was also illustrated using PAI-2-Cy5 
by confocal microscopy. At 4oC, PAI-2-Cy5 was localised at the cell-surface of 
MDA-MB-231 cells however, rapid and specific internalisation of PAI-2-Cy5 was 
observed when cells were incubated at 37oC. The rate of internalisation was 
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determined using a novel assay (developed by David Croucher, University of 
Wollongong) utilising the Alexa488/Alexa488 quenching antibody system and the 
human prostate carcinoma PC-3 cells (Al-Ejeh et al., 2004) and MDA-MB-231 
cells (Unpublished manuscript by Amy Wyatt, School of Biological Sciences, 
University of Wollongong, 2003). Maximal PAI-2 internalisation by these cells 
was achieved over a similar time frame (within ~ 15 - 20 minutes) at 37oC to 
that described for 125I-uPA:PAI-1 complex in murine LB6 clone 19 cells via the 
uPA/uPAR-mediated pathway (Nykjær et al., 1997). Internalised PAI-2 was 
localised in lysosomes with MDA-MB-231 cells and in both endosomes and 
lysosomes within the metastatic prostate cancer cells, PC-3 (Al-Ejeh et al., 
2004). These results clearly illustrate that PAI-2 was localised in endosomes 
and lysosomes where PAI-2 (and presumably uPA) is degraded. 
The internalisation process of PAI-2 appeared similar to that described 
for all other serpin:uPA complexes, whereupon the latter is degraded within 
lysosomes while uPAR is recycled back to the cell surface (Andreasen et al., 
1997; Nykjær et al., 1997; Nykjær and Willnow, 2002; Strickland et al., 2002). 
Given that PAI-2 forms a stable irreversible complex with receptor-bound uPA 
and that PAI-2 internalisation occurs via the uPAR/uPA pathway as other 
serpin:uPA complexes, then PAI-2 should initiate the internalisation of uPA. 
Evidence for the PAI-2-mediated internalisation of cell-surface uPA was 
observed by the loss or clearance of uPA from the cell surface upon inhibition by 
PAI-2. In the absence of added PAI-2 the disappearance of cell surface uPAR-
bound uPA levels was slow. The addition of PAI-2 initially greatly accelerated 
this process. Similar clearance characteristics were described for bound 
exogenous radiolabelled uPA in the absence and presence of PAI-2 using 
monocytic cells with low endogenous PAIs (Estreicher et al., 1990). The 
internalisation of the majority of uPA-occupied cell-surface uPAR within the first 
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10 min was in agreement with the internalisation of PAI-2. The reappearance of 
uPAR on the cell-surface after 10 min was in agreement with the previously 
reported recycling of uPAR after the internalisation of serpin:uPA complexes 
(Nykjær et al., 1997). Thus, results from this study are largely in agreement with 
previously published reports of uPA:PAI-1 internalisation. However, PAI-2-
mediated clearance of uPA from the cell-surface stabilised at 20 - 30 % of the 
total uPA after the initial rapid clearance. This result seemed at odds since the 
majority of bound PAI-2 was internalised within 40 min incubation at 37oC 
whereas there was only an apparent 20 - 30 % decrease in cell-surface uPA 
during this time frame. The low uPA clearance in the presence of PAI-2 may be 
explained by concomitant cell surface uPA replenishment since the cells used in 
this study continuously express cell bound uPAR and secrete pro-uPA (Ranson 
et al., 1998; Andronicos and Ranson, 2001). If the initial internalisation of 
inhibited uPA is concomitantly counterbalanced by the secretion of pro-uPA, 
some of which ligands unoccupied uPAR originally present on the cells and/or 
recycled uPAR; then it is possible that secreted pro-uPA replenishes a 
proportion of these receptors. This suggestion was tested by assaying the 
binding of exogenous uPA to MDA-MB-231 cells incubated with PAI-2. The 
decreased binding of exogenous uPA overtime during uPAR/uPA:PAI-2 
internalisation indicated that unoccupied uPAR was being masked from 
exogenous uPA. This provides preliminary evidence for the replenishment of 
cell-surface uPA during uPAR/uPA:PAI-2 internalisation. Thus, while the 
majority of uPAR/uPA:PAI-2 were internalised causing the observed 
internalisation of the majority of PAI-2 and uPAR within the first 10 min of 
incubation, secreted uPA liganded to previously unoccupied uPAR resulting in 
the observed decrease of unoccupied cell-surface uPAR levels and the 
stabilisation of uPA clearance. This was supported by the effect of uPAR-
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saturation with uPA prior to the addition of PAI-2 where a larger decrease in cell-
surface uPA (~ 60 %) was observed and stabilisation occurring between 30 and 
60 min of internalisation where uPAR would be recycled to the cell surface and 
secreted uPA may ligand to these newly presented unoccupied receptors. The 
addition of PAI-2 to THP-1 cells preloaded with exogenous uPA resulted in 
similar effects on the rate of uPA disappearance with 30 – 40 % of the total cell-
associated uPA also lost by 60 min at 37oC (Estreicher et al., 1990). While ~ 60 
% exogenous radioactive uPA:PAI-1 complex is lost from the cell surface of U937 
monocytic (Cubellis et al., 1990) or trophoblastic cells (Jensen et al., 1990) by 
60 min, a similar biphasic pattern was also apparent. The higher percentage 
loss using PAI-1 may either reflect slightly different mechanisms between PAI-1 
and PAI-2 and/or different cell types and/or methods of analysis. 
Given the wide involvement of the LDLR family members in processes of 
endocytosis including that of uPA:PAI-1 (Nykjær and Willnow, 2002; Strickland 
et al., 2002), it is not surprising to find that this family is at least partially 
responsible for endocytosis of uPA:PAI-2 complexes (as indicated by RAP 
inhibition experiments performed by Croucher D. in Al-Ejeh et al., 2004). (RAP: 
receptor associated protein, inhibitor of LDLR endocytosis). Certain LDLR family 
members when associated with uPAR complexed with uPA:PAI-1 sustain the 
cell-signalling pathways that are activated via uPAR, resulting in enhanced uPA 
and uPAR levels among other effects (Nykjær and Willnow, 2002; Strickland et 
al., 2002). Thus, it is also conceivable that in the presence of PAI-2, LDLR-
mediated signalling pathways would be activated and may also enhance the 
secretion of intracellular pro-uPA stores. This effect may take up to 10 min at 
37oC thus accounting for the biphasic effect of PAI-2 on uPA clearance (i.e. 
rapid then slow clearance) observed. Assuming that a proportion of the newly 
liganded uPA stays in the pro-enzyme form despite the presence of any residual 
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cell bound plasmin, then only the two-chain uPA would be internalised by the 
PAI-2 still present in the cell environment. 
Along with published data (Al-Ejeh et al., 2004), the results presented in 
this chapter allow the proposal of a model for the internalisation of PAI-2 (Figure 
47). In this model, PAI-2 forms complexes with uPAR-bound uPA where uPAR 
occupancy is generally less than 70 %. The internalisation of uPA:PAI-2 
complexes occurs shortly after complex formation and endocytosis of  
uPAR/uPA:PAI-2 is mediated by a member of the low-density lipoprotein 
receptor (LDLR) gene family. During the internalisation of the majority of  
uPAR/uPA:PAI-2 complexes formed on the cell surface, a signal (possibly 
mediated by LDLR) initiates the secretion of uPA from an intracellular reservoir. 
The cell-surface is replenished with uPA, which leads to increased occupancy of 
uPAR. The uPA:PAI-2 complex is degraded in the lysosomes while uPAR 
reappears on the cell surface possibly via recycling along with the LDLR, as 
previously documented (Nykjær et al., 1997). 
It is noteworthy that as in the case of T-47D cells (see Chapter 3),  
MDA-MB-231 cells showed preferential maintenance of partially unoccupied 
uPAR levels on the cell surface despite the continual secretion of uPA by these 
cells. As discussed in Chapter 3, it is possible that unoccupied uPAR may be 
essential for other uPAR-related functions such as uPA-independent signalling 
(Gellert et al., 2003) or cell-attachment to ECM via interaction of uPAR clusters 
with integrins and matrix proteins (Wei et al., 1999; Ossowski and Aguirre-
Ghiso, 2000; Wei et al., 2001). 
Figure 47: Mechanism proposal for the internalisation of uPAR/uPA:PAI-2 complexes 
For simplicity plasminogen receptors are not shown. 
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In summary, this study, as published by Al-Ejeh et al. (2004), provides 
the first conclusive evidence for the internalisation of PAI-2 by human 
carcinoma cells, which represents an advance in the understanding of the 
regulation of cell-surface plasminogen activation. Together with the fact that 
PAI-2 binding capacity and internalisation is uPA-dependent, these results 
clearly indicate that PAI-2 would not only preferentially target uPA-expressing 
tumour cells by very efficiently and irreversibly inhibiting uPA, but would also 
efficiently deliver attached cytotoxins to the intracellular space. The 
endosomal/lysosomal localisation of PAI-2 further promotes the utility of α-
emitting radionuclide-PAI-2 constructs (or any other PAI-2-cytotoxin construct) 
as a uPA-targeted anti-tumour drug (Kruithof et al., 1995; Hang et al., 1998; Li 
et al., 2002; Ranson et al., 2002; Allen et al., 2003). Furthermore, the 
quantification of PAI-2 binding capacity in terms of KI values is important for 
determining PAI-2 concentrations required for delivering sufficient amounts of 
cytotoxins to the target cell. 
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Chapter 5: OPTIMISATION OF RADIOLABELLING OF PAI-2 





The clinical significance of uPA as a marker of metastatic cancers has 
been established for several human cancers and the elevated levels of uPA in 
malignant tumours compared to normal tissue is commonly discussed as a 
therapeutic target (Duffy, 1993b; Duffy, 1996; Andreasen et al., 1997; Schmitt 
et al., 1997; Brunner et al., 1999; Duffy et al., 1999; Gershtein and 
Kushlinskii, 1999; Look and Foekens, 1999; Mazar et al., 1999). As illustrated 
in Table I (Chapter 1), there is conclusive evidence indicating the prognostic 
significance of uPA in various human cancers and, in the case of breast cancer, 
level-1 of evidence exists for this prognostic significance (Duffy, 2004). 
Identification of such a strong marker allows the development of therapy tactics 
which exploit the ability to target uPA. 
Modulation of uPA expression and the use of antagonist of the 
uPA/uPAR binding have shown success in regulating cancer metastasis and 
invasion (see Section 1.7.). In the case of transfection methods, the therapeutic 
potential of such strategy in humans is limited due to the requirement of cancer 
cell-specific gene delivery methods. Thus antagonists of the uPA/uPAR binding 
seem more feasible for clinical applications. Although such pharmaceuticals 
may be administered to inhibit tumour growth, migration or differentiation, 
tactics such as cytotoxins or toxic radiation for the killing and clearance of 
tumour cells present more valuable curative advantages. 
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Radionuclides have been long used for medical applications. α-emitters 
emit high energy (6 - 9 MeV) over a short distance (40 to 80 µm) (Waldmann, 
1991; Behr et al., 1998; Behr et al., 1999; Chatal and Hoefnagel, 1999; Griffiths 
et al., 1999), thus this energy is mainly deposited in the targeted cells and very 
few nuclear hits are required to kill these cells (Lloyd et al., 1979; Kassis et al., 
1986). Monoclonal antibodies radiolabelled with α–emitting radionuclides (e.g. 
213Bismuth and 211Astatine) are starting to show promise in radio-
immunotherapy (Couturier et al., 1999; Nikula et al., 1999; McDevitt et al., 
2000; Zalutsky and Vaidyanathan, 2000; McDevitt et al., 2001; Jurcic et al., 
2002). 
Several biological and biochemical characteristics of PAI-2 advocate the 
possible utilisation of this serpin as a cancer radiotherapeutic agent. Biological 
characteristics that favour PAI-2 for targeting uPA include: (1) PAI-2 inhibits 
uPA-mediated invasion of cancer cells in vitro (Kirchheimer and Remold, 1989; 
Brückner et al., 1992; Stahl and Mueller, 1994); (2) Exogenously added 
recombinant PAI-2 inhibits cancer invasion and metastasis in vivo (Baker et al., 
1990a; Shinkfield et al., 1992; Montgomery et al., 1993; Reiter et al., 1993; 
Billström et al., 1994; Evans and Lin, 1995) and (3) PAI-2 preferentially 
accumulates in cancer tissue compared to normal tissue in tumour-bearing 
mice compared to mice without tumours (Hang et al., 1998). Taken together, 
and despite the presence of PAI-1 in malignant tumours, it is apparent that uPA 
is accessible to exogenously administered PAI-2 in several tumour types in vivo. 
Biochemical characteristics which favour the use of PAI-2 for cancer therapy 
include, the specific and efficient inhibition of uPAR-bound uPA while reserving 
thrombosis as suggested by the low second order inhibition rate constant 
towards tPA and protection of fibrin-bound tPA from inhibition by PAI-2 
(Kruithof et al., 1995). Secondly, PAI-2 is very stable in vitro (Ranson et al., 
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2002), unlike PAI-1 which is subject to oxidation (Baker et al., 1990b), implying 
that PAI-2 can be easily modified for radiolabelling. These characteristics of PAI-
2 in addition to the recent documentation of the internalisation of uPA:PAI-2 
complex (Al-Ejeh et al., 2004) encourage the use of PAI-2 for radiotherapy of 
human cancers. 
Previous studies describe the conjugation of PAI-2 to the metal chelator, 
cDTPA, followed by radiolabelling of PAI-2-DTTA product with the α-emitter, 
213Bismuth. In these ‘proof-of-principle’ studies, the resulting adduct (PAI-2-
DTTA-213Bismuth) shows preferential targeting of metastatic breast cancer cells 
in vitro (Ranson et al., 2002) and targets tumour xenografts and 
micrometastates in vivo (Li et al., 2002; Allen et al., 2003). The efficient 
cytotoxicity of PAI-2-DTTA-213Bismuth is explained by the efficient binding and 
rapid internalisation of uPA:PAI-2 complexes after their formation on the cell 
surface (Chapter 4, Al-Ejeh et al., 2004). Bismuth-213 (213Bi) is efficiently eluted 
from Actinium-225 (225Ac) column (Li et al., 2002; Ranson et al., 2002). Due to 
213Bi being eluted from the 225Ac column with 0.075 M HI, pH fluctuations were 
observed that affected the solubility PAI-2-DTTA. 
5.1.A. RATIONALE AND AIMS 
The aim of this chapter was to further characterise PAI-2-DTTA. 
Furthermore, mainly due to the short half-life of 213Bi (45 min), a quick, 
efficient, reproducible and reliable method for radiolabelling of PAI-2-DTTA with 
213Bi needed to be developed for this alpha therapy tactic to be accessible. Thus, 
another aim of this chapter was to test buffers which prevent PAI-2-DTTA 
precipitation and optimisation of radiolabelling with 213Bi. 
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5.2. METHODS 
5.2.A. CONJUGATION OF PAI-2 TO CDTPA 
Generally, PAI-2 was reacted with a 50-fold molar excess of the metal 
chelators as described by Ranson et al. (2002). In a final 450 µl volume of 1 x 
PBS (pH 7.2), 31 µl of freshly prepared anhydrous 25 mg/ml cDTPA in DMSO 
was reacted with 2 mg of PAI-2 at RT for 1 h with vigorous shaking. Conjugation 
was stopped using 50 µl 1 M Tris-HCl (pH 7.2) (10 % v/v final concentration). 
PAI-2-DTTA was separated from free chelator moieties (cDTPA) using 30-kDa 
cut-off microconcentrators. Briefly, reactions were placed in the top chamber of 
30 kDa cut-off microconcentrator units and centrifuged at 7430 x g for 3 - 5 
min. The retained volume was washed three times by centrifugation with 500 µl 
of 1 x PBS (pH 7.2). The washes were discarded and the final retained volume 
was removed to a fresh tube. The microconcentrator filter was washed (no 
centrifugation) using 1 x PBS (pH 7.2) and the washes were added to the fresh 
tube and stored at 4oC.  
The BioRad® DC protein concentration assay kit was used to determine 
the concentration of conjugated PAI-2 against standard BSA and/or PAI-2 
solutions (see Section 2.2.B.1.). The activity of PAI-2-DTTA conjugates was 
compared to unconjugated PAI-2 using gel shift and the Spectrozyme-UK® 
assays as described in Section 2.2.B.4. 
5.2.B. ELECTROSPRAY IONISATION MASS SPECTROSCOPY 
For electrospray ionisation mass spectroscopy (ESI-MS) of PAI-2 and  
PAI-2-DTTA, samples were washed five times by centrifugation at 7430 x g for 3 
- 5 min with milliQ water using 30 kDa cut-off microconcentrators. The retained 
washed samples were finally prepared in milliQ water and diluted 1:1 in 50 % 
methanol: 10 % acetic acid (v/v) solution at a final protein concentrations in the 
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range of 1 - 10 µM. Samples were injected in the Q-TOF mass spectrometer 
(Department of Chemistry, University of Wollongong) and analysed using a 30 
volts cone and 5000 resolution power. Data collected were analysed using the 
software provided with the mass spectrometry instrument. 
5.2.C. RADIOLABELLING OF PAI-2-DTTA WITH 213BISMUTH 
5.2.C.1. MAINTENANCE OF 225ACTINIUM COLUMN 
The total amount of 225Ac (Oak Ridge National Laboratory, United States 
Department of Energy, USA) was dissolved in 300 µl of 0.1 M HNO3 and the 
solution was loaded onto resin (AG® 50W-X4, provided in column Oak Ridge 
National Laboratory, United States Department of Energy, USA) pre-equilibrated 
with 1 ml 0.1 M HNO3. The column was washed with 250 µl of dH2O. When not 
in use, the 225Ac column was stored in 0.1 M HNO3 and washed with 1 ml of 
dH2O prior to use. The 225Ac column was stripped and reloaded on a weekly 
basis. Stripping was performed by washing 3 times with 250 µl of 8 M HNO3 in 
a fume hood. Washes were collected in a 20 ml glass vial, 15 µl of H2O2 was 
added and content was evaporated on a hot plate until dryness. The evaporation 
step was repeated by adding 25 µl of 8 M HNO3 and 5 µl of H2O2. The final 
remaining volume was loaded onto a fresh resin as described above. 
5.2.C.2. OPTIMISATION OF LABELLING PAI-2-DTTA WITH 213BI (α-PAI-2) 
213Bi was eluted in a final solution containing 0.075 M HI and 1 x PBS as 
previously described (Ranson et al., 2002). The pH of the elution solution (0.075 
M HI; 1 x PBS) only was measured using pH strips (0 - 14 pH range). In 
addition, the pH was measured for elution solution titrated with three different 
solutions - 1 M sodium hydroxide, 3 M Sodium acetate (pH 5.5) and 1.5 M citric 
acid (citrate, pH 5.5). The effect of control and titrated elution solution on the 
solubility of various concentrations of PAI-2-DTTA was assessed as follows. 
161 
After the addition of PAI-2-DTTA, these solutions were centrifuged at 7430 x g 
for 2 min in order to pellet any precipitated PAI-2-DTTA. Pellet formation was 
assessed in these solutions in comparison to incubations containing the elution 
solutions or PAI-2-DTTA alone. 
The radioactivity of elutions was measured (in µCi) using the AtomLab 
200 dose calibrator (regularly calibrated using a Caesium source) before and 
after pH adjustment. ITLC was performed before and after pH-adjustment as 
described earlier (Section 4.3.A.2.) and the strip sections were counted using a 
normalised γ-counter for 213Bi counting (15 – 350 keV window). Generally,  
PAI-2-DTTA was added to the pH-adjusted elution and ITLC was performed 
using 1 µl samples in selected mobile phases (specified for each experiment in 
Figure legends). 
The radiolabelling of PAI-2-DTTA with 213Bi was investigated with respect 
to PAI-2-DTTA concentration, 213Bi concentration and time. All reactions were 
conducted in a final 150 µl volume and for 10 min at RT (unless specified 
otherwise) and stopped with 5 µl of 0.5 M EDTA. For all assays, ITLC performed 
using 213Bi alone incubated identically to radiolabelling reactions was used as a 
control. For the effect of protein concentration, increased concentrations of  
PAI-2-DTTA were incubated with a set concentration of 213Bi (200 µCi/ml) and 
213Bi incorporation was determined by ITLC. The effect of increasing 213Bi 
concentration on the radiolabelling reaction was assayed using a set 
concentration of PAI-2-DTTA (100 µg/ml) and incorporation was measured. In 
order to determine the effect of reactants’ concentrations on the radiolabelling 
reaction, equal amounts of PAI-2-DTTA and 213Bi (maintained at µg: µCi ratio of 
1:1) were incubated in different final volumes and incorporation was assayed 
using ITLC. The time course experiments were conducted using 30 µg PAI-2-
DTTA and 30 µCi  213Bi in a final 150 µl volume and ITLC was performed at 
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specified time points. The zero time point was obtained by the addition of 30 µCi 
213Bi to PAI-2-DTTA solution containing 5 µl of 0.5 M EDTA and the sample was 
used immediately for ITLC. 
5.2.D. STABILITY OF α-PAI-2 
213Bi-labelled PAI-2-DTTA (α-PAI-2) was prepared at different specific 
radioactivities (µCi/µg). Under identical radiolabelling conditions, PAI-2 (not 
conjugated to cDTPA) was incubated with 213Bi. Protein concentration in all 
samples was 100 µg/ml and 20 µl aliquots from each reaction were incubated in 
triplicate with 0, 0.09, 0.9 or 9 µg of hydrolysed DTPA in a final 110 µl volume of 
RPMI-1640 containing 5 % FCS. Reactions were incubated at 37oC for 45 min 
and ITLC was performed in order to assess the stability of incorporated 213Bi in 
the presence of excess free DTPA and FCS. 
5.2.E. INTEGRITY OF α-PAI-2 
Optimally radiolabelled PAI-2-DTTA was assessed for structural integrity 
and uPA binding ability using SDS-PAGE (as described in Section 2.2.B.4.) 
followed by autoradiograph. α-PAI-2 prepared at different specific radioactivities 
(µCi/µg) was incubated in the presence or absence of uPA at 37oC for 45 min. 
Samples were fractionated by reducing 12 % SDS-PAGE (Section 2.2.B.2.) and 
autoradiography was performed as described in Section 2.2.B.3. 
5.3. RESULTS 
5.3.A. CONJUGATION OF CDTPA TO PAI-2  
cDTPA was conjugated to PAI-2 in several different reactions and the 
protein was efficiently recovered (> 90 % recovery). The ability of PAI-2-DTTA to 
form SDS-stable complexes with uPA was identical to that of free untreated  
PAI-2 (Figure 48). PAI-2 (47 kDa) formed complexes of 80 and 98 kDa with low- 
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and high-molecular weight uPA subunits (33 kDa, 55 kDa), respectively. 
Similarly, PAI-2-DTTA (lane 4) formed stable complexes with similar sizes when 
incubated with uPA (Figure 48). 













55 kDa HMW - uPA
33 kDa LMW - uPA
 
Figure 48: PAI-2-DTTA forms SDS-stable complexes with uPA 
PAI-2 and PAI-2-DTTA (2 and 1 µg, respectively) were incubated in a final 20 µl volume 
of PBS in the presence or absence of uPA (1 µg) (low and high molecular weight subunits 
33 and 55 kDa respectively) at 37oC for 90 min. At the end of the incubation, samples 
were fractioned using 12 % reducing SDS-PAGE. Sizes of the molecular weight marker 
bands in kDa are displayed on the left; lane 1: uPA; lane 2: PAI-2; lane 3: PAI-2 
incubated with uPA; lane 4: PAI-2-DTTA; lane 5: PAI-2-DTTA incubated with uPA. 
Similar data were obtained for the other PAI-2-DTTA conjugates prepared and for PAI-2-
DTTA conjugates when analysed 6 months after preparation. 
Incubation of PAI-2 conjugates at 1:1 molar ratio with uPA completely 
inhibited uPA enzyme activity (Figure 49). A dose-dependent decrease in the 
inhibition of uPA activity was seen as the ratio of PAI-2 to uPA was decreased. 
There were no significant differences between the inhibitory activity of PAI-2-



















Figure 49: PAI-2-DTTA inhibits uPA enzymatic activity 
Active uPA (20 IU, ~ 0.33 µg) was incubated with equimolar amount of unconjugated 
PAI-2 (clear bars) and PAI-2-DTTA conjugate (filled bars). In addition conjugates were 
incubated at 0.5:1 and 0.1:1 molar ratio of PAI-2:uPA. BSA (negative control) was also 
incubated with uPA (no effect on activity, data not shown). uPA activity was measured 
using Spectrozyme®-UK assay (see Section 2.2.B.4). Data presented are the mean ± 
standard error of the mean (SEM, n = 6 replicates). Similar data were obtained for the 
other PAI-2-DTTA conjugates prepared. 
When analysed by electrospray ionisation mass spectroscopy, the 
spectrum of free PAI-2 showed a single band with a molecular weight of 46844.8 
± 0.7 Da (data not shown). In comparison, spectra of PAI-2-DTTA conjugates 
displayed at least 2 additional peaks with higher molecular weights than that of 
free PAI-2 (Figure 50). The difference between these high molecular weight 
peaks and the PAI-2 peak was always a whole multiple of 429 Da (Figure 50 - 
inset). These increments corresponded to one partially hydrolysed cDTPA ion 
(373.35 Da) with a chelated iron atom (Fe 55.85 Da). The source of iron was 
expected to be from the stainless steel bar that the samples face before being 
sprayed in the electro-field (Mr Larry Hicks, personal communications). Thus, 
the mass spectroscopy data demonstrated that the PAI-2-DTTA preparations 
contain a mixture of several PAI-2-DTTA moieties. The percentage of free PAI-2 
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in all PAI-2-DTTA preparations was less than 10 %. Mass spectroscopy analysis 
performed immediately or up to 5 months after the preparation of PAI-2-DTTA 
(stored in dark at 4oC) produced identical spectra for the same samples, 
indicating that PAI-2-DTTA was relatively stable (data not shown). 




Figure 50: Electrospray mass spectroscopy of PAI-2-DTTA 
Samples were washed, adjusted to obtain approximately 1-10 µM final concentration 
and analysed by Q-TOF ESI-mass spectrometer at 30 volts cone and 5000-resolution 
power. Spectrum of PAI-2 only showed one peak (data not shown). The spectrum shown 
is from one PAI-2-DTTA preparation and the numbers displayed on the peaks represent 
the mass in Da. Similar spectra were obtained for other PAI-2-DTTA conjugates; 
however the spectra varied in the number of peaks observed (data not shown). Inset: 
The difference between the PAI-2 peak and each PAI-2-DTTA peak observed in spectra 
(labelled as 1-5) was plotted against the peak number. Each increase in the molecular 
weight represented an increase by the exact molecular weight of hydrolysed cDTPA 
molecule with a chelated iron atom. 
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The number of cDTPA molecules conjugated to PAI-2 in different 
conjugation experiments varied although the same batch of PAI-2 was used. 
This variation was also observed between different batches of PAI-2. The 
number of cDTPA molecules conjugated to PAI-2 varied between different 
batches and within different reactions using the same batch of PAI-2. The 
minimum number of conjugated cDTPA molecules was 2, the maximum was 5 
and the average was 3 - 4 molecules (n = 15, data not shown). 
5.3.B. PREPARATION OF 213BI ELUTION SOLUTION FOR RADIOLABELLING 
The solution used for eluting 213Bi from the 225Ac column, 0.075 M HI/1 x 
PBS, had a pH of 0.5. PAI-2-DTTA precipitated when added to this solution at a 
concentration of 0.19 – 1.1 mg/ml, possibly due to the low pH. The elution 
solution could be titrated using 1 M sodium hydroxide, 6 M sodium acetate pH 
5.5 or 1 M citrate pH 5.5 (Figure 51). Adjustment of pH of elution solution to pH 
5 – 6 was essential since radiolabelling with 213Bi is optimal at this pH (McDevitt 
et al., 1999) and PAI-2-DTTA is expected to be soluble at this pH as the pI of 
PAI-2 is 5.5 (Kruithof et al., 1995). 
Sodium hydroxide showed a steep titration curve at around pH 5 - 6, 
thus pH adjustment of the 213Bi-elution solution required gradual careful 
addition of sodium hydroxide. Although successful radiolabelling of PAI-2-DTTA 
with 213Bi was possible using this system (data not shown), the use of 1 M 
sodium hydroxide was aborted due to the time lost during pH adjustment and 
irreproducibility of this method because of the pH leap. Titration of the elution 
solution using a final concentration of sodium acetate between 0.2 - 0.6 M 
showed that a buffering region existed where the pH ranged between 4 and 5.5. 
Nevertheless, precipitation of PAI-2-DTTA was observed when added at different 
protein concentrations (0.2 – 1 mg/ml) to elution solution adjusted with various 
concentrations of sodium acetate (0.1 - 0.6 M) (data now shown). 
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Figure 51: Titration of the 213Bi elution solution 
Elution solution (0.075 M HI/1 x PBS) was titrated with (A) 1 M sodium hydroxide, (B) 6 
M sodium acetate, pH 5.5 or (C) 1 M citrate buffer, pH 5.5. The pH of the solution was 
measured and plotted against the final concentration (mM) of the titration buffer in the 
final total volume. 
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5.3.B.1. LABELLING OF PAI-2-DTTA WITH 213BI USING CITRATE BUFFER 
Incubation of PAI-2-DTTA at 1 mg/ml with elution solution adjusted with 
0.09 – 0.13 M citrate showed that protein precipitation decreased as the final 
molar concentration of citrate increased (Table V – A). PAI-2-DTTA precipitation 
was not observed when the elution solution was buffered using 0.13 M citrate 
(final solution pH 5.5 – 6). Incubation of various concentrations of PAI-2-DTTA 
in elution solutions adjusted with 0.13 M final concentration of citrate buffer 
did not result in precipitation of the protein (Table V – B). Omission of PBS from 
the elution solution resulted in PAI-2-DTTA precipitation (pH 5.5, data not 
shown), the reason for this precipitation was not clear. 
 
 
Table V: Effect of citrate buffered elution on PAI-2-DTTA precipitation 
A 
Elution solution Final [citrate](M) 
[PAI-2-DTTA] 
(mg/ml) pH Precipitation 
0.09 1 3.5 - 4 Most (+++) 
0.10 1 4 - 4.5 Less (++) 
0.11 1 4.5 - 5 Less (+) 
0.12 1 5 – 5.5 Least (-) 
0.075 M HI and 1 
x PBS 
0.13 1 5.5 - 6 No precipitation 
B 
Elution solution Final [citrate](M) 
[PAI-2-DTTA] 
(mg/ml) pH Precipitation 
0.13 0.58 5.5 - 6 No 
0.13 0.73 5.5 - 6 No 
0.13 1.16 5.5 - 6 No 
0.075 M HI and 1 x 
PBS 
0.13 1.93 5.5 - 6 No 
(A) Elution solution was titrated with 1 M citrate buffer (pH 5.5); PAI-2-DTTA was added 
at 1 mg/ml and precipitation was assessed. (B) PAI-2-DTTA was incubated at different 
concentrations in elution solution buffered using 1 M citrate buffer (pH 5.5) at 0.13 M 
final concentration. The pH of the final solution was measured and protein precipitation 
was assessed. 
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The studies performed with citrate-buffered elution solution above did 
not contain 213Bi radionuclide. Nevertheless, as shown in Table VI, the presence 
of 213Bi at various concentrations did not affect the pH of the citrate-buffered 
solution. ITLC performed using 1 µl of citrate-buffered 213Bi elution showed that 
using 0.1 M citrate buffer as the mobile phase, 99 % of radiation moved to the 
solvent front (Table VII - A). As other buffers showed that significant level of 
radiation remained at the origin, these could not be used for assessing the 
percentage incorporation of 213Bi using ITLC. No precipitation of protein was 
observed when PAI-2-DTTA was incubated with buffered 213Bi solution (0.075 M 
HI/1 x PBS/0.13 M citrate) for 15 min. The incorporation of 213Bi when buffered 
213Bi solution was incubated with PAI-2-DTTA at 1 µCi:1 µg ratio was 93 and 
93.7 % at 1 and 5 min, respectively (Table VII – B). 
 

















100 0 13 17 130 0 5.5-6
75 25 13 17 130 0.12 5.5-6
50 50 13 17 130 0.24 5.5-6
25 75 13 17 130 0.36 5.5-6
0 100 13 17 130 0.48 5.5-6
213Bi was eluted using 250 µl of 0.15 M HI followed by 250 µl of dH2O. Different volumes 
of 213Bi elution were mixed with different volumes of 0.075 M HI in a final volume of 100 
µl. The pH was adjusted using 10 x PBS and 1 M citric acid solution (pH 5.5) and the pH 
of the final 130 µl volume was measured. 
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Table VII: Effect of different solvents on separation of free and  
PAI-2-DTTA-incorporated 213Bi by ITLC 
A: Mobility of free 213Bi 
ITLC buffer Radioactivity at origin 
0.5 M acetate 58 % 
0.1 M citrate 1 % 
1 x PBS 33 % 
dH2O 20 % 
B: Mobility of PAI-2-DTTA-213Bi 
Reaction 213Bi incorporation 
1 min 93.0 % 
5 min 93.7 % 
(A) 2 µl of buffered 213Bi (0.075 M HI/1 x PBS/0.13 M citrate, pH 5.5 – 6) was spotted 
onto ITLC strips and chromatography was performed using the specified mobile phases. 
Radioactivity at the origin was calculated as the percentage of radioactivity at origin over 
the radioactivity at both the origin and solvent front. (B) ITLC was performed using 0.1 
M citrate (pH 5.5) solution as the mobile phase at 1 and 5 min from the incubation of 
PAI-2-DTTA with buffered 213Bi at 1 µg: 1 µCi ratio at RT. The percentage of activity at 
the origin (% origin/[origin + solvent front]) was calculated as a measure of 213Bi 
incorporation. 
5.3.C. OPTIMISATION OF RADIOLABELLING OF PAI-2-DTTA WITH 213BI 
(α-PAI-2) 
Using the citrate buffering system for preparing a suitable 213Bi-elution 
solution, the radiolabelling of PAI-2-DTTA with 213Bi was optimised in terms of 
protein/radioactivity concentrations and time. High percentage incorporation of 
213Bi (> 90 %) was obtained when PAI-2-DTTA was incubated with 213Bi to give 
specific radioactivity less than 10 µCi/µg (Figure 52 – A and B). In addition to 
the effect of the 213Bi: PAI-2-DTTA ratio, 213Bi percentage incorporation was also 
affected by the final concentrations of 213Bi and PAI-2-DTTA even when both 
reactants were maintained at 1 µCi: 1 µg ratio (Figure 52 – C). 
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Figure 52: Radiolabelling optimisation of PAI-2-DTTA with 213Bi 
(A) Buffered 213Bi solution (200 µCi/ml) was incubated with increasing concentrations of 
PAI-2-DTTA for 10 min at room temperature. 213Bi incorporation was assessed by ITLC 
using 0.1 M citrate (pH 5.5) as mobile phase. (B) 100 µg/ml PAI-2-DTTA was incubated 
with increasing concentrations of buffered 213Bi and incorporation was assessed. (C) 
PAI-2-DTTA (7.25 µg) and buffered 213Bi (7.25 µCi) were incubated in different final 
volumes for 10 min. Data presented in Figure are the mean incorporation percentages ± 
SEM (n = 3). Note: the percentage 213Bi incorporation is the percentage of 213Bi 
incorporated into PAI-2-DTTA over the total 213Bi added. 
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At high final concentrations (200 µCi and 200 µg per ml), the 
radiolabelling of PAI-2-DTTA with 213Bi was rapid and reached maximal within 
the first 5 min of incubation (Figure 53). The incorporation of 213Bi into PAI-2-
DTTA was solely due to the DTTA moiety as PAI-2 failed to incorporate any 213Bi 
in comparison to PAI-2-DTTA (Figure 54 – A). Incorporated 213Bi was strongly 
chelated since only 15 and 16 % of 213Bi was stripped from PAI-2-DTTA-213Bi 
prepared at 1 and 5 µCi/µg, respectively, when challenged with excess amount 
(80 µg/ml) of free DTPA (Figure 54 – B). 



















Figure 53: Kinetics of the PAI-2-DTTA 213Bi-labelling reaction 
PAI-2-DTTA (200 µg/ml) and buffered 213Bi (200 µCi/ml) were incubated at room 
temperature and at the specified time points the reaction was stopped by the addition of 
EDTA (20 mM final concentration). 213Bi incorporation was assessed using ITLC and 











































Figure 54: Specificity and stability of the 213Bi-labelling reaction 
(A) PAI-2-DTTA or PAI-2 were incubated for 10 min at RT with buffered 213Bi at 1 or 5 
µCi/µg in the same final volume. 213Bi incorporation was assessed and data presented 
are the mean incorporation ± SEM (n = 3). (B) PAI-2-DTTA labelled with buffered 213Bi at 
1 (clear bars) and 5 (filled bars) µCi/µg were incubated at 37oC for 45 min in RPMI-1640 
+ 5 % FCS containing increasing concentrations of hydrolysed cDTPA (DTPA). 213Bi 
incorporation was assessed and data presented are the mean ± SEM (n = 3). There was 
no significant differences in the percentage of 213Bi remaining with the protein between 
the 1 and 5 µCi/µg α-PAI-2 preparations after challenge with all DTPA concentrations (p 
> 0.05, n = 3). However, challenge of both specific radioactivities with 80 µg/ml DTPA 
caused a small but significant loss of 213Bi label from the protein compared to 
unchallenged controls (*, p < 0.05, n = 3). 
**
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5.3.D. INTEGRITY OF α-PAI-2 
α-PAI-2 prepared at specific radioactivities decreased the structural and 
functional integrity of PAI-2. The intensity of the band corresponding to PAI-2 
(47 kDa) detected by SDS-PAGE decreased as the specific radioactivity of α-PAI-
2 increased from 0.1 to 10 µCi/µg (Figure 55 – A). In agreement, 
autoradiography (Figure 55 – B) showed an increase in the intensity of possible 
radioactive degradation products at the bottom of the gel with increasing 
specific radioactivities of α-PAI-2. The intensity of the 47 kDa band in the 
autoradiogram increased with higher specific radioactivity of α-PAI-2 which 
reflects higher incorporation of 213Bi (lanes 2, 4, 6 and 8 in Figure 55 – B). 
The ability of α-PAI-2 to from SDS-stable complexes with uPA was also 
affected by its specific radioactivity. α-PAI-2 prepared at 0.1 and 1 µCi/µg 
efficiently formed complexes with uPA as bands for free α-PAI-2 were not evident 
(lanes 3 and 5 compared with lanes 2 and 4, respectively, Figure 55 – B). In 
contrast, for the 5 and 10 µCi/µg α-PAI-2, large amounts of free α-PAI-2 were 
evident even after incubation with excess uPA (lanes 7 and 9 compared with 
lanes 6 and 8, respectively, Figure 55 – B). This indicated that although a 
fraction of 5 and 10 µCi/µg α-PAI-2 remained intact, only a fraction of this 
intact α-PAI-2 at these specific radioactivities were able to form SDS-stable 
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Figure 55: α-PAI-2 integrity and uPA-binding ability 
PAI-2-DTTA was radiolabelled with buffered 213Bi to produce α-PAI-2 at specific 
radioactivities of 0.1, 1, 5 and 10 µCi/µg. The protein concentration for all incubations 
was identical and the same volume from each specific radioactivity was incubated at 
37oC for 60 min in the absence or presence of excess uPA containing high (55 kDa) and 
low (33 kDa) molecular weight uPA. Aliquots containing the same protein amounts were 
fractionated by 12 % reducing SDS-PAGE. (A) The SDS-PAGE gel was stained in 
Coomassie blue stain solution, destained and documented after (B) exposure to 
phosphor screen for 3 h and scanning using the Storm® scanner. Lane 1: molecular 
weight marker. Lane 2: 0.1 µCi/µg α-PAI-2; lane 3: 0.1 µCi/µg α-PAI-2 + uPA; lane 4: 1 
µCi/µg α-PAI-2; lane 5: 1 µCi/µg α-PAI-2 + uPA; lane 6: 5 µCi/µg α-PAI-2; lane 7: 5 
µCi/µg α-PAI-2 + uPA; lane 8: 10 µCi/µg α-PAI-2; lane 9: 10 µCi/µg α-PAI-2 + uPA and 





5.3.E. CYTOTOXICITY OF α-PAI-2 
5.3.E.1. CYTOTOXICITY OF BUFFER-EXCHANGED α-PAI-2 
α-PAI-2 prepared at 1, 5 and 10 µCi/µg specific radioactivities were 
efficiently  buffer exchanged from the labelling buffer into RPMI-1640 + 5 % FCS 
using 30 kDa cut-off microconcentrators (90 % of the initial activity recovered, 
data not shown). α-PAI-2 under these conditions showed slight cytotoxicity to 
MDA-MB-231 cells (Figure 56 - A). At 3 µCi/100 µl dose of 1, 5 and 10 
µCi/µg α-PAI-2, the percentage of surviving cells compared to control cells was 
79.4 ± 0.5, 80.2 ± 0.2 and 83.6 ± 2.4 %, respectively. The cytotoxicity was not 
significantly different using the different specific activities of α-PAI-2 (p > 0.05, n 
= 3). In a separate experiment, treatment of the MDA-MB-231 cells with buffer-
exchanged 1 µCi/µg α-PAI-2 significantly decreased cell survival to 75.4 ± 1.3 % 
(p < 0.05, n = 5, Figure 56 - B). The survival of the non-invasive breast cancer 
cells, T-47D cells, was not significantly affected by the addition of this dose of 
washed α-PAI-2 (p > 0.05, n = 5). This suggested that the cytotoxicity of α-PAI-2 
observed on MDA-MB-231 cells was due to high cell-surface uPA levels on these 
cells compared to T-47D cells. Despite the success of this assay, the cytotoxicity 
level of buffer-exchanged α-PAI-2 was lower than that previously reported by 
Ranson et al. (2002). This may be explained by difference in the radiolabelling 
procedure (Ranson et al., 2002). Higher doses of α-PAI-2 (> 3 µCi/100 µl) were 
not possible due to the dilution of radioactivity during buffer exchange 


































Figure 56: Cytotoxicity of buffer-exchanged α-PAI-2 
(A) MDA-MB-231 cells cultured for 48 h were detached and incubated with 5 µg/ml 
plasminogen for 5 min at room temperature. Cells (2 x 104) were washed and incubated 
overnight in triplicate 100 µl volumes of RPMI-1640 + 5 % FCS in the absence or 
presence of specified doses of buffer-exchanged α-PAI-2 prepared at 1 (clear bars), 5 
(light grey) and 10 (dark grey) µCi/µg. Cells were washed and incubated with 100 µl of 
phenol-free binding buffer containing 5 % FCS and 20 µl of MTS/PMS substrate. The 
absorbance of the product (at 495 nm) was measured after 3 h incubation at 37oC, 
blanked against absorbance of solution in the absence of cells and cell survival was 
calculated as the percentage of absorbance of α-PAI-2-treated cells against control cells. 
(B) MDA-MB-231 cells (clear bars) and T-47D cells (filed bars) were subjected to 
treatment with 3 µCi/100 µl dose of 1 µCi/µg α-PAI-2 as described for A and cell 
survival was calculated (mean percentage survival ± SEM, n = 5). Asterisk denotes 
significant difference between control and treated MD-MB-231 cells (p < 0.05). The 
treatment of T-47D cells did not significantly affect cell survival compared to control  
T-47D cells (p > 0.05, n = 5). 
 
178 
5.3.E.2. CYTOTOXICITY OF NON-BUFFER-EXCHANGED α-PAI-2 
In order to avoid the time lost during the purification of α-PAI-2 due to 
the short half-life of 213Bi and to prevent the dilution caused by the purification 
procedure, non-buffer-exchanged α-PAI-2 preparations were investigated for use 
in cytotoxicity assays. Control experiments showed that the percentage of 
surviving cells decreased with increasing concentrations of buffered elution 
solution (0.075 M HI, 1 x PBS, 0.2 M citrate, pH 5.5 - 6) added to culture media 
in comparison to cells incubated with culture media only (Figure 57 - A). In 
contrast to the cytotoxic effect of the elution solution, increased cell proliferation 
was observed with increasing concentrations of unlabelled PAI-2-DTTA added to 
culture media (Figure 57 - B). Thus, in order to account for these confounding 
effects, control treatments were included in cytotoxicity assays which were 
identical to the α-PAI-2 treatments except for the absence of 213Bi. 
In comparison to the control solutions described above, cytotoxicity of 
non-buffer-exchanged α-PAI-2 preparations on MDA-MB-231 cells depended on 
both the specific radioactivity and the dose of α-PAI-2 added. At all specific 
radioactivities, there was a dose-dependent, significant decrease in MDA-MB-
231 cell-survival (Figure 58 – A). In comparison to MDA-MB-231 cells, T-47D 
cells resisted treatment with low doses (1 and 2 µCi/100 µl) at all specific 
radioactivities (p < 0.05, n = 3) (Figure 58 – B). The use of high doses (4 and 8 
µCi) of all specific radioactivities did not show significant difference between the 
survival of T-47D and MDA-MB-231 cells (p > 0.05, n = 3). This indicated that 
high doses of α-PAI-2 sufficiently targeted both cell lines. The highest specific 
radioactivity of α-PAI-2 (10 µCi/µg) had the least cytotoxic effect on both MDA-
MB-231 and T-47D cells. For example using 1 µCi/µg α-PAI-2, cells survival at 
each dose used significantly decreased compared to that using 5 or 10 µCi/µg 
α-PAI-2 (Figure 58 – A and B). This was in agreement with decreased integrity 
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and uPA-binding ability of α-PAI-2 with increasing specific radioactivity (refer to 
Figure 55). 
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Figure 57: Effect of elution solution and PAI-2-DTTA on cell survival 
(A) MDA-MB-231 cells were incubated overnight in RPMI-1640 + 5 % FCS in the 
absence or presence of buffered elution solution (0.075 M HI/1 x PBS/0.2 M citrate, pH 
6). Cell survival was measured after overnight incubation in comparison to control 
treatment (RPMI-1640 + 5 % FCS only) and the mean ± SEM (n = 3) was plotted against 
the concentration of buffered elution solution in the 100 µl volume (v/v %). (B) MDA-
MB-231 cells were incubated with increasing concentrations of unlabelled PAI-2-DTTA. 
Cell survival was compared to control cells and plotted against the concentration of PAI-
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Figure 58: Optimised cytotoxicity of α-PAI-2 on MDA-MB-231 and T-47D cells 
(A) MDA-MB-231 and (B) T-47D cells, cultured for 48 h, were detached and treated with 
the specified doses of α-PAI-2 prepared at 1 (■), 5 (●) and 10 (▲) µCi/µg. For each dose 
of the different specific radioactivities, the corresponding control treatment involved the 
addition of the same volume of buffered elution solution and the same amount of 
protein in the form of unlabelled PAI-2-DTTA. Survival was determined after overnight 
treatment compared to these controls and data presented are the mean ± SEM (n = 3). 
(A) Survival plots of MDA-MB-231 cells were fitted to one-phase exponential decay 
model. (B) Survival plots of T-47D cells were fitted to sigmoidal dose-response model. 
The sigmoidal shape indicated that T-47D cells were resistant to low doses of α-PAI-2; 
however toxicity was achieved at high doses. Models were selected according to the best 
fit and none of the data deviated from the fitted model as judged by runs test performed 
by GraphPad® software. The dotted lines represent the toxic dose (Do, 37 % survival). 
Data presented are representative from two independent assays. 
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5.3.E.3. PROLIFERATIVE CAPACITY OF CELLS SURVIVNG α-PAI-2 EXPOSURE 
After overnight treatment with 4 and 8 µCi/100 µl doses of 1 µCi/µg  
α-PAI-2, 62 ± 0.6 and 70 ± 0.9 % of the total cell population compared to control 
cells did not survive, respectively (Figure 59 – A and B). Whether the remaining, 
presumably not targeted, cells were healthy and able to proliferate was checked 
by examining cell survival 48 h after treatment with 1 µCi/µg α-PAI-2. Using 
both 4 and 8 µCi/100 µl doses of 1 µCi/µg α-PAI-2 the cell numbers were 
significantly recovered (to 92.1 ± 3.2 and 54.1 ± 1.5 % compared to controls, 
respectively) after 48 h compared to the overnight time point (Figure 59 – A and 
B). This indicated that the surviving remaining cells after overnight treatment 
with 1 µCi/µg α-PAI-2 retained their ability to proliferate. Cells treated with 4 
and 8 µCi/100 µl doses of 5 and 10 µCi/µg α-PAI-2 showed less than 50 % 
recovery between overnight and at 48 h (Figure 59 – A and B). Thus, although  
5 and 10 µCi/µg α-PAI-2 were less cytotoxic than 1 µCi/µg α-PAI-2 after 
overnight incubation (Figure 59, clear bars), these higher specific radioactivity 
preparations appeared to decrease the proliferative capacity of the remaining 
cells that survived after overnight treatment during 48 h incubation after 
treatment (Figure 59, filled bars). This suggests that since treatment with  
1 µCi/µg α-PAI-2 appeared not to affect the proliferation of surviving cells then  
1 µCi/µg α-PAI-2 caused minimal co-lateral cytotoxicity. That is surviving cells 
(untargeted) were not affected by 1 µCi/µg α-PAI-2 in the media, therefore 
proliferated normally. 
5.3.E.4. EFFECT OF CELL ATTACHMENT ON α-PAI-2 CYTOTOXICITY 
Attached MDA-MB-231 cells, treated identically to detached cells, were 
less sensitive to the cytotoxicity of α-PAI-2. Nevertheless, cell survival depended 
on the dose and specific radioactivity of α-PAI-2 (Figure 60 – A). This indicated 
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that attachment of MDA-MB-231 cells did not affect the targeting mechanism of 
α-PAI-2; however, only a fraction of the administered dose may have targeted 
these cells. In agreement, higher levels of PAI-2-Cy5 bound to detached MDA-
MB-231 cells compared to attached cells (Figure 60 - B). This binding was 
similarly inhibited by blocking the B-chain of uPA (data not shown). Thus, the 
effect of cell attachment on the binding of PAI-2-Cy5 and the cytotoxicity of  
α-PAI-2 may be due to the unavailability of uPAR-bound uPA which is involved 
in focal adhesion during cell attachment. 
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Figure 59: Recovery of α-PAI-2-treated MDA-MB-231 cells at 48 hour post treatment
MDA-MB-231 cells cultured for 48 h were detached and treated with (A) 4 µCi/100 µl 
and (B) 8 µCi/100 µl doses of α-PAI-2 prepared at 1, 5 and 10 µCi/µg as described for 
Figure 58. For each dose of the different specific radioactivities, control treatments 
involved the addition of the same volume of buffered elution solution and unlabelled 
PAI-2-DTTA. The percentage of surviving cells compared to control treatments was 
determined after overnight incubation (clear bars) and 48 h past the treatment (filled 
bars). Data presented are the mean ± SEM (n = 3). The number of cells in control 
treatments was approximately doubled between the overnight time point and the 48 h 
time point (data not shown). 
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Figure 60: Effect of cell-attachment on ability of PAI-2 to access cell-surface uPA 
(A) Attached MDA-MB-231 cells (2 x 104 cells) cultured for 48 h were activated with plasminogen and treated with the specified doses of α-PAI-2 
prepared at 1 (■), 5 (●) and 10 (▲) µCi/µg. Survival was determined compared to control treatments as described for Figure 58 and data presented are 
the mean ± SEM (n = 3). (B) Detached (left column) and attached (right column) MDA-MB-231 cells pre-activated with plasminogen were incubated with 
PAI-2-Cy5 for 5 min at 37oC, cells were washed and then analysed by confocal microscopy. Top row are the transmission images and the scale bars 
represent 10 µm. Bottom row are the Cy5 scan of the transmission images. One representative sample (n = 6) is shown for each treatment and pre-
incubation of cells with anti-B-chain uPA monoclonal antibody (#394) completely inhibited PAI-2-Cy5 binding (data not shown). 
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5.4. DISCUSSION 
The results of this chapter describe the successful efficient radiolabelling 
procedure of PAI-2-DTTA with the α-emitter radioisotope, 213Bi. It was confirmed 
that conjugation of PAI-2 to the metal chelator, cDTPA, did not affect the 
binding ability or the inhibitory effect of PAI-2 towards uPA (see also Ranson et 
al., 2002). Mass spectroscopy confirmed the addition of a variable number of 
DTTA moieties to PAI-2 in the PAI-2-DTTA preparations. Ranson et al. (2002) 
also showed that conjugation with cDTPA did not affect PAI-2 function and their 
preparation contained a mixture of modified PAI-2 containing 1 – 4 DTTA 
molecules per PAI-2 molecule. Further investigation in this chapter showed that 
there was always a mixture of different stoichiometric ratios of PAI-2 to DTTA 
(i.e. PAI-2-DTTA, PAI-2-[DTTA]2 … PAI-2-[DTTA]n) which varied between different 
reactions and within replicates of the same reaction. This variation may be due 
to complex reaction kinetics. These complicated reaction kinetics are beyond the 
scope of this study; however, they may be related to reaction conditions and 
sterical hindrance on the surface of PAI-2 despite the fact that only limited sites 
on the surface of PAI-2 are available for reaction. Thus, although the average 
number of DTTA molecules conjugated to PAI-2 was calculated as 3 - 4 
molecules (n = 15), it is recommended that mass spectroscopy should be 
performed for each preparation due to the variation observed. 
Previous radiolabelling of PAI-2-DTTA with 213Bi showed that the 
percentage of incorporated radioactivity was greater than 90 % (Ranson et al., 
2002). However, α-PAI-2 needed to be purified from free 213Bi using size 
exclusion chromatography of the radiolabelling reaction which is a time-
consuming process. Although Ranson et al. (2002) demonstrated the uPA-
dependent cytotoxicity of their α-PAI-2 preparation, more efficient, rapid and 
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reproducible radiolabelling protocol was needed considering the short-life of 
213Bi and for potential clinical applications. The radiolabelling reaction of PAI-2-
DTTA with 213Bi was first optimised in terms of the buffer used for this reaction. 
PAI-2-DTTA was readily precipitated when added to the solution used to elute 
213Bi due to the very low pH of this solution (pH 0 – 1). Although sodium acetate 
was described to neutralise the elution solution (Ranson et al., 2002), it was 
found that PAI-2-DTTA precipitated even when the elution solution was 
adjusted to pH 5.5 using sodium acetate. The reason for the unreported 
precipitation in the α-PAI-2 prepared by Ranson et al. (2002) may be due to the 
very low protein concentrations used in their study (5 – 10 µg in a 550 µl typical 
elution volume). Furthermore, considering that the average activity eluted in 
550 µl volume is higher than 500 µCi, the previous labelling involved the 
addition of 100 µCi of 213 Bi per 1 µg of PAI-2-DTTA (Ranson et al., 2002). The 
authors described the preparation of 15 – 20 µCi/µg of α-PAI-2 after PD-10 
column purification, indicating that only 10 – 15 % of added 213Bi was 
incorporated thus necessitating further purification. This inefficient 
radiolabelling (Ranson et al., 2002) and the precipitation of PAI-2-DTTA reported 
in this thesis when using sodium acetate as buffering system suggested that 
alternative methods were required to optimise the radiolabelling of PAI-2-DTTA. 
The use of citric acid buffer (pH 5.5) showed that protein precipitation by 
the elution solution was prevented by the presence of 0.13 – 0.2 M final 
concentration of citrate. Initial radiolabelling reactions under citrate buffering 
system described an efficient incorporation of 213Bi (> 90 %) which was 
confidently assessed using 0.1 M citrate (pH 5.5) as the mobile phase for ITLC. 
Using these conditions for pH adjustment and ITLC, the radiolabelling of PAI-2-
DTTA with 213Bi was optimised with respect to the ratio of radioactivity to 
protein, concentration of reactants and time. A standard operating procedure 
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(SOP) for pre-clinical analyses was developed for the radiolabelling reaction 
where 213Bi is eluted using 250 µl of freshly prepared 0.15 M HI and 250 µl of 
dH2O into reaction tube containing 85 µl of 1.5 M citrate (pH 5.5) and 65 µl of 
10 x PBS (pH 7.2) then PAI-2-DTTA is added and incubated for 5 – 10 min. 
Using the developed SOP, PAI-2-DTTA was radiolabelled with 213Bi at 
different specific activities and 213Bi incorporation was shown to be specific and 
stable. There was a loss in the integrity and uPA-binding ability with increasing 
specific radioactivity of α-PAI-2 preparations. In agreement, higher specific 
radioactivity (5 and 10 µCi/µg) preparations of α-PAI-2 were less cytotoxic 
towards MDA-MB-231 and T-47D cells compared to lower specific radioactivity 
(1 µCi/µg) preparation. T-47D cells tolerated low doses (< 4 µCi/100 µl) of  
1 µCi/µg α-PAI-2 compared to MDA-MB-231 cells. This indicated that cytotoxic 
effect of 1 µCi/µg α-PAI-2 was uPA-dependent at doses less than 4 µCi/100µl. 
However, doses higher than 4 µCi/100 µl of 1 µCi/µg α-PAI-2 efficiently reduced 
the survival of suspension cultures of both high and low uPA expressing  
MDA-MB-231 and T-47D cells, respectively. Cells significantly recovered when 
incubated for 48 h after treatment with all doses of 1 µCi/µg α-PAI-2. On the 
other hand, cells treated with 5 and 10 µCi/µg α-PAI-2 did not recover as 
efficiently at 48 h incubation after treatment. This suggested that although 5 
and 10 µCi/µg α-PAI-2 showed less cytotoxic effect than 1 µCi/µg α-PAI-2, these 
high specific radioactivity preparations may have caused co-lateral damage to 
untargeted cells and affected their proliferation ability. Finally, attached  
MDA-MB-231 cells tolerated the same doses of α-PAI-2 (1, 2, 4 and 8 µCi/100 
µl) at the different specific radioactivities (1, 5 and 10 µCi/µg) delivered to 
suspension MDA-MB-231 cells. This increased tolerance maybe explained by 
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less binding of PAI-2 to these cells when attached compared to when in 
suspension. 
The results of this chapter are important for the preparation and 
assessment of the use of α-PAI-2 in pre-clinical in vivo trials. Based on these 
results, the 1 µCi/µg α-PAI-2 preparation was suggested for use for pre-clinical 
trials since: (1) this preparation did not affect the structural integrity of PAI-2 or 
its uPA binding ability, (2) 213Bi incorporation was highly stable, (3) the uPA-
dependent cytotoxic effect of α-PAI-2 was highest on both detached and 
attached cells and (4) the 1 µCi/µg α-PAI-2 preparation appeared to cause the 
least co-lateral damage. 
In conclusion, this chapter described the efficient conjugation of cDTPA 
to PAI-2 and methods required for characterisation of the final product of this 
reaction. Furthermore, the preparation of PAI-2-DTTA and its radiolabelling 
with 213Bi was optimised into a standard operating procedure, which was 
adopted for the preparation of 213Bi-PAI-2 for pre-clinical trials of radiotherapy 
using mouse models of human tumours (Stutchbury et al., manuscripts in 
preparation). These pre-clinical trials showed that mice tolerated buffered 213Bi 
elution and that 1 µCi/µg α-PAI-2 effectively reduced tumour growth and 
conferred a survival advantage (Stutchbury et al., manuscript in preparation). 
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Chapter 6: CONCLUSIONS AND FUTURE WORK 
The kinetics of the inhibition of cell-surface uPA on breast cancer cells by 
PAI-2 were directly described using appropriate parameters (KI and kinact) in this 
thesis as compared to the previous indirectly assayed second order rate 
constant (Ellis et al., 1990). uPA was identified as the major specific target for 
PAI-2 on the cell surface. The inhibition parameters measured in this thesis 
characterise PAI-2 as a very specific potent inhibitor of uPAR-bound uPA on the 
cell surface. Inhibition of cell-surface uPA by PAI-2 is rapidly followed by the 
endocytosis of PAI-2, uPA as well as uPAR which seems to mimic the previously 
reported internalisation of cell surface uPA/uPAR induced by other serpins 
(Andreasen et al., 1997). Data also indicate that uPAR may be recycled to the 
cell surface which is in agreement with previous findings using other serpins 
(Nykjær et al., 1997). Members of the LDLR family are involved in part in the 
internalisation of PAI-2 (Al-Ejeh et al., 2004). Despite these similarities between 
PAI-2 induced internalisation of uPAR/uPA:PAI-2 complexes and other 
uPAR/uPA:serpin complexes, data suggests that the mechanism of PAI-2 
internalisation may be novel in terms of endocytosis mediators (Croucher D., 
personal communications). During the internalisation of uPAR/uPA:PAI-2, uPA 
may be replenished on the cell surface in the pro-enzyme form. These results 
lead to an entire new PhD project (undertaken by Croucher D., Dr. M. Ranson 
Laboratory, University of Wollongong) to provide definitive evidence for the 
suggested replenishment of cell-surface uPA and the recycling of uPAR as well 
as deducing the complete mechanism of uPAR/uPA:PAI-2 internalisation. 
The evident internalisation and the perinuclear localisation of 
internalised PAI-2 provide a definitive biological rationale for the targeted alpha 
therapy being developed using this serpin (Li et al., 2002; Ranson et al., 2002; 
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Allen et al., 2003). The standard operating procedures for the preparation and 
characterisation of α-PAI-2 described in this thesis were adopted by Dr Marie 
Ranson and collaborators (University of Wollongong, Australia) in pre-clinical 
development of α-PAI-2 for treatment of breast and prostate cancer. Given 
further time and resources, separation of the different PAI-2-DTTA moieties in 
the conjugation reactions by high-pressure liquid chromatography would have 
been advantages for at least two reasons. First, such separation would result in 
a more uniform solution of PAI-2-DTTA for clinical use. Secondly, as tryptic 
digest and peptide mass finger printing using mass spectroscopy resulted in 
very complex spectra (data not shown), separation of different PAI-2-DTTA 
moieties before fingerprinting may simplify these results. This may be employed 
in order to deduce the sites of cDTPA conjugation to PAI-2 and completely 
characterise this promising cancer targeting vehicle. 
Finally, transfection of the non-invasive breast cancer T-47D cells with 
uPAR cDNA was also useful for the PAI-2 binding studies. Furthermore, the 
overexpression of uPAR in the non-invasive T-47D cells caused an interesting 
modulation of other components of the urokinase-type plasminogen activation 
cascade. Using this technique, initial and preliminary explanations were 
provided for elucidating links between the upregulation of uPAR expression and 
the adoption of metastatic phenotype. Although such a link has been described 
previously (e.g. Ranson et al., 1998), the findings in this thesis gave deeper 
insights into the adoption of the malignant phenotype by cancer cells and raised 
new questions which may be the subject for future research. The possibility that 
the non-active site epitope on uPA suggested by Ellis et al. (1999) can act as a 
receptor for plasminogen binding may be evaluated by developing antibodies to 
this epitope. This would provide an explanation for increased plasminogen 
binding when increasing cell-surface uPA and the co-localisation of 
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uPA/plasminogen on T-47D cells. Furthermore, the possible effect of 
uPAR/uPA-transient overexpression on the expression of plasminogen receptors 
may be characterised by proteomic comparison between control and transfected 
T-47D cells. The ability to knock out the expression of uPAR in the invasive 
MDA-MB-231 cells would provide useful material for comparison with uPAR-
overexpressing T-47D cells, however, consistent preparation of uPAR-
downregulated MDA-MB-231 cells in this study failed. Further work is required 
to prepare uPAR--MDA-MB-231 cells and new techniques such as small 
interfering RNA (siRNA) transfection technology would be recommended. siRNA-
transfection is showing more success than cDNA transfection methods in 
silencing the expression of cellular components (Caplen and Mousses, 2003). In 
addition, the possibility that increased cell-surface plasmin activity by the 
addition of exogenous uPA or transient overexpression of uPAR/uPA may 
activate latent plasminogen receptors needs to be tested. It is well known that 
increased cell-surface uPAR/uPA leads to an increase in plasmin-dependent 
proteolysis and invasion both in vitro and in vivo and that plasmin generation is 
mediated by the proteolytic activity of uPA on receptor-bound plasminogen (see 
review by Andreasen et al., 1997). However, it is not clear whether this involves 
modulation of plasminogen receptors on the cell surface. Altogether, the future 
work suggested above may be incorporated into a PhD project aimed at 
understanding the molecular details of the increased plasminogen binding due 
increased of cell-surface uPAR/uPA. 
In conclusion, this thesis described the direct inhibition parameters of 
cell-surface uPA by PAI-2 and the internalisation of PAI-2:uPA complexes 
formed on the cell-surface. This published study (Al-Ejeh et al., 2004) also 
provided a biological rationale for the use of PAI-2 as uPA-based anti-cancer 
therapy, one of which is the use of cytotoxic alpha radiation. Alpha-PAI-2 
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preparation was successfully optimised according to standard operating 
procedures and these procedures showed success in trials of radiotherapy using 
mouse models of human tumours (Stutchbury et al., manuscripts in 
preparation). Finally, in addition to their use in elucidating the binding of PAI-2, 
transiently uPAR-overexpressing cells provided preliminary insights into the 
relationship between metastatic phenotype and plasminogen binding (used in 
part in Stillfried G. et al., manuscript in preparation) and may be expanded to a 
new PhD thesis. 
192 




7.1. APPENDIX 1: NORMALISATION OF GAMMA-COUNTER 
The radionuclide (2.5 µCi) was dissolved in 1 ml of PBS and 200 µl 
aliquots were transferred to 5 γ-counter tubes (0.5 µCi in 200 µl per tube). 
Tubes were placed in normalisation rack at positions 1, 5, 9, 13 and 17 to 
normalise the 5 detectors of the Cobra 5005R γ-counter using specified 
normalisation window for each radionuclide. Machine was normalised for 
‘position 2’ which was ideal for counting 0.2 ml – 0.5 ml samples. The Chi-
Square test produced after normalisation was used to judge whether detectors 
were normalised efficiently (Chi Square 99 % confidence range = 7.63 – 36.19). 
In the case where detectors were out of this range, normalisation was repeated 
and in some cases only the efficiently normalised detectors were selected for 
counting. 
 
7.2. APPENDIX 2: QUANTIFICATION AND PURITY OF DNA 
PREPARATIONS 
Agarose gel electrophoresis of plasmid DNA against known amounts 
molecular weight marker allowed the quantification of the amounts of DNA 
present in the sample. The amount of each band in the molecular weight 
marker, Figure 61, was calculated using the ratio of the band size to the size of 
λDNA (85500 bp) multiplied by the amount of marker used (180 ng). The 
amount of DNA in bands, for example lane 1 and 2 Figure 61, was calculated 
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based on the standard curve constructed for the relationship between staining 
intensity and the amount from the molecular weight marker. The amount of 
DNA in the original sample was calculated based on the amount measured in 
the loaded volume and considering the dilution factors. For the example shown, 
the average amount of DNA was 263 ng in the 10 µl loaded. Thus, the amount 
in the 25 µl total volume was 657.5 ng which was acquired using 0.5 µl of 
plasmid solution. The concentration of the original plasmid solution calculated 
using this method (1.32 µg/µl) was compared to value obtained by 
spectrophotometric method (Table VIII). The concentration of DNA in plasmid 
solution was calculated from the absorbance at 260 nm and found to be 1.38 
µg/µl. The average concentration (1.35 ± 0.03 µg/µl) from the two methods was 
used to represent the concentration of plasmid solution. The ratio of the 
absorbance at 260 nm to that at 280 nm (2.0) indicated that the preparation 
was of high purity and very small amounts of protein was present in the 
sample. 





DNA concentration 6.9 µg/ml 
Concentration of stock 
preparation 
1.38 µg/µl 
Plasmid was diluted 1:200 in dH2O and the absorbance 
at 260 and 280 nm was measured using dH2O as blank. 
DNA concentration was measured given that 0.1 
absorbance ≡ 50 µg/ml (Maniatis et al., 1989). The 
concentration of the stock was then measured by 
multiplication with the dilution factor (200). The purity of 
DNA sample was measured as the ratio of 






Figure 61: Quantification of DNA preparation 
(A) pcDNA3/uPAR- (0.5 µl) was diluted in a final 20 µl dH2O and mixed 5 µl of 5 x DNA 
loading dye. Lane 1 and 2: 10 µl of pcDNA3/uPAR- solution and lane 3: 5 µl of 37 ng/µl 
of λDNA/Hind III marker. Electrophoresis was performed using 1.2 % agarose gel at 70 
volts for 1 h and gel was stained in ethidium bromide solution, washed and 
documented. (B) Analysis of the gel image using GelProTM Analyzer software. (C) 
Quantification of the size and amount of bands observed in lanes 1 and 2 using 
standard curves constructed from the molecular weight marker (lane 3). The molecular 
weight of the bands (mol.w.) is in base pairs unit and the amount is in ng. 
7.3. APPENDIX 3: UPA ACTIVITY STANDARD CURVE 
The inhibition of uPA activity due incubation of PAI-2 was assayed using 
a colorimetric assay which utilised synthetic substrate for uPA, Spectrozyme®-
UK. The kinetics of substrate conversion to the coloured product was assayed at 
405 nm for uPA pre-incubated with PAI-2 and compared to standard curve for 
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the relationship between the activity units of uPA (IU) and the rate of substrate 
conversion. The standard curve was constructed using serial 1:2 dilutions of 20 
IU of uPA incubated with 2 mM of Spectrozyme®-UK. The change in absorbance 
at 405 nm over time was plotted against the activity units (Figure 62) and the 
linear correlation was used to interpolate the activity of uPA retained after 
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Figure 62: Standard curve for the rate of substrate conversion and uPA 
concentration 
See method in Section 2.2.B.4. The rate of substrate conversion (change in absorbance 
overtime) was plotted against the concentration of uPA and a linear correlation (r2 = 
0.996) was fitted to the data (mean ± SEM, n = 3). 
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7.4. APPENDIX 4: BUFFERS AND SOLUTIONS 
 
Agarose gel 
1.2 % w/v agarose 
dissolved in 1 x Tris-Borate-EDTA (TBE) buffer 
 
Binding buffer (Hank’s buffered saline solution) 
9.5 g/l Hank’s powder 
1 mM HEPES 
0.1 % w/v bovine serum albumin (BSA) 
1 mM CaCl2 
1 mM MgCl2 
pH 7.4 
Filtered with 0.22 µm filters 
* Phenol red-free binding buffer was prepared identically however using phenol 
red-free Hank’s powder 
 
Coomassie blue stain 
0.1 % w/v Brilliant Blue R250 
40 % v/v methanol 
10 % v/v glacial acetic acid 
 
Coomassie blue destain 
40 % methanol 
10% glacial acetic acid 
60 % water 
 
Culture media 
10.4 g/l of RPMI-1640 powder (contains 2 mM glutamine) 
2 g/l sodium bicarbonate 
adjusted to pH 7.2 
Filter-sterilised using 0.22 µm sterile filters units 
 
DNA precipitation buffer 
1.5 M sodium acetate pH 8 
250 mM EDTA 
 
DNA sample buffer [5 x concentration] 
30 % glycerol 
0.125 % w/v xylene cyanol 
0.125 % w/v bromophenol blue 
 
Elution solution for 213Bi 
250 µl of 0.15 M HI followed by 250 µl of H2O (0.075 M HI) 




Elution buffer for PD-10 columns 
1 x PBS 




0.1 % gelatine buffer 
0.1 g gelatine 
150 mM NaCl 
20 mM Tris-HCl 
In 100 ml of dH2O and adjusted to pH 8.4 
 
 
Luria Broth (LB)  
10 g/l trypton 
5 g/l yeast extract 




1 x PBS containing 10 % v/v glycerol 
 
 
5 x non-reducing sample buffer 
60 mM Tris-HCl 
2 % w/v SDS 
10 % v/v glycerol 
0.01 % w/v bromophenol blue 
 
* 5 x reducing sample buffer prepared as for non-reducing sample buffer but 
including 5 % w/v 2-β-mercaptoethanol 
 
 
1 x Phosphate buffered saline (PBS) 
8 g/l NaCl 
0.2 g/l KCl 
1.44 g/l Na2HPO4 
0.24 g/l KH2PO4 
pH adjusted to 7.4 
Filtered with 0.22 µm filters 
(10 x PBS was prepared by adding 10 x the concentrations above). 
* Note: When 1 x PBS was used with cells (e.g. washing), MgCl2 and CaCl2 were 
added each at 1 mM final concentration. 
 
 
1 x running buffer for SDS-PAGE 
3.03 g/l Tris-HCl 
14.4 g/l glycine 





12 % v/v of liquid 40 % acrylamide 
0.1 % w/v SDS 
375 mM Tris-HCl pH 8.8 
0.1 % v/v TEMED 




4 % v/v of liquid 40 % acrylamide 
0.1 % w/v SDS 
126 mM Tris-HCl pH 6.8 
0.1 % v/v TEMED 
0.05 % w/v APS 
 
SOC medium 
Sterile solution containing: 
2 % w/v Bactotryptone 
0.5 % w/v yeast extract 
10 mM NaCl 
2.5 mM KCl 
20 mM MgCl2 
10 mM MgSO4 
20 mM Glucose 
 
TBE buffer 
10 x buffer prepared at: 
108 g/l Tris-HCl 
55 g/l boric acid 
40 mM EDTA pH 8.0 
diluted 1 in 10 for use at 1 x concentration 
 
TE buffer 
10 mM Tris-HCl, pH 7.4 
1 mM EDTA 
 
Z-agar plates 
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